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Abstract 
Synaptic vesicles (SVs) can exocytose via Full fusion (FF) or by Kiss-and-Run 
(KR) mechanisms. In this thesis, synaptosomes prepared from adult rat 
cerebrocortex demonstrated that these modes can be switched by regulating 
the intracellular calcium levels and/or protein phosphorylation reactions. The 
stimuli employed were: 30 mM K+ (HK), 1 mM 4-aminopyridine (4AP) and 5 M 
ionomycin (ION) together with 5 mM Ca2+. In this model employed, myosin-II 
and dynamins can regulate the closure of the fusion pore of the readily 
releasable pool (RRP) of SVs during KR but are independent of each other’s 
actions.  
In biochemical assays, synaptosomes were maximally labelled with FM2-10 dye 
such that both the RRP and the RP were loaded and such terminals were 
subsequently evoked to release the dye and this was compared to the 
endogenous release of glutamate (GLU). Results show that the rise in [Ca2+]i at 
the active zone produced by HK5C activates PKC isoforms, which in turn cause 
phosphorylation of myosin-II and dynamins. It is hypothesised that dynamins 
are active at relatively lower increases in [Ca2+]i that do not activate PKCs 
whereas myosin-II is active at relatively higher increases in [Ca2+]i that activate 
certain PKCs. Such activation of PKC stimulates myosin-II -but inhibits the 
action of dynamins – and it is this active protein that can close the fusion pore. 
ION5C, however, activates dynamin(s) but not myosin-II, and under such 
conditions dynamin can close the fusion pore. This dynamin-dependent KR 
mode is independent of clathrin because this is not perturbed by the blockade of 
clathrin action using the drug, pitstop2TM and the HK5C evoked myosin-II-
dependent KR is independent of both clathrin and dynamin. Therefore, the KR 
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mechanism described, herein, is distinct from ultra-fast endocytosis that has 
both a dynamin and clathrin dependence. Pre-treatment of synaptosomes with 
DYN and/or pitstop2TM prior to the initial pre-stimulation with HK5C inhibits all 
dynamin and clathrin dependent processes so that SVs that recycle after the 
HK5C pre-stimulation would be perturbed if they had such a requirement. 
Indeed, following this treatment some SVs were not released by ION5C, 
although, the 4AP5C evoked GLU release is not affected and it would appear 
that the 4AP5C sensitive pool (the RRP) can still release following blockade of 
dynamin and clathrin. This demonstrates that the RRP underwent KR during the 
first pre-stimulus (actually via a myosin-II- dependent process) and was 
available to release again during the second round, and again this cannot be via 
ultra-fast endocytosis. 
The role of cAMP and PKA pathways in regulating the modes was investigated. 
Adenylate cyclase activation by forksolin inhibits the release of the RP but 
switches all the RRP vesicles to KR when evoked by 4AP5C. Adenylate cyclase 
inhibition by 9-Cyclopentyl-Adenine (9-Cp-Ade) has no effect on GLU release or 
exocytotic mode. Forskolin’s action on the RP is due to a specific increase in 
cAMP, because pre-treatment of synaptosomes with 9-Cp-Ade before forskolin 
prevents the forkskolin action. The PKA activator, Sp-5,7-dichloro-cBIMPs 
(cBIMPS) does not affect evoked GLU release although it does switch some of 
the RP to a KR mode whereas inhibiting PKA with KT 5720 has not effect on 
GLU release but induces the RRP to undergo FF. Clearly, forskolin’s action on 
both the RP and the RRP SVs is distinct from PKA activation and it may work 
through activating the exchange protein directly activated by cAMP (EPAC). 
Previous experiments have showed that inhibition of protein phosphatase 2A 
(PP2A) by okadaic acid (OA) switches the RRP to FF for all stimuli, but OA pre-
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treatment before forskolin failed to prevent 4AP5C switching some SVs in the 
RRP from FF to KR. This suggests that an adenylate cyclase pathway can 
override the OA-sensitive pathway. 
The Seahorse extracellular flux analyser was used to measure various 
mitochondrial respiration parameters (basal, ATP production, spare capacity, 
maximum respiration, proton leakage and non-mitochondrial respiration). 
Employing 0.3 and 3 M phenyl arsine oxide appears to perturb the spare 
respiratory capacity, whilst 0.1 M did not. This indicated that we were 
previously using too high a concentration of this drug to study modes of 
exocytosis. Such a result led to the testing of the drugs employed in this study 
on exocytosis to check that they did no produce a non-specific effect on the 
bioenergetics of the synaptosomes: 9-Cp-Ade, Blebb, Go 6983, cBIMPs, 
forskolin or OA did not change the mitochondrial respiratory parameters 
indicating that any exocytotic effects shown were specific.  
The specific phosphorylation of Ser-778, Ser-774 and Ser-795 on dynamin 1 
was investigated using well characterized commercial antibodies and western 
blotting. It was concluded that the phosphorylation of Ser-774 and Ser-778 
showed no correlation with dynamin’s activity towards regulating closure of the 
fusion pore although these sites may well correlate with clathrin dependent 
endocytosis and bulk endocytosis. However, the phosphorylation of Ser-795 on 
dynamin may play an important role in the inhibition of dynamin’s activity 
towards closing the fusion pore during KR. Phosphorylation on Ser-795 may be 
under the regulation of PKC as demonstrated using a PKC activator, phorbol 
myristate acetate, and an inhibitor, Go 6983. Therefore, endogenous PKC 
activation may phosphorylate this site when a very high Δ[Ca2+]i is achieved at 
the active zone. It was difficult to obtain a conclusion as to which PKC isoform 
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could regulate the mode of SV exocytosis by phosphorylation of Ser-795 on 
dynamin due to the low phosphorylation levels obtained whilst employing Go 
6983 and Go 6976. 
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Chapter 1 
Introduction 
 2 
1.1 Background 
For over a century, the neuron doctrine (put forth in early 1900s) -which states 
that the neuron is the structural and functional unit of the nervous system- has 
provided the fundamental essence for neuroscience. Santiago Ramón y Cajal is 
identified as the leading protagonist of the neuron doctrine and he made 
detailed observations about the functional contact points between neurons, later 
described as ‘synapses’ by Sherrington in 1897 (Yuste, 2015; Guillery, 2005). 
The synapse is the point at which one neuron communicates with another 
neuron and is composed of the presynaptic terminal, the synaptic cleft and the 
postsynaptic terminal. Communication between neurons is known as synaptic 
transmission which can be either electrical or chemical and the neurons can 
receive either an excitatory or inhibitory signal. These synaptic connections can 
process and exchange prodigious amounts of information over a distributed 
neural network in the matter of milliseconds (Marois and Ivanoff, 2005). The 
approximate distance between pre and post synaptic membrane in an electrical 
synapse is 4nm. Synaptic delay is virtually absent across the gap junctions, 
which are specialized protein structures that conduct the flow of ionic current 
from presynaptic to postsynaptic terminal. Electrical synapses have bidirectional 
transmission and are employed to transmit rapid and stereotyped depolarizing 
signals. In a chemical synapse, the distance between the pre and post synaptic 
membrane is 20-40nm. It has a synaptic delay of at least 0.3 ms but usually 1-5 
ms or longer and has a unidirectional transmission. Chemical synapses can 
amplify the neuronal signal and also mediate either excitatory or inhibitory 
changes post-synaptically. They can also produce electrical changes that can 
last from milliseconds to minutes in the post synaptic cell. The majority of the 
synapses in the brain are chemical (Kandel, 2013). On arrival of an action 
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potential, the neurotransmitter that is present pre-synaptically is released in a 
calcium-dependent manner due to the opening of voltage-gated calcium 
channels in response to presynaptic depolarization (Martini, 2007). The 
neurotransmitter which is stored in synaptic vesicles is released to activate 
specific receptors present post-synaptically. The amount of neurotransmitter 
released is directly proportional to intensity of the stimulation.  This release of 
transmitter occurs at the active zone. These active zones contain proteins that 
perform specialized functions like priming and docking of the synaptic vesicles, 
recruiting the appropriate calcium channels and certain other proteins and 
mediating short and long-term plasticity. The regions on either side of the active 
zones are called peri-active zones where some forms of endocytosis take place 
to replenish the pool of vesicles (Martini, 2007; Sudhof and Rizo, 2011). This 
has been demonstrated in figure 1.1. 
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Figure 1.1 A diagram showing the events involved in neurotransmission (Sudhof 
and Rizo, 2011). 
1.2 Synaptic vesicles 
Synaptic vesicles are organelles present in synaptic boutons that play a critical 
role in neurotransmission. They are the best characterized of all organelles. 
Palade and Palay (1954) presented the first electron microscopy images that 
confirmed the existence of synaptic vesicles. Later Whittaker and Sheridan 
(1965) performed biochemical analyses to isolate acetylcholine from synaptic 
vesicles. Takamori et al., (2006) used various molecular, biophysical, electron 
microscopy and modelling techniques to determine a quantitative description of 
the synaptic vesicle using rat brain homogenate as shown in figure 1.2.2. 
Synaptic vesicles have an average size of 40nm and can hold 1790 molecules 
of glutamate at a concentration of 150mM (this varies for other 
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neurotransmitters). Synaptic vesicles contain a diverse array of trafficking 
proteins as shown in figure 1.2.1. With the exception of V-ATPase which is 
present only in one or two copies, vesicles contain multiple copies of proteins 
required for membrane traffic and uptake of neurotransmitter (Takamori et al., 
2006). Takamori et al., (2006) have shown that synaptic vesicles are 
biochemically homogenous in that all SVs contain the same constituents. 
However, Crawford and Kavalali (2015) have suggested that synaptic vesicles 
are not homogenous organelles and possess intrinsic molecular differences and 
different interaction partners (Crawford and Kavalali, 2015). Future studies are 
necessary to ascertain the possibility of molecular heterogeneity and distinct 
biochemical fingerprints (Alabi and Tsein, 2012). Hua et al., (2011) have shown 
that v-SNARE distribution differs in synaptic pools which serves as a molecular 
tag in distinguishing different synaptic pools. (Hua et al., 2011). 
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Figure 1.2.1 Molecular model of outside view of an average synaptic vesicle 
(Takamori et al., 2006). 
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Figure 1.2.2 Image shows the physical parameters and composition of an 
average synaptic vesicle as explained in section 1.2 (Takamori et al., 2006) 
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1.3 synaptic vesicle pools 
Birks and MacIntosh (1961) put forth the concept that synaptic vesicles are not 
functionally equivalent after they investigated acetylcholine release from cat 
sympathetic ganglia and discovered that some vesicles underwent exocytosis 
more easily than others. Later Elmqvist, et al., (1965) obtained similar results 
with human intercostal muscles. Chemical synapses have a distinctive feature 
of an asS.E.M.bly of synaptic vesicles in the presynaptic terminal.  These 
vesicles participate in a cycle which allows sustained activity of the nerve 
terminal. Vesicle pools have been extensively investigated in all major synaptic 
preparations, including synapses as different as the Drosophila larval 
neuromuscular junction (NMJ), goldfish retinal bipolar cells, the frog NMJ, the 
mammalian calyx of Held (a giant synapse in the auditory system), and cultured 
hippocampal synapses cells (Rizzoli and Denker, 2010).  
In all these synapses, three major synaptic pools have been proposed which 
have been given a varied array of names. For this thesis, they will be referred to 
as ready releasable pool, reserve pool and silent pool as shown in figure 1.3. 
The ready releasable pool is situated closest to the active zone and is recruited 
for release upon arrival of low frequency stimulation.  Before these vesicles can 
exocytose, the vesicles are primed and docked. The second category of 
synaptic vesicle pool is the reserve pool. It is spatially distant from RRP and is 
released once RRP has been exhausted. The third type of synaptic vesicle pool 
that is thought to exist is the silent pool. This silent pool makes up almost eighty 
percent of the total vesicle pool. It is situated farthest from the active zone and 
does not release under normal physiological conditions. The number of vesicles 
belonging to each pool differs across synapses (Ashton and Ushkaryov, 2005).  
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Besides, the aforementioned three pool model, several other pool models have 
been proposed. Out of these, the main pools are spontaneous pool which 
release without stimulation, super-pool of vesicles which are shared between 
boutons and surface pool of vesicles which are stranded or deposited in a state 
of fusion with the plasma membrane and are available for compensatory 
retrieval from there in response to exocytosis of other vesicles. These new 
concepts provide a new outlook in the functioning of synaptic vesicles but due 
to lack of understanding about their exact mechanism these concepts prove to a 
debatable issue (Mochida, 2015). 
 
Figure 1.3 A diagram showing the three synaptic vesicle pools namely ready 
release pool (RRP), reserve pool and silent pool (Rizzoli and Betz, 2005). 
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1.4 Overview of synapse and active zone (AZ) 
The intercellular junctions between a presynaptic neuron and a postsynaptic 
cell, the latter of which can also be a neuron, represent synapses. Synapses 
receive information in the form of an action potential and transmit in to the 
postsynaptic cell through the release of neurotransmitter. Thus, they act as 
“computational devices” that help in transmission of action potential encoded 
information (Sudhof, 2012). The information received at the synapse can, in the 
form of action potential trains, bring about use-dependent changes in the 
postsynaptic neuron. These changes can either be long-term or short-term; 
termed as long-term plasticity or short-term plasticity respectively.  Synapses 
differ from each other in various parameters like neurotransmitter type, release 
probability and post synaptic receptor composition. There are various types of 
neurons in the mammalian brain, which form a multitude of synapses that 
display distinguished properties depending on the pre and postsynaptic 
neurons. Thus, there are hundreds of distinct types of synapses with unique 
computational properties (Sudhof, 2012). The strength of synaptic transmission 
and its regulation rely on the complex set of proteins that are required for 
synaptic function and that contribute to the active zone and the postsynaptic 
density. Wilhelm et al., (2014) have performed a detailed characterization using 
fluorescence microscopy for localization of proteins, quantitative immunoblotting 
and mass spectrometry for determining protein numbers and electron 
microscopy for measuring organelle numbers, sizes and positions using the 
cortex and cerebellum of adult rats as shown in figure 1.4. Using these 
techniques, they generated a 3D model of an average synapse which shows 
300,000 proteins in atomic detail.  
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Figure 1.4 A diagram showing 3D model of synaptic architecture. A)  A section 
of synaptic bouton, showing 60 proteins B) High zoom view of active zone area 
C) High zoom view of vesicle cluster D) High zoom view of a section of plasma 
membrane in the vicinity of AZ. The graphical legend to the right indicates the 
different proteins (Wilhelm et al., 2014). 
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The presynaptic bouton is a specialized site characterized by the presence of 
active zones. In vertebrates the active zones are mainly disc-like structures with 
a diameter of 0.2-0.5 μm. Active zones are flanked by peri-synaptic zones on 
either side. They allow a presynaptic action potential to lead to the release of a 
chemical signal with high spatial and temporal precision (Kittel and Heckmann, 
2016). The active zone contains a set of specialized proteins which are 
described later in sections 1.7-1.9. 
1.5 Synaptic vesicle cycle 
The synapses formed by neurons are independently regulated. The major event 
in the synaptic vesicle cycle is exocytosis by membrane fusion. The presynaptic 
boutons contain numerous synaptic vesicles filled with neurotransmitter. On 
arrival of an action potential, the predocked vesicles at the active zone undergo 
a Ca2+-dependent fusion at the active zone resulting in neurotransmitter release 
through the formation of a fusion pore.  Fusion pores help regulate the rate and 
the amount of release of neurotransmitter. The exocytosed vesicles are then 
retrieved via endocytosis for refilling the neurotransmitter and are also docked 
and primed for re-release (Jackson et al., 2015). The events of the 
conventionally discussed synaptic vesicle cycle are discussed in the legend for 
figure 1.5. 
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Figure 1.5 Figure shows events that orchestrate neurotransmitter release at the 
synapse (full fusion): 1) Synaptic vesicles are filled with neurotransmitter using 
specific transporters in the SV membrane. This process is ATP dependent. 2) 
The synaptic vesicles are moved to the active zone 3) They are then docked at 
the AZ 4) and primed for fusion event 5) On arrival of an action potential, there 
is an influx of calcium through the opening of the voltage gated calcium 
channels that triggers the fusion of the synaptic vesicles to the plasma 
membrane for release of transmitter release 6) The vesicles then move away 
from the active zone and gathered in coated pits for endocytosis 7) The coated 
vesicles begin to acidify and the clathrin coat is removed by a chaperone 8) The 
endocytosed vesicles are then fused with an early endosome for sorting and 
reconstitution 9) with SV then ready for re-use (Brady and Siegel, 2012). 
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1.6 Different modes of exocytosis and 
endocytosis 
This conventional model only takes into account the full fusion mode of 
exocytosis when in fact, there are two forms of exocytosis: full fusion (FF) and 
Kiss-and-run (KR).    
1.6.1 Full fusion 
Full fusion was initially described in 1973 by Heuser and Reese at the frog 
neuromuscular junction (NMJ). In this mode, the SVs manifest a complete 
aqueous continuity between vesicle lumen and external medium and full lipid 
continuity vesicle membrane and plasma membrane, causing near-
instantaneous neurotransmitter release at the active zone as shown in figure 
1.6.1 (Harata et al., 2006). The collapsed membrane then moves away from the 
active zone and is retrieved by clathrin-mediated endocytosis, slow recycling via 
endosomal compartments or bulk endocytosis. This process has also been 
implicated in CNS terminals (Sankaranarayanan and Ryan, 2000). 
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Figure 1.6.1 Schematic diagram showing release of neurotransmitters from 
synaptic vesicles via a full fusion mechanism. The synaptic vesicles then diffuse 
laterally and are retrieved via clathrin-mediated endocytosis or endosomal 
recycling. (Wu et al., 2007). 
This process would put tremendous pressure on the RRP vesicles to maintain a 
speedy and efficient exocytosis process because the endocytosed vesicles 
would have to quickly return to the interior and then through the following 
endocytosis steps in quickly and be primed and ready for release in order to 
maintain the signal downstream, this would mean that the vesicles race back 
and forth and in the process restore the complement of proteins and lipids 
required for release; a quick exocytosis process called kiss-and run helps solve 
the kinetic dilemma of the RRP vesicles allowing them to release the 
neurotransmitter and help maintain the signal.  
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1.6.2 Kiss-and-run 
KR or non-classical mode of fusion was also discovered in 1973 by Ceccarelli 
and colleagues at the frog NMJ.  KR results in the formation of a transient pore 
for release of neurotransmitter, without complete loss of identity of SVs and 
cessation of this would occur by closing of the fusion pore. Thus, the SVs are 
available for rapid re-use. 
 
Figure 1.6.2 Diagrammatic representation of the comparison between kiss-and 
run and full fusion. (Burgoyne et al., 2001). 
 
Harata et al., (2006) have proposed that KR helps to conserve the resources 
during periods of stimulation and this ensures that the synapses are ready for 
high frequency firing with a full quota of fusion-competent vesicles. These 
processes co-exist in nerve terminals with frequency of stimulation being the 
deciding factor. KR and FF are at variance with each other (as shown in figure 
1.6.2) on various factors like lack of lipid and protein continuity when the SV 
fuses with the plasma membrane or vesicle location after fusion.  KR still 
remains a debatable concept. Harata et al., (2006) have shown the prevalence 
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of KR in the hippocampal cells by using bromophenol blue to quench the 
incompletely released FM dye. He et al., (2006) have performed capacitance 
measurements at giant synapses to demonstrate the prevalence of KR while 
Zhang et al., (2009) have used recycling of quantum dots in SVs technique to 
show KR.  KR mode of exocytosis involves the endocytic stage where the 
fusion pore closes (Harata et al., 2006). 
Ashton et al., (unpublished data) have shown that a switch in the mode of 
exocytosis can be brought about by modulating [Ca2+]i and protein 
phosphorylation. Strong stimulation of nerve terminals causes the RRP to 
undergo KR while the RP fuses via FF.   
In synapses at a given time period, the number of vesicles undergoing 
exocytosis can surpass the reserve of precursor synaptic vesicles delivered 
from the cell body. Thus, to the balance the demand and supply of vesicles, 
nerve terminals have developed efficient endocytic ways for recapturing and 
reusing membranes that have fused with the plasmalemma for neurotransmitter 
release. Electrophysiological studies using extracellular endocytic tracers 
performed at the frog NMJ by Heuser and Reese and Ceccarelli and collegues 
have given rise to two schools of thought: one holding that vesicles acquire 
tracers directly via a reversible exo/endocytic sequence in which they 
consistently maintain their biochemical identity during transient continuity with 
plasma membrane, the other that synaptic vesicles acquire tracers indirectly via 
the formation of clathrin coated vesicles which are spatially and temporally 
separate from exocytosis and reverse a temporary loss of vesicles’ individual 
identity upon merger with plasma membrane (Heuser, 1989) Depending on the 
intensity of stimulation at various synapses the time taken for endocytosis can 
vary (Saheki, and De Camilli, 2012).  There are in fact four different forms of SV 
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endocytosis: a) clathrin mediated endocytosis (CME) b) KR (mentioned earlier) 
c) bulk endocytosis/ activity dependent bulk endocytosis (ADBE) and d) ultrafast 
endocytosis. 
1.6.3 Overview of CME 
Clathrin mediated endocytosis is a ubiquitous process occurring in all eukaryotic 
cell types to internalize nutrients, antigens, pathogens and recycling receptors. 
In nerve terminals, clathrin coated vesicles (CCVs) bud off from the presynaptic 
plasmalemma at the peri-active zone. After full fusion of SVs they are 
translocated into the cell. This process requires sequential and progressive 
asS.E.M.bly of CCVs which serve to converge the cargo proteins and lipids into 
the emerging vesicle thereby providing a self-propelled medium to deform the 
membrane into a vesicular bud as shown in figure 1.6.3. Pitstop (2-(4-
Aminobenzyl)-1,3-dioxo-2,3dihydro-1H-benzo[de]isoquinoline-5-sulfonic acid 
sodium salt) serves as an inhibitor for CME by selectively inhibiting ligand 
association with the clathrin terminal domain (Kleist et al., 2011). Work by 
Heuser and Reese (1973) suggested that clathrin coated vesicles fuse to an 
internal endosome from which SVs are pinched off. However, more recent 
findings suggest that the coated vesicles simply lose the clathrin coat and the 
SV is recovered. 
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Figure 1.6.3 CME involves several morphologically distinct steps from clathrin 
coat binding, invagination of the coated bud, constriction and fission of the neck 
of CCV and subsequent uncoating of the CCV. An endosome intermediate is 
not required for CME (Shupliakov and Brodin, 2010). 
 
The clathrin coat consists of two layers, one being the inner layer of adaptors 
and the outer layer comprised of a clathrin lattice. The inner layer is made up of 
various proteins that may contain, a membrane binding and folded module with 
flexible arms and this may terminate into a small folded module. The former part 
binds to the cytoplasmic exposed domains of the membrane proteins and to the 
head group of PI(4,5)P2 while the arms serve as a  link for the clathrin heavy 
chain and other adaptors as well as other endocytic factors. The outer clathrin 
lattice layer is composed of a triskelion shaped scaffold protein made up trimers 
of heavy chains with three bound light chains (Saheki and De Camilli, 2012; 
Takei and Haucke, 2001; Kononenko and Haucke, 2014; Shupliakov et al., 
2002).  
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Initiation of the clathrin coat asS.E.M.bly is aided by the accumulation of PIP2 
and adaptor proteins for example AP-2 at the invagination site. Accessory 
proteins help form protein-protein interactions to assist the asS.E.M.bly of the 
clathrin coat. As the clathrin coat asS.E.M.bles around the budding vesicles the 
membrane acquires an increasing curvature until a deeply invaginated coated 
pit is formed.  
Growth of CCVs requires BAR domain proteins and actin reorganization. 
Constriction and fission of the coated pit requires the GTPase dynamin. 
Uncoating of the clathrin layer is an ATP-dependent step requiring Hsc70 
ATPase and its DnaJ-like cofactor auxilin (Saheki and De Camilli, 2012; Takei 
and Haucke, 2001; Kononenko and Haucke, 2014; Shupliakov et al., 2002).  
The time constant for CME is 15-20 seconds while for KR the fusion pore closes 
with 0.5 seconds. KR mode of exocytosis/endocytosis bypasses the need for 
CME or any other form of endocytosis. 
1.6.4 Overview of ADBE 
The concept of ADBE was first reported by Miller and Heuser in 1984 at 
amphibian NMJ (Clayton and Cousin, 2009). This pathway is activated during 
intense stimulation conditions, wherein a large number of SVs fuse with the 
plasma membrane in a short period of time. The excess plasmalemma is 
captured by the formation of plasma membrane infoldings. These infoldings 
later undergo fission to form cisternae and intracellular vacuoles. The 
endosome-like compartments which form in response to synaptic vesicular 
exocytosis may contain the proteins and lipids which are abundantly present in 
the plasma membrane. These endosome-like intermediates eventually 
disappear as new SVs are formed, thereby suggesting a precursor-product 
relationship between the newly formed SVs and these organelles (Saheki and 
 21 
De Camilli, 2012). The SVs bud from these endosomes in clathrin and adaptor 
protein dependent manner (Cheung and Cousin, 2013). Cousin and colleagues 
have suggested that the ADBE form of endocytosis replenishes the reserve 
pool of vesicles (Cheung and Cousin, 2013). The time constant and speed for 
this process is still a debatable issue. This process is recruited during intense 
stimulatory conditions when clathrin dependent machinery is saturated and 
persists for minutes after termination of the stimulation. This process in 
comparison to CME is much slower thereby placing the nerve terminal in a 
dangerous situation to rapidly correct the large increase in membrane area 
produced by this process (Clayton et al., 2008). Figure 1.6.4. shows a 
schematic comparison between CME, KR and ADBE.  
ADBE is dependent on two events: activation of calcium/calmodulin dependent 
protein phosphatase, calcineurin, which in turn dephosphorylates GTPase 
dynamin I during intense stimulation, which results in an interaction with F-BAR 
protein syndapin. Thereby necessitating the dependence of this process on 
extracellular calcium (Cheung and Cousin, 2013). The exact molecular 
machinery behind this process is unknown. Although bulk endocytosis does 
occur, the molecular mechanisms elucidated by Cousin and colleagues is now 
questioned. They have emphasised the role of dynamin I in the process and its 
regulation by phosphorylation. However, bulk endocytosis still occurs in KO 
mice which lack dynamins I or I and III (Cheung and Cousin, 2013). 
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Figure 1.6.4 Schematic comparison of the three forms of endocytosis: a) CME 
b) KR c) ADBE (Wu et al., 2007).  
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1.6.5 Overview of ultrafast endocytosis 
The concept of ultrafast endocytosis was put forth by Watanbe et al., (Watanbe 
et al., 2013) in recent experiments in C.elegans and mouse hippocampal 
neurons. In this process as shown in figure 1.6.5, the docked vesicles fully 
collapse into the plasma membrane synaptic and are retrieved by endocytic 
invaginations that appear 50-100 ms after SV fusion. The transition from 
synaptic vesicle to synaptic endosome takes one second after stimulation. After 
3 seconds coated vesicles pinch off from the endosome. These coated vesicles 
transition to small diameter SVs 5-6 seconds after stimulation. This process 
occurs at the interstitial zone, which is a region adjacent to the AZ and is less 
densely packed with proteins and cytoskeletal elements and surrounding this 
zone is the periactive zone, where ADBE and CME take place. The endocytic 
invaginations formed are approximately 80nm in diameter, which is equivalent 
to four SVs rather than one, thus differing from KR. This form of endocytosis 
has been observed in mild stimulatory conditions (most experiments use only 
one action potential). Also, the time taken for this recycling process is around 5 
secs whereas KR is only limited by the time it takes for SV to reload with 
neurotransmitter which is only about 1 secs. KR may still be a faster recycling 
mechanism than ultrafast endocytosis which may only occur under such low 
stimulation conditions. Figure 1.6.6. highlights the differences between CME, 
ultrafast endocytosis and KR The exact molecular mechanism for this process 
is unknown, however, some studies have indicated that dynamin, actin and 
endophilin may help regulate this process (Watanbe et al., 2013; Watanbe et 
al., 2014; Kononeko. and Haucke, 2014; Zhou et al., 2014; Saheki, and De 
Camilli, 2012).   
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Figure 1.6.5 Diagram showing the process of ultrafast endocytosis (Watanbe et 
al., 2014). 
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Figure 1.6.6 Diagram showing a comparison between CME, ultrafast 
endocytosis and KR. A and B are dynamin and clathrin dependent later in this 
thesis we show that KR also is dynamin dependent. The timings relate to when 
the invagination pinches off from the membrane and not the recycling time for a 
SV to be reavailable for further rounds of SV exocytosis (Kononeko. et al., 
2013). 
  
 26 
1.7 Dynamins 
Dynamin derived from the word ‘dynamic’ was named so to demonstrate its 
molecular motor-like properties and was first isolated as a microtubule binding 
protein which on addition of ATP caused the microtubules to slide past each 
other (Sheptner, and Vallee, 1989). Dynamin is a 100 KDa protein that plays an 
important role in endocytosis. Three dynamin genes can be found in 
mammalian genomes. These proteins have the same domain organization and 
share 80% of the homology but have distinctive expression patterns.  Dynamin I 
has a high expression level in neurons but not in non-neuronal tissues however 
it can be detected in cultured cell lines. Dynamin 2 has a ubiquitous expression 
level. Dynamin 3 like dynamin 1 can be found in neurons but has a relatively 
lower expression level, it can also be found in testis and in lower levels in lungs 
as well. These three different isoforms form different protein-protein interactions 
and have different quantitative properties, which include affinities for SH3-
domain proteins, GTPase activity levels, oligomerization efficiency rates and 
lipid binding properties which in turn affect the membrane fission rate (Liu et al., 
(2011)  
Dynamin belongs to a family of GTPases which are known as dynamin-like 
proteins (DLPs) also called dephosphins. Its domain structure and the function 
of each domain are shown in figure 1.7.1. Dynamins are cytosolic proteins, 
having an amino terminal G domain; a ‘middle’ or ‘stalk’ region; a pleckstrin 
homology domain (PH domain); a GTPase effector domain (GED) and a 
proline-rich carboxy terminal region, typically referred to as the proline-rich 
domain (PRD).  The PH domain mediates the interaction between dynamin and 
lipids in membranes, in particular it interacts with phosphoinositide 
phospholipids. GED interacts with the G domain and PRD helps in protein-
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protein interactions. Dynamins hydrolyze GTP and the rate depends on its 
interaction with other molecules, regulated by the phosphorylation state of 
dynamin. 
 
Figure 1.7.1 Domain organization of dynamin and their function (Courtesy: 
Mettlen, et al., 2011) 
 
Dynamins form dimers in solutions and these dimers form tetramers at higher 
concentrations. This polymerization creates a spiral array and is the result of 
side by side placement of dimers through interactions of the stalk tips. This 
spiral forms around membrane invaginations and through GTP hydrolysis, 
scission of the invagination in vesicles can occur. The angle at which dynamins 
interact determines the diameter of the vesicle neck, also called fusion pore 
(FP). The core is formed by the stalks and the BSE and G domains of each 
dimer project towards the adjacent rungs of the dynamin helix. It is after this 
asS.E.M.bly that G-domain dimerization takes place across adjacent rungs. 
Once the dynamin polymerization is complete around the neck of the endocytic 
intermediate, its GTP-hydrolysis-dependent structural reorganization triggers 
constriction. There are three models that have been proposed regarding the 
mechanism of dynamin for membrane fission which are the twistase model, 
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constrictase model and the poppase model. Dynamin may contribute to multiple 
forms of endocytosis, but its action is best understood in the context of clathrin 
mediated endocytosis as described in figure 1.7.2. During the formation of 
endocytic buds, a subset of scaffold proteins, and clathrin adaptors are first 
recruited to the phosphoinositol lipid containing regions of the plasma 
membrane. These components help to cluster cargo, inducing membrane 
curvature and also have actin-nucleating properties. This coat subsequently 
grows through the clathrin lattice which in turn recruits additional cargo adaptors 
and endocytic factors. Dynamin then begins to accumulate around this growing 
pit. This asS.E.M.bly then results in deep invagination of the bud and formation 
of a narrow neck. The next step in this process is recruitment of BAR domain 
proteins which in turn causes dynamin to rapidly accumulate at bud necks to 
mediate fission (Ferguson & Camilli 2012), Mettlen et al., (2011) have proposed 
another role for dynamin wherein dynamin functions as a regulatory GTPase. 
And the GTP bound dynamin serves to regulate the effectors that control 
vesicle formation. The self-asS.E.M.bling property activates an internal GAP 
domain (GED) that exerts a negative control on dynamin function and 
terminates dynamin-effector interactions. 
  
 29 
 
Figure 1.7.2 Diagram illustrating the functions of dynamin in CME. A) the 
mechanochemical function acts to bring about membrane fission. B) The 
regulatory function acts to terminate the dynamin-effector interactions (Mettlen 
et al., 2011). 
 
Ferguson and Camilli (2012) have suggested that dynamin 1 phosphorylation 
depends, at least in part, on CDK5, and, upon nerve stimulation, dynamin is 
rapidly dephosphorylated by calcium and calmodulin-dependent phosphatase 
calcineurin; thereby facilitating endocytosis (Ferguson & Camilli 2012). The 
action of calcineurin (PP2B) can be inhibited by the action of cyclosporine A.
 Graham, et al., (2007) have shown that in synaptosomes dynamin I has seven 
phosphorylation sites in vivo: Ser774, Ser778, Ser822, Ser851, Ser857, 
Ser512, and Ser347.  On further analysis, it was found that the Thr780 
phosphorylation site does not undergo phosphorylation in vivo but does so in 
vitro. Moreover, their quantification analysis led to the conclusions that Ser774 
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and Ser778 were the major sites of phosphorylation (Graham et al., 2007).  Not 
much information is available for dynamin 2 and dynamin 3. However, since 
dynamin 1 and 3 share common mechanisms it is believed that dynamin 3 is 
phosphorylated at the equivalent sites as dynamin 1.  
Besides endocytosis dynamin also interacts with the cytoskeleton and plays an 
important role in cytokinesis. The absence of dynamin 2 show links to tissue 
specific diseases like Charcot-Marie disease and centronuclear myopathy 
(CNM). Mutations in dynamin 1 specifically affect the nervous system. The 
dynamin1 gene can be considered a target for idiopathic causes of epilepsy 
(Ferguson & Camilli, 2012). Also, the invasive activity of pancreatic ductal 
carcinoma was associated with upregulation in dynamin 2 expression 
(Ferguson & Camilli, 2012).  
The action of dynamins 1 and 2 can be inhibited by DYN (3-
Hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxybenzylidene)hydrazide). 
Dynole-34-2TM(2-Cyano-N-octyl-3-[1-(3-dimethylaminopropyl)-1H-indol-3-
yl]acrylamide) acts as a dynamin 1 inhibitor. Dyngo-4a (3-Hydroxy-N'-
[(2,4,5trihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide) inhibits 
dynamin 2. 
1.8 Myosin-II 
Each molecule of myosin-II is made up of 6 polypeptide chains, which are 
arranged as dimers of heavy chains; each dimer is associated with one 
essential light chain (ELC) and one regulatory light chain (RLC); this light chain 
is associated with the heavy chain in a tight non-covalent fashion. In mammals, 
three different genes for non-muscle myosin heavy chains (NMHC) have been 
identified which in turn give rise to three myosin II protein complexes called IIA, 
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IIB and IIC. Each NMHC can be divided into various structurally defined 
domains with each domain performing a different function. Figure 1.8.1 shows 
the domain structure of myosin-II. The N-terminal portion of the NMHC peptide 
forms a globular head, which is also referred to as the motor domain because it 
mediates the ATPase- and actin-binding activities of the molecule. The ELC and 
RLC associate with the heavy chains via interaction with IQ motifs that reside 
near the C-terminal end of the globular head, in a region often referred to as the 
neck domain. After the neck domain is an α-helical coiled-coil rod/tail domain, 
which mediates heavy chain homodimerization and filament asS.E.M.bly, and 
the molecule terminates with a nonhelical tailpiece (NHT) of approximately 34-
44 amino acids (Sandquist and Means 2008). 
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Figure 1.8.1 A diagram depicting the domain structure of myosin II (Sandquist 
and Means, 2008). 
 
All these three isoforms perform two basic functions which are asS.E.M.bly into 
bipolar filaments and contraction of F-actin in an ATP-dependent manner. The 
functions performed by non-muscle myosin can be regulated through various 
ways, the best characterised method being phosphorylation of RLC at Ser19. 
Phosphorylation on Ser19 of the RLC stimulates the actin-activated ATPase of 
myosin-II and promotes the asS.E.M.bly of myosin-II into filaments.  One of the 
key enzymes regulating the phosphorylation status of the RLC is Rho kinase 
(ROCK), which can directly phosphorylate the RLC as well as phosphorylate 
and inactivate the targeting subunit of the myosin light chain phosphatase. The 
other method of regulating myosin II is through PKC. When activated by phorbol 
esters (PMA), PKC can phosphorylate Ser1/2 residues of RLC in vivo and it can 
also phosphorylate Thr9 in vitro. This PKC phosphorylation, not only inhibits the 
rate of MLCK phosphorylation, but also inhibits the ATPase activity of myosin-II 
once it is phosphorylated by MLCK (Bresnick 1999). In case of heavy chains of 
myosin-IIa, Ser1916 and Ser1943 are phosphorylated by PKC and casein 
kinase II respectively; whereas, on the other hand, Ser1939 and Ser1941 of 
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myosin–IIb are phosphorylated by PKC (Bresnick 1999). Myosin-II has been 
proved to be involved in the mobilization of RP to near the synaptic membrane  
(Ryan, 1999).  
Recently, it has been suggested that dephosphorylated myosin-II can act as a 
molecular motor by hindering the dilation of fusion pores thereby possibly 
regulating the size of the pore. Moreover, it can also regulate the amount of 
vesicular release by manipulating the duration of the fusion pore opening 
(Aeeco et al., 2008; Aoki et al., 2010). It should be noted that the PKC 
phosphorylations of these other sites may be involved in activation of myosin II. 
Thus, it will clearly depend upon what amino acids are phosphorylated as to 
what specific roles myosin II may play. A diagrammatic representation of 
regulation of NM II has been shown in the figure 1.8.2; wherein various proteins 
like TRPM7 (transient receptor potential melastatin 7), PKCb, PKC, PKCz and 
CK II have been shown to regulate the activity of NMHC. Human RLC is 
encoded by myosin heavy chain 9 (MYH9), NMHC IIB by MYH10 and NMHC 
IIC by MYH14. Kinases PKC, MLCK, ROCK, MRCK/CDC42BP (myotonic 
dystrophy kinase-related CDC42-binding kinase, ZIPK/ DAPK3 (leucine zipper 
interacting kinase) and citron kinase can regulate the activity of RLC (Vincente-
Manzanares M. et al., (2010)).  The action of myosin II can be inhibited by the 
action of Blebb (±)-1,2,3,3a-Tetrahydro- 
3a-hydroxy-6-methyl-1-phenyl-4H-pyrrolo[2,3-b]quinolin-4-one). 
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Figure 1.8.2 Diagrammatic representation of regulation of activity of NM II 
(Vincente-Manzanares et al., 2010). 
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1.9 Ca
2+
 dependent regulation of exocytosis 
(Refer to Figure 1.5) 
A rapid increase in intracellular Ca2+ acts as a trigger for exocytosis. In neurons, 
the proteins that form a part of the exocytotic machinery are: soluble N-
ethylmaleimide-sensitive factor attachment protein (SNAP) receptors 
(SNAREs), ATPase N-ethylmaleimide-sensitive factor (NSF) and its co-factor -
SNAP, Munc18/Sec1, Munc13, synaptotagmins and Rab3 and its effectors.   
1.9.1 Step 1) SNARE proteins, the engine of membrane fusion 
Role of SNAREs  
SNAREs belong to the family of membrane proteins which regulate membrane 
fusion and are characterised by the presence of SNARE motif which consists of 
approximately 60 amino acids and has a a-helical coiled coil domain structure. 
There are 36 SNAREs in the human genome. Based on their localisation on the 
plasma membrane whether vesicular or target membrane, they were previously 
classified as v-SNAREs and t-SNAREs. Fassheur et al., (1998) have re-
classified SNAREs into R-SNAREs and Q-SNAREs depending on the 
conserved arginine or glutamine sequence respectively in the SNARE motif. 
Synaptobrevin (Vesicle-associated membrane protein (VAMP-2)) which is a R-
SNARE contains a single SNARE motif, syntaxin 1 which is Q-SNARE also 
contains a single SNARE motif while SNAP-25 (25-kDa synaptosomal 
associated protein) which is a Q-SNARE contains two SNARE motifs, these 
three proteins come together to form the SNARE complex. Neuronal SNAREs 
form protein-protein interactions with Munc18/Sec1, Munc13, synaptotagmins 
and complexin. Post exocytosis, the SNARE complex is disasS.E.M.bled and 
individual proteins are recycled. This process is mediated by the action of -
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SNAP and ATPase activity of NSF (Jahn and Fasshauer, 2012; Barclay et al., 
2005; Seino and Shibasaki, 2005).  
1.9.2 Step 2) Priming the SNARE engine  
Munc18/Sec 1 or SM proteins belong to the family of hydrophobic proteins with 
no recognizable motifs. Unc-18 was first discovered in C.elegans and later 
discovered in yeast as Sec1. The mammalian homologs of Unc-18 and Sec1 
are named Munc-18 and Sec1 respectively. There are seven homologs present 
in the human genome. Munc18 acts as a negative regulator of the SNARE 
complex asS.E.M.bly by binding to the Habc domain of syntaxin 1 in its closed 
formation (Jahn and Fasshauer, 2012; Barclay et al., 2005; Seino and 
Shibasaki, 2005).   
Munc-13 has a phorbolester (PMA) binding domain (C1) and two calcium 
binding C2 domains that flank the MUN domain. Munc-13 acts as a positive 
regulator of the SNARE complex by hindering the binding of Munc-18 to 
syntaxin 1, through regulating the activity of the Habc domain on syntaxin 1, thus 
activating the formation of SNARE complex. This process helps with synaptic 
transmission by priming the synaptic vesicles. Munc-13 can also interact with 
Rim and Doc2. Munc-13 can bind to calmodulin to form a Ca2+ sensor, which 
has been described to control short-term synaptic plasticity (Jahn and 
Fasshauer, 2012; Barclay et al., 2005; Seino and Shibasaki, 2005).  
RIM functions as the central organiser of the active zone. It contains a zinc 
finger motif and two C2 domains. RIM interacts with Rab3 once SVs have 
docked with GTP-bound Rab3. In this way, orchestrating the attachment site of 
SVs (Jahn and Fasshauer, 2012; Barclay et al., 2005; Seino and Shibasaki, 
2005).  
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1.9.3 Step 3) Ca2+-dependent triggering starts the SNARE 
engine: 
Synaptotagmins were initially named p65 but after cloning renamed as 
synaptotagmins. There are 13 isoforms of synaptotagmins and they are 
characterised by the presence of two C2 domains. This is a rigid motif with 
calcium binding loops; C2A, which binds to two calcium ions and C2B, which 
binds to three calcium ions, and are linked to each other and the membrane by 
flexible linkers. In the presence of Ca2+, the C2 domains interact with acidic 
phospholipid enriched membranes. The binding of synaptotagmin to syntaxin or 
syntaxin-bound SNARE complex occurs via C2 domains (Jahn and Fasshauer, 
2012; Barclay et al., 2005; Seino and Shibasaki, 2005).    
Calmodulin (CaM) is a Ca2+ effector protein with two EF-hand domains on both 
its N and C terminals connected to each other by a short linker region. Each of 
the EF domains bind to Ca2+ with low affinities. The basic function of calmodulin 
is to exert regulatory effects of Ca2+. Even though calmodulin has 4 Ca2+- 
binding sites, the cytosolic calcium level rarely saturates these sites. However, 
fluctuation of cytosolic Ca2+ levels can also lead to competitive binding of CaM 
to its targets. The major targets of CaM are CaMKII (Ca2+/CaM-dependent 
protein kinase type II) and calcineurin (CaN).  
CaMKII is a serine/ threonine kinase mainly found in neurons, it plays an 
essential role in synaptic function, synaptic plasticity and memory consolidation.  
Its activity was first described by Schulman and Greengard in the late 1970s. In 
mammals, it is encoded by genes a, b, g and d. The former two isozymes are 
abundantly expressed in neurons. Each of these isozymes produce multiple 
splice variants. CaMKII is made up of 12 monomers, each derived from either of 
the four genes. Each of these monomers asS.E.M.ble to form the haloenzyme 
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which gives rise to numerous combinations for the haloenzyme structure. Each 
of the homomers can form dodecamers each of which can bind to CaM. In its 
basal state, it is inactive due to the action of the auto-inhibitory domain which 
causes steric block of substrate binding. Binding of Ca2+ to calmodulin results in 
alteration of the domain adjacent to it, which in turn results in a conformational 
change, leading to the activation of CaMKII. Prior to the phosphorylation of the 
exogenous substrates, the activated kinase causes the intersubunit to undergo 
rapid autophosphorylation at a site located within the autoinhibitory domain at 
Thr286. This step has three important functions: a) promotes the binding of 
CaMKII with PSD, partly through its interaction with NMDA receptor b) it 
decreases the dissociation rate of Ca2+ CaM at the post-synaptic membrane c) 
retaining a substantial kinase activity even after the dissociation of Ca2+ -CaM. 
Thus, a sustained CaMKII activity is achieved independent of the action of Ca2+ 
and CaM, and persists till the appropriate protein phosphatase 
dephosphorylates Thr286. The binding of PSD-CaMKII can be modulated by 
action of protein phosphatase 1 (PP1) (Shifman et al., 2006; Griffith, 2004; Liu 
and Murray, 2012; Ghosh and Giese, 2015; Barclay et al., 2005; Seino and 
Shibasaki, 2005; Soderling, and Derkach, 2000).   
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Protein phosphatases play a major role in signal transduction pathways. They 
functionally counteract protein kinases. In mammalian cells the major serine/ 
threonine phosphatase catalytic subunits consist of four forms namely PP1 
(protein phosphatase 1), PP2A (protein phosphatase 2A), PP2B (protein 
phosphatase 2B (CaN)) and PP2C (protein phosphatase 2C). They are 
classified so based on their substrate specificity, dependence on metal ions and 
sensitivity to inhibitory agents. PP1 and PP2A are not dependent on any 
divalent cations while PP2B and PP2C are Ca2+ and Mg2+ dependent 
respectively. PP1, PP2A and PP2B share the homologous catalytic subunits 
and are complexed with one or more regulatory subunits. PP2C is found in 
minor amounts in tissues (Hugh et al., 2006; Yamamato et al., (1999)).   
CaN is formed of two subunits; CaNA (60 kDa) and CaNB (20 kDa) (Fraga, et 
al., 2010). CaNA forms the CaM-binding catalytic subunit while CaNB forms the 
regulatory Ca2+ -binding subunit. The catalytic subunit contains some 
phosphatase activity. It has a unique domain structure which distinguishes it 
from other phosphatases; a catalytic domain in N-terminal half, a regulatory part 
consisting of a CaNB-binding domain and a CaM-binding domain, an 
autoinhibitory domain. The CaNB subunit binds tightly to subunit A and 
activates it. The CaNB subunit is formed of four EF-hand Ca2+ -binding motifs. 
CaN regulates the Ca2+ signalling pathways indirectly through the action of 
other signalling proteins and also helps in regulating intracellular Ca2+ channels 
which are located in different subcellular Ca2+ stores. CaN also regulates the 
activity of dynamins (Fraga, et al., (2010)).   
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PKCs are a large family of multi gene protein serine/threonine kinases that sit at 
the crossroads of various signal transduction pathways and their role has been 
implicated in various cellular functions. Previously it was thought that activation 
of PKC enzymes was through proteolysis, however, experiments with tumour 
promoting-PMA has helped in the identification of 15 PKC isoenzymes. These 
15 isoenzymes can be classified into three groups based on their structure and 
cofactor regulation; conventional, novel and atypical. , I, II and  belong to 
the conventional isoforms while , ,  and  belong to the novel isoforms and 
Mζ and ι/λ refer to the atypical isoforms. Irrespective of the disparity between 
these isoforms the term PKC refers to the entire family. Like all other kinases, 
PKC has a regulatory and catalytic subunit. The catalytic subunit contains a 
highly conserved domain which consists of ATP/substrate-binding and catalysis 
motifs. The regulatory domain helps maintain the inactive conformation of the 
enzyme. The domain structure of the isoforms has been shown in figure 1.9. 
cPKCs are activated by the action of DAG and calcium. Hydrolysis of PIP2 
(phosphatidylinositol 4,5 biphosphate) by PLC (phospholipase C) forms DAG 
and IP3 (inositol 1,4,5-triphosphate). IP3 then diffused through the cell and 
binds to IP3-sensitive Ca2+ channels located in the ER, thereby increasing the 
cytosolic calcium levels. cPKCs then bind to these calcium ions which mediate 
its translocation to the cell membrane aiding its interaction with DAG through 
the C1 domain. The resulting conformational change brings about the 
phosphorylation of its substrates. nPKCs are activated by the action of DAG 
only. The C1 domains of nPKCs have a higher affinity for DAG than cPKCs thus 
allowing their direct recruitment to the membrane. Activation of aPKCs is 
independent of the action of calcium and DAG, such aPKCs are activated by 
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lipid metabolite second messengers (Wu-Zhang and Newton, 2013, Mochly-
Rosen et al., 2012; Khalil, 2010; Steinberg, 2008). 
 
Figure 1.9 Domain structure of PKC isoforms.  (Steinberg, 2008) Top: PKCs 
contain a conserved domain structure (shown in teal) and more variable 
regulatory domains. All the regulatory domains contain a pseudosubstrate motif, 
depicted in green, NH2 terminal to the C1 domain (shown in pink). The C1 
domains, shown in orange, function as sensors for PMA/ DAG in cPKCs and 
nPKCs. The C1 domain in aPKCs does not bind to DAG nor PMA. C2 domains, 
shown in yellow act as calcium-dependent phospholipid binding sites in cPKCs. 
nPKCs have a C2 domain which does not bind to calcium. The PKC-C2-like 
domains a phosphotyrosine binding module. The grey regions shown above are 
the variable regions.  
Bottom: ribbon diagrams of the domains.   
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1.10 cAMP-dependent Protein Kinase A (PKA) 
cAMP is known as a universal secondary messenger that plays a major role in 
cellular responses to extracellular signals. It regulates a range of biological 
activity for example controlling axon guidance, axonal regeneration, sensory 
function and memory. Adenyl cyclases when activated by G protein-coupled 
receptors coupled to Gs produce cAMP (Sieburth and Wang, 2013). The 
molecular targets for cAMP are PKA, cAMP-GEF/EPAC, CNG and HCN 
channels (Seino and Shibasaki 2005).   
PKA is an enzyme which plays a major role in neuronal processes like learning 
and memory, synaptic plasticity and regulation of neuronal excitability (Zhong et 
al., 2009) It was amongst the first kinases to be characterised. PKA is a 
heterotetrameric protein consisting of two identical regulatory subunits and two 
catalytic subunits (Seino and Shibasaki 2005). PKA isozymes are encoded by 
four genes for regulatory subunit (RI, RI, RII and RII) and four genes for 
the catalytic subunit (C, C, C and PrKX). The regulatory subunits can form 
homodimers and heterodimers, which adds to the molecular diversity of PKA. A-
kinase anchoring proteins (AKAPs) mediate the localisation and specificity of 
PKA. The inactive holoenzyme is a R2C2 tetramer. The regulatory subunits 
contain a phosphate binding cassette which binds to cAMP cooperatively on 
two sites A and B, in the inactive form the catalytic subunit inhibit this 
interaction.  In the inactive form, only site B is exposed for cAMP binding. On 
stimulation, cAMP binds to site B on both the regulatory subunits thereby 
inducing the binding of cAMP with the A site on both the regulatory subunits. 
Thus, the binding of four cAMP molecules results in a conformational change 
and dissociation into a regulatory subunit dimer with 4 bound cAMP molecules 
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and two catalytic monomers which in turn are catalytically active, thereby 
causing the phosphorylation of its substrates (Seino and Shibasaki, 2005).    
Turner et al., (1999) have suggested that protein phosphorylation plays an 
important role in in synaptic plasticity. Thus, modulating the action of various 
protein phosphatases and kinases can alter neurotransmitter release.  For 
example, Nagy et al., (2002) have shown that phosphorylation of SNARE 
SNAP-25 at Ser187 expedites vesicle recruitment and thereby modulates the 
formation of the SNARE complex and in PC12 cells this process leads to 
exocytosis (Yamamori et al., 2014; Gao et al., 2016; Kohansal-Nodehi, 2016).  
Also, Gao et al., (2016) have also shown that phosphorylation of SNAP-25 at 
Thr138 disrupts the SNARE complex and thus prevents exocytosis. Liu et al., 
(1994) have shown that dynamin is dephosphorylated by calcineurin and this 
dephosphorylation of dynamin alters its interactions with the binding proteins 
involved in endocytosis (Clayton and Cousin, 2009) Thus, it can be concluded 
that protein phosphorylation and dephosphorylation can alter neurotransmitter 
release and can also regulate mode of exocytosis (Henkel and Kornhuber, 
2001). In this study, the role of dynamins and myosin-II has been investigated in 
‘kiss-and-run’ mode of exocytosis. In addition to these proteins the action of 
various other kinases and phosphatases (for e.g. PKA, PP2A) has been 
studied. Regulation of exocytosis is fundamental to cellular signalling and is 
associated to an array of disorders like epilepsy, diabetes, asthma and 
hypertension (Sim et al., 2003). Thus, these protein phosphatases can serve as 
potential targets for treatments of these diseases (Sim et al., 2003).  
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1.11 Working hypothesis  
The mode of SV exocytosis can be regulated by the [Ca2+]i that the exocytosing 
vesicles are exposed to, and that this may be by regulating  the phosphorylation 
and/or dephosphorylation of certain proteins involved in the closure of the fusion 
pore through regulation of Ca2+- sensitive kinases and phosphatases.  
Main aim  
The main aim of this study was to determine the role of dynamins and myosin-II 
in regulation of SV exocytosis and to ascertain the role of various phosphatases 
and kinases that could mediate this process. Also, identifying the 
phosphorylation sites on dynamins under the effect of various drug treatments 
that would mediate a switch in the mode of exocytosis.    
Specific aims  
• To determine the role of PKCs in regulation of fusion pore  
• To investigate the effect of 160 µM DYN and 15 µM pitstop 2TM pre-
treatment on the mode of exocytosis.  
• To investigate the role of PKA and cAMP pathway in regulation of 
fusion pore  
• To investigate the effect of various drug treatments on bioenergetics of 
neuron.  
• Identifying the role of phosphorylation of ser774, ser778 and ser779 on 
dynamin I under the effect of various kinases and phosphatases in 
bringing about a switch in the mode of exocytosis. 
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Chapter 2 
Materials and Methods
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2.1 Introduction 
Nerve terminal depolarisation brings about influx of Ca2+ and release of 
neurotransmitter from the synaptic vesicles via KR or FF. Understanding the 
factors that determine the mode of release is important in determination of the 
synaptic function. This study aims to determine the factors that bring about a 
switch in the mode of exocytosis by using biochemical assays and molecular 
biology techniques. The biochemical part consisted of using endogenous 
glutamate release assay and FM dye release assay in combination with various 
drug treatments. One of the factors that plays a role in bringing about a switch 
in the mode of synaptic vesicle exocytosis is by post-translational modification 
of proteins namely dynamins and myosin-II through phosphorylation or 
dephosphorylation. The molecular biology part consisted of using western blot 
to decipher the phosphorylation sites on dynamin that are involved in regulating 
the switch in the mode of exocytosis. Understanding the metabolic profile of 
synaptosomes is important for studying synaptic function. For assessing this, 
mitochondrial stress test was performed using a Seahorse Xfp flux analyser by 
employing various modulators and inhibitors which helped give an insight about 
the metabolic profile of the synaptosomes. The method used for this entire 
study was established by Ashton et al., (unpublished study). 
2.2 Materials used  
Stimuli employed: 30 mM K+, 5 μM ionomycin or 1 mM 4-aminopyridine in the 
presence of 5 mM [Ca2+]e (HK5C, ION5C and 4AP5C respectively). 
Reagents used for preparing buffers:  
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For Lo: 125mM NaCl, 5mM KCl, 1mM MgCl2, 20mM Hepes and 
10mM glucose; pH 7.4 
For homogenisation buffer: 320 mM sucrose, 10 mM Hepes; pH 7.4 
For Bioenergetics buffer: 3.5 mM KCl, 120 mM NaCl, 1.3 mM CaCl2, 
0.4 mM KH2PO4, 1.2 mM Na2SO4, 2 mM MgSO4, 15 mM 
glucose, 2 mM glutamine, 1 mM pyruvate. 
For Wash Buffer: 3% dried skimmed milk powder, 1% Tween-20 in 
TBS; pH 7.4 
For blocking buffer: 3% dried skimmed milk powder, 1% Tween-20 in 
TBS; pH 7.4 
Drugs used [all dissolved in Dimethyl sulfoxide (DMSO)]: Okadaic Acid (OA) 
(0.8 µM), Cyclosporin A (Cys A)  (10 µM), Phorbol 12-myristate 13-
acetate (Ph est) (1 µM), DYN (DYN) (160 µM), Blebb (blebb) (50 
µM), KN-93 (10 µM), GO 6983 (1 µM), Pitstop2TM (15 µM), 
phenylarsine oxide (PAO) (0.1 µM), dyngo-4a (50 µM), dynole-34-2 
(20 µM), Go 6976 (1 µM), Forskolin (100 µM), 9-Cp-Ade (100 µM) KT 
5720 (2 µM), 1,9-dideoxyforskolin (100 µM), Sp-5,6-dichloro-cBIMPS 
(50 µM), rotenone/actimycin (0.5 µM), carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) (2 µM), oligomycin (2 
µM). 
Other reagents used: 1 mM NADPH, 36 mUnits of GDH, 100 µM FM 2-10 dye, 
NuPAGE sample reducing agent, NuPAGE MES SDS running buffer, 
Unstained MagicMark™ XP Western Protein Standard, Restore plus 
Western blotting stripping buffer, Supersignal West dura extended 
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duration chemiluminescence substrate, 4 mg/ml BSA, 50% solution 
of PEA (polyethyleneamine, NaOH, 1 mM advasep-7, coomassie 
protein stain, Instant Blue, Bradford’s reagent, Lithium Dodecyl 
Sulphate sample buffer, calibration buffer, Restore Western Blot 
Stripping buffer, dried skimmed milk powder, iBlot Transfer Stack 
(regular size), MagicMark™ XP Western Protein Standard, NuPAGE 
antioxidant, NuPAGE®Novex® 4-12% Bis-Tris Midi Protein Gels 
(12+2 well), Xf plate, Nicholls buffer. 
Equipment used: Tecan GENios Pro TM plate reader, motor driven 
homogeniser, Avanti J-25 centrifugation machine, PowerEase 500 
power pack, NU-PAGE gel system, iBlot® 7-Minute Blotting System, 
ChemiDoc XRS+, Seahorse Xfp analyser, non-CO2 incubator 
Antibodies used:  
Table 2.1: Pair of antibodies used with their final dilution factor 
Primary antibody 
dilution 
factor 
Secondary 
antibody 
dilution 
factor 
p-Dynamin (Ser-778) 
1:400 
Donkey anti-sheep 
HRP-conjugate 
1:5000 
p-Dynamin (Ser-774) 
1:1000 1:5000 
p-Dynamin (Ser-795) 
1:100 1:5000 
Dynamin-I (4E67) 1:1000 
Goat anti-mouse 
HRP-conjugate for 
dynamin 4E67 
1:5000 
 Dynamin I (4E67) is a mouse monoclonal antibody raised against 
amino acids 1-750 of Dynamin I of human origin (protein accession 
number: Q05193). The exact epitope recognized by this antibody has 
not been determined 
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 p-Dynamin I (Ser-774), is a sheep polyclonal antibody raised against 
Ser-774 phosphorylated Dynamin I of rat origin (protein accession 
number: P21575) 
 p-Dynamin I (Ser-778), is a sheep polyclonal antibody raised against 
Ser-778 phosphorylated Dynamin I of rat origin (protein accession 
number: P21575) 
 p-Dynamin I (Ser-795), is a goat polyclonal antibody raised against 
Ser-795 phosphorylated Dynamin I of human origin (protein accession 
number: Q05193) 
 The exact peptide sequences used to develop these polyclonal 
antibodies are considered proprietary. However, since these 
antibodies are phospho-specific, the peptide sequence for each one is 
a very short peptide surrounding the specific phosphorylated amino 
acid residue (Santacruz Biotechnology) 
2.1 Preparation of synaptosomes: 
For this study cerebrocotical synaptosomes -pinched off nerve terminals- 
prepared from adult male Wistar rats were used as a model system for studying 
synaptic release. Synaptosomes were first prepared by Whittaker and 
colleagues in the late 1950s and were instrumental in studying synaptic 
structure and its functional components (Whittaker,1965). For preparation of 
synaptosomes, one adult male Wistar rat was humanely killed by cervical 
dislocation and the cerebral cortex was extracted and placed in an isotonic 
sucrose solution (referred to here as homogenisation buffer 320 mM sucrose, 
10 mM Hepes; pH 7.4; 40C) The rat tissue was then homogenised using a 
motor driven homogeniser. The Teflon homogeniser disrupts the neurons in 
such a way that the nerve terminals can reseal themselves to form closed sacs. 
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Figure 2.1.1 Schematic representation of synaptosome formed from isolated 
nerve terminal (Wu, Opperman, Kaboord, 2012) 
 
The homogenate obtained after this initial disruption is a mix of isolated nerve 
terminals, nuclear debris, membrane fragments and myelin (Sihra, 1995). 
Hence, differential centrifugation was carried out at 1941 x g for 10 min at 40C 
to eliminate nuclear debris. The supernatant obtained was then centrifuged at 
21025 x g for 20 min at 40C. The crude pellet obtained was then suspended in 
modified Tyrodes’ buffer (referred as Lo; 125 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 20 mM Hepes, 10 mM glucose; pH 7.4) and then centrifuged again at 
21075 x g for 20 min at 40C. The crude mitochondrial/ synaptosomal pellet (P2) 
was then re-suspended in 8 ml of Lo. This synaptosomal fraction was kept 
oxygenated at 40C until aliquots were used for various measurements.   
Synaptosomes contain the complete presynatic terminal including mitochondria 
and synaptic vesicles plus some postsynaptic membrane including the 
postsynaptic density. Synaptosomes serve as a good model to study synaptic 
function because they represent a quasi in vitro model for neurotransmitter 
release as they contain functional ion channels, receptors enzymes and 
proteins (Atlas, 2014). 
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Figure 2.1.2 Schematic representation of the steps undertaken for preparation 
of synaptosomes. 
 
2.2. The measurement of the release of 
endogenous glutamate 
Aliquots (2ml) of synaptosomes suspension were centrifuged (9589 x g for 45 
sec) and resuspended in 1 ml of Lo buffer at room temperature (RT). The 
synaptosomes were then stimulated for 90 sec at this temperature by adding 
275 µl high potassium buffer (referred here as HK5C); 130 mM K+ and 25mM 
[Ca2+]e plus 1 mM MgCl2, 20mM Hepes): the final concentration was 30 mM K
+ 
and 5mM [Ca2+]e. This step induces the exocytosis of all releasable vesicles. 
The synaptosomes were then centrifuged, resuspended in Lo buffer and 
incubated at RT for 10min. These steps were performed to make the GLU 
assay comparable to the FM 2-10 dye release assay. The required drug or 
equivalent amount of solvent was then added to the synaptosomal suspension 
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for 5-10 min at 370C. The synaptosomes were centrifuged, resuspended in 1ml 
Lo at RT and centrifuged again. Finally, the synaptosomes were resuspended in 
1.6 ml of Lo that contained the relevant amount of drug or solvent. The drug 
was always included in the final resuspension unless it was found to interfere 
with the actual assay (either the GLU or FM dye release assay) in which case it 
was not added back: the drugs not added back were DYN, Blebb, dyngo and 
pitstop2TM. 
121 µl aliquots of the synaptosomal suspension together with 20 µl of Lo was 
added to a row of wells (12 samples) of a 96 well black microtitre plate with a 
transparent bottom. 10 µl of 20mM NADP+ (final concentration of 1mM) and 9 µl 
of glutamate dehydrogenase type II (GDH: E.C. 1.4.13) (4 mUnits) was then 
added and these wells were incubated for 10 min at RT. GLU released from 
synaptosomes incubated in the physiological buffer medium containing GDH 
and NADP+ will react with the enzyme to produce ɑ-ketoglutarate and at the 
same time NADP+ gets converted to NADPH: it is the latter compound that is 
detected fluorometrically. During this initial 10 min incubation, any GLU present 
in the extracellular buffer (prior to stimulation) will react and produce a 
background fluorescence. This background fluorescence can be subtracted so 
that upon evoked GLU release the fluorescence increase can be determined. 
This GLU assay can detect release within seconds and provides a rapid real-
time detection of GLU (Nicolls and Sihra, 1987).  After the initial 10 min 
incubation period, wells 1-5 were treated with the relevant stimulus with 5 mM 
Ca2+ (40µl of HK5C or ION5C or 4AP5C) whilst 40 µl of the corresponding 
stimulus without Ca2+ (HK0 or 4AP0 or Lo) was added to wells 6-12. The 
endogenous GLU release was measured using the Tecan Genios ProTM plate 
reader. The settings used were excitation wavelength (λ) 340 nm, emission 
 53 
wavelength (λ) 465 nm, gain was 70 (this represents the required setting for 
sufficient assay sensitivity. The machine was set for 21 cycles which means that 
each individual well (wells 1-9) was read and then this was repeated 20 more 
times: this number of cycles was sufficient to detect all the evoked GLU release. 
The machine was set so that the plate was shaken for 3 sec before the wells 
were measured, and between cycles the plate was shaken for 1 sec. Following 
these measurements, 10 µl of buffer was added to wells 7-9 and 10 µl of 1mM 
GLU (freshly prepared from 679mM stock glutamate) was added to wells 10-12. 
The change in fluorescence upon the addition of this amount of GLU (10 nmol) 
was measured using the same settings for 15 cycles for wells 7-12. This was 
actually an excess time period for measurement since normally all the 10 nmol 
of GLU had been detected and produced a maximal fluorescence after about 8 
cycles. GLU release obtained from wells 1-5 and 6-9 were averaged and the 
latter value subtracted from the former to provide a measure of the amount of 
evoked GLU release from the synaptosomes. This was in abritrary flourescent 
units (AFU).  The AFU measured upon the addition of 10 nmol GLU enables 
one to convert the release data from AFU to nmol of GLU released. 
Futhermore, as 10 nmol GLU was added after the measurement of each row of 
the microtitre plate (different treatments for the synaptosomes) this quantity of 
fluorescence could be used to correct for the sensitivity of the assay in each row 
(this can vary slightly between rows). Such normalization of the data allows 
direct comparisons between rows representing different conditions within the 
same experiment and this can also be utilized between different experiments to 
ensure all samples measured are corrected to similar sensitivity. A schematic 
representation of this has been shown in Figure 2.2.2 (A).  
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Figure 2.2.1 Schematic representation of the order in which samples were 
added to the microtiter plate for this assay (see below for further explanation). 
The order for drug treated and control rows was shuffled in a cyclic manner for 
independent experiments. In order to ensure that every drug was averaged for 
the response to the same age of synaptosomes (from time of preparation).  
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For double drug treatments for e.g for Go 6983 and DYN. The protocol slightly 
differs in the usual way that there are two sequential 5 min 37oC pre-treatments 
with drugs. This was designed to use the first 5 min period to add a drug on its 
pathway (e.g. inhibition of PKCs with Go 6983) prior to a second 5 min period 
when there is an addition of drugs that act on, in this example on, dynamins. 
Obviously, as a control the first 5 min incubation period would just have solvent 
added and for the total control, relevant amounts of solvent would be added 
during the first and the second incubation period. Note that Go 6983 is 
incubated with the synaptosomes for 10 mins at 370C and the results for this 
drug alone include the addition of an amount of solvent equivalent to the 
addition of the other drug during the second 5 min incubation period and this 
has been and this has been schematically represented in the figure 2.2.2.(B). 
For chapter 4, a slightly different protocol was followed wherein the 
synaptosomes were treated with DYN or pitstop 2 or a mixture of both the drugs 
prior to pre-stimulation with HK5C and this has been schematically represented 
in the figure 2.2.2 (C). 
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Figure 2.2.2 General schematic representation of the sample preparation 
timeline to study the effect of (A) treatment with various drugs; or (B) treatment 
with combination of two drugs; or (C) treatment with combination of two drugs 
before the pre-stimulation step; on evoked Glu by the stimulus of interest. 
Please note that in experiments involving double drug treatments, all the 
experiments performed as in (B) were performed with treatment of drugs in 
series (i.e. in two series of steps), whereas, for those in (C), this double drug 
treatment was performed in a single step.  
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2.3 FM 2-10 dye release assay 
1 ml of synaptosomes were gassed with O2 at RT for 15 min at RT and 
subsequently centrifuged (see section 2.2) and resuspended in 1 ml of Lo buffer 
at RT (Final volume is 1.1 ml as the pellet has some volume). 2.2 l of 50 mM 
FM 2-10 dye was then added (final concentration 100 M) and following a 60 
sec incubation 275 l of buffer containing 130 mM K+ and 25 mM Ca2+ (plus 1 
mM Mg2+ and 20 mM Hepes) was added (to give a final concentration of 30 K+ 
and 5 mM Ca2+) and synaptosomes were incubated for a further 90 sec at RT. 
This step ensures exocytosis of all releasable SVs and their subsequent 
labelling with FM 2-10 dye. The synaptosomes were then centrifuged and 
resuspended in 1 ml Lo containing 100 M FM 2-10 dye and incubated for 10 
min at RT: this step ensures that all recycled SVs have FM dye bound to their 
luminal domain. Subsequently, the synaptosomes were incubated for 5-10 min 
at 37oC with the desired drug or equivalent amount of solvent. 4 l of 250 mM 
advasep-7 (1 mM final concentration) was then added to the synaptosomes 
before their centrifugation.  Advasep-7 serves as a soluble high affinity 
scavenger for FM dye and this reduces the background fluorescence. Indeed, it 
has a higher affinity for FM dye than the dye has for membranes and so 
advasep-7 strips dye from the plasma membrane. However, the seven negative 
charges on this molecule make it membrane impermeable, so this drug cannot 
remove dye from the internalized SVs (Kay et. al., 2007). The synaptosomes 
were then washed by centrifugation and resuspension to ensure the removal of 
most of the plasma membrane bound dye and finally the terminals were 
resuspended in 1.5 ml of Lo buffer containing the appropriate concentration of 
the relevant drug or solvent. In some cases, the drug was not included in the 
final resuspension (see 2.2). 160 l aliquots of this suspension were added to 
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wells 1-8 of a black micotitre plate which had a black bottom. The 
measurements were taken using a Tecan Genios ProTM plate reader.  The 
settings used were excitation wavelength (λ) 485 nm, emission wavelength (λ) 
555 nm, gain was 40 (this represents the required setting for sufficient assay 
sensitivity). The machine was set for 461 cycles which means that each 
individual well was read 461 times which took 120 sec: this number of cycles 
was sufficient to detect all the evoked FM2-10 dye release. In this assay, the 
actual machine injected 40 l of the stimulus or the basal buffer into the well (so 
final volume in well was 200 l). Prior to any measurements, the two injectors in 
the plate reader were primed: one contained the relevant stimulus and the other 
contained Lo. Four wells were then injected with the stimulus and four wells 
were injected with the basal buffer. Each well was measured separately 
following the 40 l injection. This process was then repeated using another row 
of the micotitre plate following the preparation of dye loaded drug treated 
synaptosomes. Each condition was repeated twice in the same experiment. 
One row had the stimulation added to wells 1-4 and Lo added to wells 5-8 but 
on the second repeat of the condition Lo was injected into wells 1-4 and the 
stimulus added to wells 5-8. This ensured that the age of the synaptosomes 
(since first made) was taken into account and no artifacts were created from 
such a factor. When the experiment was repeated the order of the various drug 
treatment was changed again to counteract the age of the synaptosomes from 
when they were first prepared.  To determine the specific FM2-10 dye evoked 
released, the corrected average data from basal samples was subtracted from 
the corrected average data from stimulated samples. Prior to this all individual 
wells were corrected such that they had the same starting value of FM 2-10 dye 
fluorescence. This normalization procedure ensured that all experiments were 
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directly comparable. A schematic representation of this has been shown in 
Figure 2.3.2 (A).  
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Figure 2.3.1 Schematic representation of the order in which samples were 
added to the microtiter plate for this assay and has been explained above. The 
order for drug treated and control rows was shuffled in a cyclic manner for 
independent experiments.   
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For double drug treatments with FM 2-10 dye release assay the protocol 
followed was similar to the protocol followed for double drug treatment for 
glutamate release assay as shown in Figure 3.2.2 (B). 
 
 
 
Figure 2.3.2 General schematic representation of the sample preparation 
timeline to study the effect of (A) treatment with various drugs; or (B) treatment 
with combination of two drugs; on FM2-10 dye release by the stimulus of 
interest.  
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2.4 Statistical analysis 
The results presented are the average of several independent experiments (n). 
All basal values from such multiple experiments were averaged as were all the 
stimulated values. Then average basal value was subtracted from average 
stimulated values, the statistical analysis was performed using Microsoft Excel 
and GraphPad Prism software. The values were statistically analysed by 
comparing control and test values using unpaired student’s t-test. p<0.05 was 
considered as significant. The results were presented in a graphical format as a 
percentage of maximum control. For ease of presentation, selective data points 
at an interval of 10 sec have been shown, wherein the error bar indicates the 
standard error of mean (S.E.M). In chapters 3-7, ‘n’ if shown in the figures as 
part of the results includes replicates of the same experiment while ‘n’ 
represented below the figures as part of the legend indicates the number of 
independent experiments, the latter in this study is 3 unless stated otherwise. 
Also, the control in this entire thesis indicates non-drug treated synaptosomes 
unless stated otherwise. It should be noted that for all the 4AP5C experiments 
the error bars seem larger but this is simply because 4AP5C only induces the 
release of the RRP and so this is a smaller amount of Glu release but we have 
shown the figures as a percentage of the maximal control release induced by 
4AP5C, unless stated otherwise. 
2.5 Bioenergetics assay (mitochondrial stress 
test) 
Mitochondrial respiratory activity of synaptosomes via direct measurement of 
oxygen consumption rate can be monitored using Seahorse Xf Cell Mito Stress 
test. The parameters measured are through injection of various modulators and 
inhibitors which target the electron transport chain thereby measuring basal 
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respiration, ATP production, maximal respiration, proton leakage and spare 
capacity.   
Synaptosomes (P2 pellet) obtained by the aforementioned method were 
suspended in 4.5 ml of Lo buffer. 0.02 ml aliquot of synaptosomes were then 
centrifuged at 9589 x g for 45 sec. The synaptosomal pellet obtained was then 
resuspended in 1.2 ml bioenergetics buffer (3.5 mM KCl, 120 mM NaCl, 1.3 mM 
CaCl2, 0.4 mM KH2PO4, 1.2 mM Na2SO4, 2 mM MgSO4, 15 mM glucose, 2 mM 
glutamine, 1 mM pyruvate) plus 4 mg/ml of bovine serum albumin at 4°C. There 
is no buffer present in this solution as proton production would not be 
measurable in presence of a buffer. The pH of this solution was adjusted with a 
small amount of NaOH (the pH of the solution was adjusted as the synaptomes 
are acclimatized to a neutral pH and any change in pH would cause a change in 
the metabolic profile). The synaptosomes were initially suspended in Lo buffer 
but it was later observed that the in the later steps synaptosomes did not 
adhere to the plate hence Nicholls buffer was preferred over Lo buffer. This 
buffer was employed because it is the one that has been characterized for use 
with synaptosomes and the Seahorse Xfp analyser (Brand and Nicholls, 2011).  
  
 64 
 
Figure 2.5.1 Schematic representation of the Xfp utility plate and cartridge. This 
asS.E.M.bly is also supplied with a clear lid which is placed on top of the 
sensory cartridge which is removed during measurements. 
 
6 x 0.175 ml aliquots of the synaptosomal suspension were added to wells B-G 
of the Xf plate. Wells B-D act as the experimental wells while wells E-G act as 
the control wells. Wells A and H act as background wells. The purpose of the 
background wells is to filter out artefacts, such as temperature and buffering 
capacity that affect the oxygen and pH (changes not due to metabolic activity of 
the synaptosomes). Also, they serve as a starting point for troubleshooting the 
assay with unexpected results, to point out changes due to temperature 
fluctuations or potential thermal problems. Moat chambers prevent evaporation 
when the plate is incubated in a non-CO2 incubator at 37
0C overnight (explained 
below) or when running the assay 
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Figure 2.5.2 Schematic representation of the top of the sensory cartridge 
showing the drug ports. Port A loaded with optimised concentration of 
oligomycin, Port B: loaded with optimised concentration of FCCP. Port C loaded 
with optimised concentration of Actimycin A/ Rotenone (Seahorse manual). 
 
A day prior to running the assay, wells A-H of two utility plates were pretreated 
with 1:1500 of 50% solution of PEA (polyethyleneamine) and incubated at room 
temperature. This helps the synaptosomes adhere to the bottom of the plates. 
The solution was then removed and the plates were allowed to dry. The sensor 
probes were hydrated by adding 200 µl of calibration buffer to wells A-H (PBS, 
pH 7.4, supplied by Seahorse Biosciences). 400 µl of calibration buffer was 
added to the moat chambers. The cartridge was then placed over the utility 
plate and the entire asS.E.M.bly was then placed in a sealed box with moist 
paper towels (to prevent evaporation) and then placed in a non-CO2 incubator 
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at 370C overnight. After the sensor probes were hydrated (on the day of the 
assay) keeping the cartridge in the utility plate for one of the cartridges the drug 
ports are loaded with the relevant drug concentrations of oligomycin, FCCP, 
actimycin A/ rotenone in the relevant port. This entire asS.E.M.bly was then 
placed in the Seahorse Xfp Flux analyzer and allowed to equilibrate at 370C for 
12 min.  After the equilibration was done, the sensor cartridge was placed on 
the other utility plate which contained the adhered drug treated synaptosomes. 
These were prepared as outlined next.  
After the synaptosomes were aliquoted onto the utility plate pretreated with 
PEA, the synaptosomes on the plate were centrifuged at 2000 X g for 20 min at 
40C. This was done to adhere the synaptosomes to the plate. Wells A and H 
have no synaptosomes aliquoted into them. The supernatant from the wells was 
discarded. 0.2 ml of bioenergetics buffer (370C) containing the relevant drugs or 
DMSO was added to wells B-G. The synaptosomes were incubated for 5 min at 
370C. The solution was then decanted and 0.175 ml of fresh bioenergetics 
buffer containing BSA (370C) was added. These samples were added to the 
sensor cartridge that had been equilibrating in the analyzer washed with such 
buffer before the final buffer addition. The relevant programme was then used to 
measure:  
a) 3 x 3 min measurements of basal oxygen consumption and proton 
production;  
b) following the automatic injection of 0.025 ml of 16 µM oligomycin from 
port A to all wells, 3 x 3 min measurements of oxygen consumption and 
proton production (final concentration of oligomycin is 2 µM)  
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c) following the automatic injection of 0.025 ml of 18 µM FCCP from port B 
to all wells, 3 x 3 min measurements of oxygen consumption and proton 
production (final concentration of FCCP is 2 µM)  
d) following the automatic injection of 0.025 ml of 5 µM of rotenone/ 
actimycin A from port C to all wells, 3 x 3 min measurements of oxygen 
consumption and proton production (final concentration of rotenone/ 
actimycin A is 0.5 µM)  
e) The machine converts all the data from changes in oxygen consumption 
or proton production into plots and rates. This data was analyzed using 
wave 2 software 
2.6 Statistical analysis  
The results presented are the average of 2-3 independent set of experiments 
(n). The data was analyzed using wave 2 software and Microsoft Excel. The 
Mito stress test report generator automatically calculates the key metrics that 
determine the mitochondrial function of each group. The key metrics are spare 
respiratory capacity, coupling efficiency, basal response, ETC accelerator 
response and ATP coupler response. It gives a graphical representation of the 
data which is then exported to MS Excel where the error bars represent SD. 
The control and the experimental group values obtained were analyzed using 
unpaired student’s t-test. p<0.05 was considered significant. From the raw data, 
we can average several experiments. As the machine does 3 x 3 min 
measurements we can average all these data points or we can average those 
that represent either the maximum or minimum vales (depending on the port 
addition). We can manually determine from such multiple experiments; a) basal 
bioenergetics; b) maximal respiratory capacity; c) spare respiratory capacity; d) 
proton leakage; e) non-mitochondrial respiration. 
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2.7 Western blotting 
2.7.1 Sample preparation 
The first step in western blotting workflow is sample preparation which sets the 
foundation for the quality of results. The initial steps for sample preparation 
were carried out in the same manner as described in section 2.1. After which 
the synaptosomes were treated with the drug or DMSO for 5-10 mins at 370C 
and suspended in 1 ml Lo then centrifuged at 9589 x g for 45 sec (as described 
in glutamate assay). The synaptosomes were re-suspended in 225 µl of Lo 
buffer plus the relevant amount of drug or DMSO (except for DYN, Blebb, 
dyngo, pitstop). 25 µl aliquot from this suspension was used to determine the 
protein concentration of the sample using Bradford assay and the remaining 
200 µl was used for sample preparation. This 200 µl suspension was distributed 
as 2 x 100 µl aliquots, one of which was treated with the required stimulus and 
the other with Lo buffer. Depending the conditions being tested, the stimulation 
was applied for either 2, 15, 30 or 300 sec (these stimulation periods were 
chosen as RRP exocytoses in 2 sec, the changes produced at 15 sec represent 
the cellular processes preparing dynamin I for endocytic processes e.g. CME, 
the changes produced at 30 sec would represent the dephosphorylation 
changes  that lead biochemical interactions which are preparing dynamin I to 
contribute to CME and since we measure FM dye release for about 5 min 
changes produced at 300 sec would help in comparison) was immediately after 
which 1X NuPAGE LDS (lithium dodecyl sulphate) sample buffer and 1X 
dithiothreitol were added to solublise the proteins and reduce the di-sulphide 
bridges. The same process was carried out for the non-stimulated samples in 
which L0 was added for the various time points. 1X NuPAGE LDS sample 
buffer and 1X dithiothreitol were added. The samples were then vortexed using 
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a bench top vortex mixer and heated at 700C for 10 min. The samples were 
then stored at -200C. The desired final protein concentration was 1.5 mg/ml and 
the samples were diluted depending on the results obtained from the Bradford 
assay. 
2.7.2 Electrophoresis 
Prior to each electrophoresis run, the samples were re-heated for 10 min at 
700C. To separate the proteins based on molecular weight, Novex NuPAGE 
SDS-PAGE gel system with NuPAGE Novex 4-12% Bis-Tris Midi Protein Gels 
(12+2 wells) were used.  The gel tank components were asS.E.M.bled and 1X 
NuPAGE MES SDS buffer was used as running buffer and checked for leakage. 
Then 45 µl of the relevant sample (67.5 µg protein) was loaded in to each of the 
sample wells. For the two marker lanes, either 7 µl of diluted MagicMark XP 
western protein standard (dilution 1:7) or 7 µl of Novel sharp unstained protein 
standard was loaded depending if the latter process was to carry out western 
blotting or to carry out coomassie protein stain. After loading the gels, the lid 
was placed on the tank and the asS.E.M.bly was connected to the PowerEase 
500 power pack and the relevant settings were chosen. Electrophoresis was 
carried out at 120 mA (constant current). The gels were electrophoresed for 1 
hour and 20 min.   
This gel system was preferred as LDS sample buffer minimises the Asp-Pro 
cleavage and when LDS containing samples are heated to 700C the pH 
changes to 8 from 8.5, which serves as an ideal condition for protein reduction, 
alkylation and also helps in preserving the protein integrity. The precast gels 
give a good separation of proteins and also employ a neutral pH thereby 
minimising protein modifications. Also, this gel system reduces the sample run 
time. (Invitrogen)   
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After the electrophoresis run was complete, either protein staining or western 
blotting (described below) was carried out. For coomassie protein staining, 
InstantBlue was used. The gel was incubated with this stain for 15 min and the 
bands were visualised using ChemiDoc XRS+. This stain gave better signal to 
noise ratio and hence was preferred over other protein stains. 
2.7.3 Western blotting 
For carrying out western blotting iBlot 7-Minute Blotting system was used which 
consisted of iBlot Gel Transfer Device and iBlot Gel Transfer Stacks. After the 
electrophoresis was complete the gel was placed on a PVDF membrane 
(polyvinylidene fluoride) and the transfer stacks were layered to perform blotting 
of proteins. The transfer stacks function as ion reservoirs that contain the anode 
and cathode buffers incorporated into the gel matrix thereby eliminating the 
need for pre-made buffers. The stacks also contain the electrodes. The 
asS.E.M.bly was placed on the blotting surface of the transfer device and P3 
program was selected. The transfer device helps in efficient transfer of proteins 
onto the PVDF membrane in 7 minutes thus providing a quick method for 
performing western blotting. After the transfer was complete the PVDF 
membrane was blocked using 30 ml of blocking buffer (3% dried skimmed milk 
powder, 1% Tween-20 in TBS; pH 7.4) for 60 min at RT.  This blocking step 
helps enhance the specific signal for antigen-antibody interaction while 
decreasing the background noise ratio. After this incubation step, blocking 
buffer was drained and the membrane was incubated with the 5ml of primary 
antibody solution (appropriate primary antibody concentration, 1% dried 
skimmed milk powder,1% Tween-20 in TBS) for 30 min at RT and for 30 min at 
370C. The antibody solution was then removed and the blot was washed 6 
times with an interval of 5 min between the washes using 25 ml of wash buffer 
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for each wash (0.05% Tween-20, 25mM Trizma base, 0.15M NaCl; pH 7.3-7.4). 
The wash buffer was drained and the membrane was incubated with the 5ml of 
secondary antibody solution (appropriate secondary antibody concentration, 1% 
dried skimmed milk powder, 1% Tween-20 in TBS) for 30 min at RT and for 30 
min at 370C. The antibody solution was removed and the blot was washed 6 
times with an interval of 5 min between the washes using 25 ml of wash buffer 
for each wash. After this step, the membrane was incubated with 3 ml of 
SuperSignal west dura chemiluminescent substrate for 5 min. The PVDF 
membrane was then visualised using ChemiDoc XRS+ image lab software. 
2.7.4 Re-probing / stripping the PVDF membrane 
After visualising the membrane, the membrane was washed 3 times using 25 ml 
of wash buffer with an interval of 5 minutes in between the washes. After 
washing the membrane, the wash buffer was drained and the membrane was 
incubated with 15 ml of Restore Western Blot Stripping buffer at RT. After the 
incubation, the membrane was washed 4 times using was 25 ml of wash buffer 
with an interval of 5 minutes in between the washes. The wash buffer was then 
drained and the membrane was then incubated with the desired primary 
antibody followed by washing and then incubation with the desired secondary 
antibody followed by washing again (as described above).  The membrane was 
first probed for the desired phosphorylated residue and then stripped and 
probed with dynamin-I 4e67 antibody. The stripping buffer provides efficient 
removal of chemiluminescent substrate, primary antibody and secondary 
antibody as they bind to the membrane surface and the stripping buffer 
dissociates this bond leaving the PVDF membrane intact. The stripping step 
thus helps eliminate the need to run the samples again and helps cut down the 
cost. 
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2.7.5 S.E.M.i-quantification of blots: 
For estimating the protein quantities for each visualized band on the blotted 
membranes, ChemiDoc XRS+ image lab software was used. For each 
membrane that was visualized, six images at multiple exposure times were 
taken. This was done to eliminate any error arising due to the time taken for 
each band to appear. As there were various drug treatments loaded on one gel, 
the time taken for all the bands to appear for the desired antibody may differ.  
Thus, as the exposure time was increased the band intensity showed a linear 
increase as well. However, overexposure would give a false representation of 
the true intensity of a band, so it was important to have an exposure time which 
was in the linear range of detection. Differences between gels were expressed 
to the maximum intensity lane and a correction factor was used when probing 
the equivalent phosphorylated tracks. To give a true representation of the 
amount of phosphorylation, each band for each drug treatment was compared 
to the corresponding dynamin-I 4e67 value. Dynamin-I 4e67 recognizes the 
total dynamin-I content for each band and is a good control. 
For carrying out S.E.M.i-quantification of membranes, volume analysis tool was 
used. This tool helps draw a border around each band of interest which then 
subtracts the intensity of pixels around the border (the background) from the 
intensity of pixels observed for that band. This is represented as adjusted 
internal volume. These values are then exported to Excel where each band is 
expressed as a percentage of a particular selected band (control basal band). 
This gives a relative quantity of amount of protein present. The value obtained 
for each band was then compared to dynamin-I 4e67 value and thus expressed 
as a ratio. For each drug treatment, the value obtained for the stimulated 
sample was compared to the unstimulated control of the same drug treatment 
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and expressed as a percentage which was then represented as a histogram 
plot.   
This process was repeated for 2-3 independent experiments and the values 
obtained were averaged together and represented as a histogram plot with the 
error bars representing standard error of mean. The statistical significance was 
carried out using unpaired student t-test wherein p<0.05 was considered 
significant.  
Also, for ease of presentation only the region of the blot that contains dynamin 
is shown in the results as the rest of the blot was blank (see representative blot 
in appendix 3).  The results shown are obtained from 3 independent 
experiments unless otherwise stated. 
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Chapter 3 
Investigating the Role of 
Protein Kinase C
 75 
3.1 Background results 
3.1.1 Introduction 
Previous work in the Ashton laboratory (e.g. Dilip Bhuva PhD thesis 2014) had 
shown that in cerebrocortical synaptosomes, SVs could undergo distinct 
exocytotic modes KR or FF and that these could be switched by various 
conditions including activation/inhibition of kinases/phosphatases. Ca2+ seemed 
to be important in regulating the mode and the Ca2+ dependent kinases, CaMKII 
and PKC, have both been implicated in regulating this process. Excitingly, the 
use of specific drugs implicated some phospho-proteins as being possible 
mediators of the closure of the fusion pore that produces KR exocytosis. 
Perturbation of the activity of such proteins can lead to the pore expanding – 
instead of closing – which leads to the vesicular membrane being fully inserted 
into the plasma membrane and this represents the FF mode. 
The two phospho-proteins that appear to play a role in regulating KT were 
dynamins (1 and 2) and non-muscle myosin-II. Dynamins action was 
investigated using the drug, DYN (Macia et al. 2006) which inhibits the dynamin 
family (160 µM perturbs the action of dynamins fully in nerve terminals (shown 
ahead in this chapter). It specifically blocks the GTPase activities of dynamin-I 
and dynamin-II (Chung et al. 2010; Hosoi et al. 2009; Zhu et al. 2010) such that 
they cannot perform their normal roles. The other phospho-protein is non-
muscle myosin II (Neco et al., 2008; Chandrasekar et al., 2013) whose action 
can be inhibited using 50 µM Blebb (e.g. Chandrasekar et al., 2013. 
This introduction aims to provide the rationale behind this study. This chapter 
includes some figures that summarize the results obtained with DYN (Figure 3.1 
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and 3.2) and Blebb (Figure 3.3 and 3.4). Such results help explain the premise 
behind many of the experiments carried out in this chapter. Figure 3.1-3.4 are 
background results but these experiments were performed again depending on 
the experiment, this was done to for maintaining controls for the experiments. 
In order to understand the results, herein, it is necessary to just remind the 
reader of what comparison between evoked Glu release and FM2-10 dye 
release reveals. FM 2-10 dye will only be maximally released from the 
preloaded SVs if the SV undergoes the FF mode of exocytosis. This is because, 
the disassociation of FM2-10 dye from the fused SV lipid membrane requires 
more time which can only occur during FF mode of exocytosis. The 
fluorescence of FM 2-10 dye decreases 20-fold when it is released into the 
extracellular matrix. Thus, there will be decrease in fluorescence of FM2-10 dye 
only when SV undergoes FF mode of exocytosis, and not when undergoing KR. 
On the other hand, the glutamate can be fully and quickly released even if 
exocytosis is via a transiently open fusion pore as observed during KR. Thus, 
the release of glutamate occurs during both, KR and FF whereas the release of 
FM2-10 dye requires FF mode of exocytosis for its release (Omiatek et al., 
2010; Zhang et al., 2007). Thus, if a drug has no effect on the glutamate release 
but can affect the FM2-10 dye release, then one can say that the drug is 
affecting the mode of SV exocytosis.   
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Figure 3.1 The effect of 160 µM DYN on Glu release evoked by (A) HK5C (B) 
ION5C and (C) 4AP5C. Data are mean +S.E.M. from 5 different experiments 
(i.e. n=5). There is no significant difference between drug treated and control 
terminals.  
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Figure 3.1 demonstrates that DYN treatment (after SV recycling), under any of 
the three stimulations, had no effect on the total Glu released from the 
synaptosomes, irrespective of the SV pool. 
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Figure 3.2 The effect of 160 µM DYN on FM2-10 dye release evoked by (A) 
HK5C, (B) ION5C and (C) 4AP5C. Data are mean -S.E.M. from 5 different 
experiments (i.e. n=5). 
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Panel A of figure 3.2 shows no significant change in the FM 2-10 dye release, 
when HK5C is used as stimulus for control and DYN treated terminals. Panels B 
and C show a significant increase in FM 2-10 dye release for DYN treated 
synaptosomes when employing ION5C and 4AP5C as stimuli. 
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Figure 3.3 The effect of 50 µM Blebb on Glu release evoked by (A) HK5C, (B) 
ION5C, and (C) 4AP5C. Data are mean +S.E.M. from 5 different experiments 
(i.e. n=5). There is no significance difference between drug treated and control 
terminals.    
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This Blebb treatment did not perturb the Glu release evoked by any of these 
stimuli and, therefore, inhibition of myosin II does not perturb the release of the 
RRP or RP of SVs.  
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Figure 3.4 The effect of 50 µM Blebb on FM2-10 dye release evoked by (A) 
HK5C, (B) ION5C and (C) 4AP5C. Data are mean -S.E.M. from 5 different 
experiments (n=5).  
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Panel A of figure 3.4 shows a significant increase in the FM 2-10 dye release for 
Blebb treated terminals compared to control when HK5C is used as stimulus. 
However, panels B and C of figure 3.4 show no change in the FM 2-10 dye 
release when control and Blebb treatment are compared for stimulation by 
ION5C or 4AP5C. 
These results confirm that myosin-II does play a role in switching the mode of 
synaptic vesicular exocytosis but only for the HK5C stimulus. 
3.1.2 Interpretation of background results 
Thus, inhibition of dynamins significantly increased the FM 2-10 dye release for 
ION5C and 4AP5C stimulation. Therefore, dynamins are required for the 
closure of the fusion pore during KR exocytosis of the RRP of SVs induced by 
these stimuli whilst such SVs are switched to FF in the absence of active 
dynamins. HK5C induces KR independently of the activity of dynamins and it 
was found that in this case myosin-II is responsible for the closure of the fusion 
pore during HK5C stimulation evoked KR release of the RRP of SVs. 
This was an interesting finding but we really wanted to know why there was 
difference in the proteins that regulated the fusion pore depending upon the 
stimulus employed. Therefore, we hypothesised that the high Ca2+ 
concentration levels induced by HK5C at the active zone enables myosin-II to 
be activated and this closes the fusion pore such that the release of the RRP 
SVs is via KR. However, ION5C and 4AP5C do not achieve these high levels of 
Ca2+ at the active zone and so myosin-II is not activated, and therefore myosin-
II plays no significant role in the fusion mode evoked by these stimuli. 
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The results also indicate that these high levels of Ca2+ - induced by HK5C - 
must inactivate dynamins otherwise, when non-muscle myosin-II is blocked, the 
dynamins could still close the fusion pore.   
3.2 Introduction to chapter 3 
As we had previously determined that various calcium dependent kinases (and 
a calcium dependent phosphatase) can regulate the mode of exocytosis, it was 
hypothesised that these same kinases may be involved in activating myosin-II 
and inactivating dynamin. Thus, in this chapter the role that PKCs may play was 
investigated by using Go 6983 (3-[1-[3-(dimethylamino)propyl]-5me-thoxy-1H-
indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole--2,5-dione) (Young et al., 2005) through 
FM 2-10 dye release assay and glutamate assay. This is a broad-spectrum 
PKC inhibitor and 1 μM Go 6983 inhibits all PKCs including the three 
categorised classes conventional, novel and atypical (Lanuza et al., 2014). 
The determination of a dynamin dependence for the mode of exocytosis of the 
RRP SVs under distinct stimulation conditions meant that it was vitally important 
to determine whether the closure of the fusion pore via dynamin exhibited 
distinct properties from other dynamin-dependent processes. It has been well 
characterized that CME has a dynamin requirement (Saheki and De Camilli, 
2012) and recently ultra-fast endocytosis has been shown to have a dynamin 
requirement (Watanabe et al., 2013). Intriguingly, although these processes are 
distinct they both depend upon clathrin action (e.g. Watanabe et al. 2014). 
Thus, if one can show that the RRP SVs exocytose independent of clathrin then 
this would suggest that the KR excoytotic mechanism described, herein, is 
distinct from these two other processes. Fortunately, a drug has been produced 
recently that specifically inhibits clathrin dependent processes by blocking the 
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terminal domain of the protein so it can no longer form productive clathrin coats. 
This drug is called Pitstop2TM (von Kleist et al., 2011). Thus, in this chapter we 
investigated whether the dynamin-dependent KR mode of RRP could be 
perturbed by blockade of clathrin processes using Pitstop2TM. 
3.3 Results 
 
Figure 3.5. The effect of 1 µM Go 6983 on Glu release evoked by HK5C. Data 
are mean + S.E.M., n= 5 different experiments. There is no significant 
difference between drug treated and control terminals. 
 
Clearly, endogenous PKCs are apparently not involved in regulating the total 
number of SVs undergoing fusion from either the RRP or the RP, since pre-
treatment with Go 6983 does not significantly decrease the amount of Glu 
released (Figure 3.5).    
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Figure 3.6 The effect of 1 µM Go 6983 on FM2-10 dye release evoked by 
HK5C. Data are mean -S.E.M., n= 3 different experiments. There is no 
significant difference between drug treated and control terminals. 
 
This result would on face value also suggest that activation of endogenous 
PKCs by the application of HK5C does not regulate the fusion mode of the RRP 
or the RP SVs. This is because there is neither more FM dye release (due to 
conversion of the RRP to FF) or less FM dye release (due to conversion of the 
RP to KR).  
The release of HK5C evoked Glu was measured following the treatment with 
both Go 6983 and Blebb (Figure. 3.7). 
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Figure. 3.7. The effect of 1 µM Go 6983 followed by 50 µM Blebb on Glu 
release evoked by HK5C. Data are mean +S.E.M., n= 3 different experiments. 
There is no significant difference between drug treated and control terminals. 
 
The double drug treatment of inhibiting endogenous PKCs and blocking myosin-
II activity fails to perturb the total number of SVs exocytosing from the RRP and 
the RP induced by the application of HK5C. Thus, we can use the same drug 
treatment to investigate whether this can regulate the modes of exocytosis of 
these SVs.  
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Figure. 3.8. The effect of 1 µM Go 6983 followed by 50 µM Blebb on FM2-10 
dye release evoked by HK5C. Data are mean -S.E.M., n=3 different 
experiments. There is no significant difference between drug treated and control 
terminals. 
 
results in Figure 3.8 (in conjunction with the results in Figure 3.7) when 
compared to Figure 3.4 clearly show that inhibition of PKCs with Go 6983 
prevents the fusion pore for RRP SVs from being regulated by myosin-II as 
Blebb no longer prevents the fusion pore closing and KR still occurs. This result 
indicates that under the double drug treatment conditions another protein must 
be able to close the fusion pore and induce KR. 
We pointed out in the introduction to this chapter that HK5C must not only 
activate myosin-II to close the fusion pore of the RRP SVs but that it must also 
inactivate the dynamins. Clearly, as inhibition of PKCs prevents myosin-II acting 
on the fusion pore (Figure 3.7 and 3.8) then it could well be that it is also the 
HK5C activated PKCs that normally inactivate dynamins. Thus, we investigated 
the effect that the double treatment with Go 6983 and DYN would have on 
HK5C evoked Glu release (Figure 3.9).    
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Figure. 3.9. The effect of 1 µM Go 6983 followed by 160 µM DYN on Glu 
release evoked by HK5C. Data are mean +S.E.M., n=3 different experiments. 
There is no significant difference between drug treated and control terminals. 
 
The double drug treatment of inhibiting endogenous PKCs and blocking 
dynamins did not prevent the SVs exocytosing from the RRP and the RP 
induced by the application of HK5C. Thus, we can use the same drug treatment 
to investigate whether this treatment can regulate the modes of exocytosis of 
such SVs.   
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Figure. 3.10. The effect of 1 µM Go 6983 followed by 160 µM DYN on FM210 
dye release evoked by HK5C. Data are mean -S.E.M. from 3 different 
experiments (i.e. n=3). There is a significant increase in the HK5C evoked FM 
2-10 dye release for Go 6983 plus DYN treated terminals compared to the non-
drug treated control. 
 
As shown in Pre-treatment with Go 6983 (inhibitor of PKCs) and DYN (inhibitor 
of Dynamin I & II) switched all of the exocytosing SVs to FF mode, including 
those belonging to RRP. From Figure 3.6 and Figure 3.8, it can be concluded 
that when PKCs and Myosin-II are inhibited, the RRP still undergoes KR. This 
means that there must be a protein involved in closure of the fusion pore of 
these RRP SVs causing them to undergo KR mode of exocytosis. From Figure 
3.10, it can be deduced that inhibition of PKCs and Dynamins causes the RRP 
vesicles to exocytose via FF mode.  
A comparison between the action of HK5C following Blebb treatment (Figure. 
3.4) and following Go 6983 plus DYN (Figure. 3.10) would suggest that there 
was an approximately equal amount of extra FM2-10 dye released compared to 
the control conditions. This represented all the RRP SVs switching to a FF 
mode. However, in view of speculation elsewhere in this thesis that the RRP 
could be heterogeneous (see Chapter 5) it was important to confirm that the Go 
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6983 -  by blocking PKCs - was able to convert the RRP SVs such that they all 
now exhibited dynamin sensitivity. In order to do this, we compared the result 
highlighted in Figure 3.10 with an experiment where we showed the dynamin 
sensitive of ION5C evoked release of the RRP of SVs (Figure 3.2). 
By comparing Figure 3.10 and Figure 3.2, it would appear that the increase in 
FM2-10 dye release following the relevant drug treatments are similar. This 
would suggest that inhibiting PKCs converts all the HK5C evoked RRP SVs so 
that the mode of exocytosis is now dynamin sensitive. 
Synaptosomes were pre-treated with 15 µM Pitstop2TM using the single drug 
addition protocol as outlined in chapter 2. This drug perturbs clathrin dependent 
processes and this enable one to investigate the role of clathrin in regulation of 
the mode of exocytosis of SVs. The terminals were evoked to release 
neurotransmitter with the usual dynamin-dependent stimulus, ION5C, as the 
purpose of this study was to investigate whether clathrin contributed to the 
dynamin-dependent closure of the fusion pore of RRP SVs during KR.  
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Figure. 3.11. The effect of 15 µM pitstop2TM on Glu release evoked by ION5C. 
Data are mean +S.E.M., n= 5 different experiments (i.e. n=5). There is no 
significant difference between drug treated and control terminals.   
 
The amount of release induced by ION5C was statistically the same in the 
control and pitstop2TM treated terminals. This indicates that the RRP and RP 
SVs both still release their Glu content by exocytosing with the presynaptic 
plasma membrane. 
Clearly, as pitstop2TM treatment did not prevent the exocytosis of the RRP and 
the RP, we were then able to determine whether such treatment perturbed the 
mode of exocytosis of these pools of SVs (Figure 3.12).     
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Figure. 3.12. The effect of 15 µM pitstop2TM on ION5C evoked FM2-10 dye 
release. Data are mean -S.E.M., n= 5 different experiments. There is no 
significant difference between drug treated and control terminals. 
 
This result would appear to suggest that the dynamin-dependent closure of the 
fusion pores of the RRP SVs that leads to KR with ION5C stimulation is not 
perturbed when clathrin activity is blocked. This would suggest that KR is 
dynamin-dependent but clathrin-independent when studied with ION5C. 
However, there remained the possibility that pitstop2TM treatment may change 
the requirements for KR independently of the dynamins as we found when 
myosin-II dependence for HK5C was switched to dynamin dependency by 
inhibition of PKCs (see above). Thus, we carried out a double drug treatment 
with Pitstop2TM and DYN to determine if the latter drug still switched the mode 
of the RRP SVs to FF (Figure 3.13 and 3.14) 
In these experiments, Pitstop2TM and DYN were added at the same time in 
single drug incubation protocol similar to the protocol followed for Figure 3.1 
except that both drugs were added at the same time.    
  
 95 
 
Figure. 3.13. The effect of 15 µM pitstop2TM plus 160 mM DYN on Glu release 
evoked by ION5C. Data are mean +S.E.M., n= 5 different experiments. There is 
no significant difference between drug treated and control terminals. 
 
The joint treatment did not affect the maximum release of Glu induced by 
ION5C which represents the RRP and the RP SVs exocytosing their 
neurotransmitter content. Thus, we were able to see whether this double 
treatment had any effect upon the mode of exocytosis of the RRP SVs (Figure 
3.14). 
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Figure. 3.14. The effect 15 µM pitstop2TM or 15 µM pitstop2TM plus 160 µM 
DYN on FM2-10 dye release evoked by ION5C. Data are mean -S.E.M. from 
experiments.  
 
It would seem that pitstop2TM did not prevent DYN from switching the mode of 
the RRP SVs to FF when ION5C is used as the stimulus. This would suggest 
that the action of dynamin on closing the fusion pore is totally independent of its 
action in a different endocytotic pathway that also involves clathrin (CME or 
ultrafast endocytosis). 
There is a significant increase in the ION5C evoked FM 2-10 dye release for 
pitstop2TM plus DYN treated terminals compared to pitstop2TM alone, results of 
three independent experiments (i.e. n=3).  
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3.4 Discussion 
3.4.1 Dynamins and Myosin-II regulate the fusion pore 
In order to investigate the role of dynamins, 160 μM DYN (DYN) was used as 
demonstrated by figure 3.1. It was found that 160 μM DYN had no effect on the 
glutamate released upon HK5C, ION5C and 4AP5C stimulations. These results 
indirectly support Ashton et al.’s unpublished data that all the three stimuli 
induce only a single round of SV release. This is because it has been confirmed 
by various studies that the dynamins are required for the clathrin-dependent 
endocytosis (Hosoi et al., 2009). If the stimuli employed induced more than one 
round of release, then a decrease in the glutamate release would be observed 
upon the inhibition of dynamins. However, the results showed that this was not 
the case thereby indicating that all three stimuli only induced a single round of 
release. 
In contrast, inhibition of dynamins significantly increased the FM 2-10 dye 
release upon ION5C and 4AP5C stimulation indicating that dynamins are 
required for the closure of the fusion pore during these stimuli and their 
inhibition would cause all the SVs undergoing KR to switch to FF mode of 
exocytosis (shown in figure 3.2). 
The role of myosin-II was assessed by specifically inhibiting it, using 50 μM 
Blebb. It was found that even though it did not affect the glutamate release 
under any of the three stimuli (Figure 3.3); it increased the amount of FM 2-10 
dye released under HK5C stimulation (Figure 3.4). This signifies that myosin-II 
is responsible for the closure of the fusion pore during HK5C stimulation 
resulting in the KR mode of exocytosis. 
 98 
These results together with the Ashton et. al., unpublished data (see 
Introduction to background results) would suggest that the dynamins are 
responsible for the KR of RRP vesicles during ION5C and 4AP5C stimuli and 
that myosin-II is responsible for the KR of RRP during the HK5C stimulation. 
Furthermore, these results also suggest that dynamins may be active and 
therefore responsible for the KR, only during lower [Ca2+]i  at the active zone as 
produced during ION5C and 4AP5C stimulations. Myosin-II may be active, and 
therefore responsible for the KR, only during higher [Ca2+]i  at the active zone as 
produced during HK5C stimulation. Thus, it can be summarised that dynamins 
and myosin-II are involved in the KR mode of exocytosis. 
These results may relate to the functional state that a particular terminal may 
find itself in which would be defined by the amount of stimulation it may have or 
be receiving. From our arguments about levels of Ca2+ at the active zone, it can 
be seen that such synaptic activity could change the mode requirements for the 
distinct proteins that we have outlined. Further as these both are (Dynamins & 
Myosin-II) phospho-proteins this means that secondary messenger pathways 
could regulate the mode by regulating dynamins and/or myosin-II. 
3.4.2 PKCs regulate the action of dynamins and myosin-II 
Synaptic transmission is highly regulated by processes of short- and long-term 
synaptic plasticity, as well as by intracellular second-messenger cascades. A 
particularly important signalling cascade that targets the presynaptic 
compartment of synapses is the PKC pathway (Lou et al., 2008).  An example 
of this is that Ahmed and Siegelbaum (2009) have shown that PKC can 
enhance N-type channel activity directly and antagonize signalling cascades 
that inhibit N-type channel opening (Ahmed and Siegelbaum, 2009).  This type 
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of information led us to question whether there could there be a role of PKC 
activation towards myosin-II regulating the fusion pore of the RRP SV. 
Double treatment of synaptosomes with 1 μM Go 6983 and 50 μM blebb 
revealed that if PKC is inhibited, myosin-II cannot regulate the mode of 
exocytosis from the RRP SVs. This suggests that PKC is involved in the KR 
mode of exocytosis and regulates the activation of myosin-II. Herein, this occurs 
when HK5C is used as the stimulus but this may occur in vivo under strong 
stimulation conditions that a nerve terminal might experience under certain 
physiological situations. 
In previous studies conducted in Ashton laboratory (Dilip Bhuva, PhD thesis 
2014) it has been shown that under such strong stimulation conditions 
activation of certain PKCs can inhibit dynamin and so this protein cannot 
regulate the fusion pore of the RRP SVs as so it does not contribute to KR. 
Clearly, this would also occur under certain physiological conditions. However, 
lower stimulation conditions will not only fail to activate myosin-II but they will 
also fail to inactivate dynamins. 
This chapter showed that HK5C also exhibited dynamin-dependent regulation of 
the fusion pore leading to KR of the RRP SVs if certain PKCs are not activated 
(the specific PKC isoforms are still unknown). Clearly, when these enzymes are 
stimulated they can inactivate the dynamins (see chapter 7). 
In summary, HK5C produces a large increase in [Ca2+]i  at the AZ and a 
subsequent generalized lower increase in Ca2+ throughout the nerve terminal. 
This elevated presynaptic calcium concentration causes activation of certain 
isoforms of PKC (yet unknown) which in turn results in phosphorylation of 
myosin-II thereby activating it. Dynamins belong to a family of dephosphins 
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which means that dynamins are active when dephosphorylated. Activation of 
PKC inhibits the action of dynamin. In this way, PKC acts as a regulator for 
closure of the fusion pore during KR mode of exocytosis by activating myosin-II 
and inhibiting dynamins when HK5C is employed. Myosin-II and dynamins both 
are capable of inducing the closure of the fusion pore of the RRP of SVs. 
Dynamins and Myosin-II are able to regulate the mode of fusion pore in a Ca2+ 
dependent manner, with each protein requiring distinct changes in [Ca2+]i. Thus, 
dynamins are generally active only during lower [Ca2+]i at the AZ whereas 
myosin-II is active only when a relatively higher [Ca2+]i is achieved at the active 
zone (Ashton et al., unpublished work). 
Another important result conducted by Ashton et al., not reported in this thesis, 
is further proof about the regulation of dynamins and myosin-II by PKCs. The 
data presented here utilised the PKC inhibitor, Go 6983. However, you can 
activate certain PKCs utilising the active phorbol ester (Ph est) (Parfitt and 
Madison, 1993; Lou et al., 2008). Ashton and colleagues have found that pre-
treatment of synaptosomes with 40 nM PMA does not affect the ION5C evoked 
release of the RRP and the RP. However, it was found that such treatment 
prevented dynamins from exerting its induction of FF for the RRP. This 
suggests that the PKC activation inactivated the dynamins. This indicates that 
PMA activates myosin-II to now close the fusion pore and induce KR but this is 
blocked by blebb. Thus, both ION5C and HK5C can under different 
circumstances have the same protein requirement for closing the fusion pore 
during KR of the RRP SVs (Refer chapter 8, Figure 8.1 for a diagrammatic 
summary). 
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3.4.3 KR is independent of CDE 
ION5C was employed as a stimulus to determine whether clathrin had a role to 
play in regulating the dynamin-dependent KR mode. One could argue that 
4AP5C could be used as part of RRP which undergoes KR which is also 
dynamin-dependent. However, this contribution of KR to the release is much 
less when compared to ION5C and it would be more difficult to produce 
statistically significant data with 4AP5C and one would perhaps need to do 
many experiments. Similarly, in chapter 6 we have demonstrated that this latter 
stimulus may work differently on distinct sub-populations of RRP SVs and this 
could also complicate the analysis. HK5C could not be used as stimulus as 
RRP undergoes KR under the influence of myosin-II; which is not linked to 
clathrin dependent endocytosis. The results employing ION5C, pitstop2TM and 
DYN indicate that the action of dynamin is independent of the clathrin which 
implies that KR is independent of CDE. It also suggests that the KR mode 
studied, herein, is probably distinct from ultra-fast endocytosis which has a 
dynamin and clathrin dependent requirement (Watanabe et al., 2013,2014). It 
should be noted that in some preliminary experiments the double stimulation 
protocol was used in which DYN was used prior to pitstop2TM or alternatively 
pitstop2TM was used prior to DYN. Under any of these conditions pitstop2TM 
failed to perturb the action of DYN on dynamins. Thus, this is extra evidence for 
the KR mode being able to be regulated by dynamins but not being regulated by 
clathrin. 
3.4.4 Dynamin-I regulates the fusion pore 
In other studies, conducted by Ashton et al., but not reported in this thesis, the 
dynamin isoform that seems to regulate the mode of exocytosis was 
investigated using some drugs that are specific for certain isoforms at specific 
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concentrations. 20 µM Dynole-34-2™ is reported to be specific for dynamin-I 
GTPase action whilst 50 µM Dyngo-4a™ is specific for the GTPase activity of 
dynamin 2 (Robertson et al., 2014). Careful comparison between these two 
drugs reveals that Dynole-34-2™ induces the RRP SV to switch to FF with 
ION5C stimulation whilst Dyngo-4a™ has no effect. This is an important 
observation because it highlights that the major dynamin present in nerve 
terminals – dynamin-I – is the protein that regulates the fusion pore whilst 
dynamin-II which is ubiquitously expressed throughout the body but is present 
at very low levels in central nerve terminals doesn’t appear to play a role. 
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Chapter 4 
Effect of pre-treatment of 160 
µM DYN and 15 µM Pitstop2
TM
  
 104 
4.1 Introduction 
4.1.1 Brief summary of results presented earlier on in this study 
A distinguishing feature of SVs is their Ca2+ dependency. The three stimuli used 
for this study are Ca2+ dependent and induce SV exocytosis by distinct 
mechanisms (Rizo & Rosenmund, 2008). As mentioned earlier, at the active 
zone HK5C produces a relatively fast and large increase in [Ca2+]i in 
comparison to ION5C and 4AP5C which do not produce such a large increase 
in Ca2+ at this region. This is due to the strategic localization of voltage-
dependent Ca2+ channels here (Ashton et al., unpublished). However, HK5C 
and ION5C induce release of both releasable SV pools with exocytosis of RRP 
by KR and the RP undergoing FF, whilst 4AP5C results in the exocytosis of 
RRP by a mixture of KR and FF (see Figure 3.2 & 3.4; Ashton et al., 
unpublished). 
All the above conclusions have depended upon the fact that these stimuli are 
present during the release period such that the terminals are constantly 
stimulated with no period of recovery unlike the situation with trains of action 
potentials in the brain. As a consequence, in this study, SVs undergo only one 
round of release. That only one round or release of these pools occurs has 
been determined by several methods. Bafilomycin A (BAF), when applied 
acutely at 1 µM in conjunction with a stimulus to rat synaptosomes, it does not 
interfere with the initial glutamate release of SVs undergoing exocytosis, but 
inhibits the re-uptake of glutamate when these SVs recycle (Ikeda and Bekkers, 
2009; Ashton et al., unpublished). It would seem that this concentration and the 
short time period (5 mins) does not interfere with the Glu content of non-
released SVs but once these have released their content and, following 
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recycling into the terminal, they are then unable to reload with Glu because the 
proton gradient required for this has been inhibited by BAF (Ikeda and Bekkers, 
2009). Therefore, if the stimuli employed induced several rounds of release of 
recycled and reloaded vesicles then there would be a difference between CON 
and BAF treated samples. Figure 4.1 indicates that this is not the case and 
there is no difference between control and BAF treated samples. 
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Figure 4.1. The effect of 1 µM BAF on HK5C, ION5C and 4AP5C evoked 
glutamate release. (Ashton et al., unpublished) Error bars represent positive 
S.E.M.., n=3 independent experiments).  
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This finding indicates that only one round of SV fusions takes place after the 
application of the stimulus.  This is actually a prerequisite for comparing 
stimulated Glu release and stimulated FM2-10 dye release. 
4.1.2 Further investigations into the distinct modes of SV 
exocytosis 
It has been established that both the RRP and RP of SVs can be released by 
exocytosis even when dynamin or clathrin-dependent processes have been 
blocked. This actually demonstrates again that the stimuli employed only induce 
one round of release of these pools. If there were recycling, reloading and re-
release of SVs during the stimulation period then any SVs recycling by a 
dynamin or clathrin-dependent process would fail to be released and so DYN or 
pitstop2TM treatment would reveal this but they fail to do so. Clearly, all SVs can 
exocytose and release their Glu content although they might not be able to 
recycle via these protein specific processes. 
All our experiments involve a pre-stimulation with HK5C which induces the RP 
and RRP SVs to exocytose. Following removal of the stimulus, these SVs can 
be made available for re-release by recycling, reloading and re-priming. 
Indeed, it should be noted that this pre-stimulation is the means by which the 
SVs are loaded with FM2-10 dye.  Such dye will label all the SVs whether they 
undergo KR or FF during this period. This is due to the property of the dye 
because whilst it has a fast association rate with the lipid membrane, it has a 
much slower dissociation rate (departition). Therefore, FM2-10 dye will label 
SVs even if they recycle by KR in <0.5 sec although a further round for release 
induced by a subsequent stimulation will mean that such KR SVs will not 
release their dye content. 
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We can actually test whether this pre-stimulation mechanism induces some SVs 
to undergo a clathrin and/or dynamin-dependent component that is distinct from 
those SVs undergoing KR. This simply involves pre-treating the synaptosomes 
with DYN or pitstop2TM prior to performing this pre-stimulation with HK5C. It is 
fortuitous that HK5C stimulation of the RRP of SVs is via a dynamin-
independent myosin II-dependent KR mechanism since such SVs will still 
recycle when dynamins are blocked. Such an experiment would also confirm 
that some SVs do have a dynamin requirement for recycling and similarly that 
these same SVs have a clathrin-dependent requirement for vesicular 
endocytosis. Such results would also confirm that DYN and pitstop2TM do act on 
these processes and that these drugs in our experiments are active i.e. these 
would represent positive controls to prove that these drugs are working in our 
preparation. 
4.2 Results 
The main aim of this chapter was to establish that KR is distinct to ultra-fast 
endocytosis. This was done by treating synaptosomes with 160 µM DYN 
(Figure 4.2, 4.4) or 15 µM pitstop2TM (Figure 4.3, 4.5) or a mixture of the two 
drugs (Figure 4.6). 
Synaptosomes were treated with DYN prior to the pre-stimulation with HK5C, 
followed by a second round of release evoked by ION5C (Figure 4.2). 
  
 109 
 
Figure 4.2 The effect that 160 µM DYN treatment before pre-stimulation exerts 
on the subsequent ION5C evoked glutamate release. Glutamate release has 
been expressed as percentage of maximum control. Error bars indicate S.E.M. 
The results were repeated with 3 individual experiments with numerous 
independent measurements (i.e. n3). p<0.05 was considered significant. 
 
A significant decrease in ION5C evoked Glu release can be observed when 
synaptosomes were pretreated with 160 µM DYN prior to the prestimulation with 
HK5C compared to the non-drug treated control. This indicates that some SV 
recycling must have a dynamin-dependent requirement and this can include 
CME (Takei et al., 2005), bulk endocytosis (Clayton et al., 2010) or ultrafast 
endocytosis (Watanabe et al., 2013). Herein, the stimuli employed for the pre-
stimulation is HK5C which can induce a dynamin-independent KR mode of 
exocytosis for the RRP SVs. Synaptosomes were treated with pitstop2TM prior 
to the pre-stimulation with HK5C, followed by a second round of release evoked 
by ION5C (Figure 4.3).     
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Figure 4.3 The effect that 15 µM pitstop2TM treatment before pre-stimulation 
exerts on the subsequent ION5C evoked glutamate release. Glutamate release 
has been expressed as percentage of maximum control. Error bars indicate 
S.E.M. The results are representative of at least 3 individual experiments (i.e. 
n3), p<0.05 was considered significant). 
 
A significant decrease in ION5C evoked Glu release can be observed when 
synaptosomes were pretreated with 15 µM pitstop2TM prior to the pre-
stimulation with HK5C compared to the non-drug treated control. This indicates 
that some SV recycling must have a clathrin-dependent requirement and this 
obviously includes CME but it also includes ultrafast endocytosis. 
By comparing Figure 4.2 and Figure 4.3 the glutamate release occurs from a 
pool of SVs that do not require CME, bulk endocytosis or ultra-fast endocytosis 
for recycling. 
HK5C induces all the RRP to undergo KR and as it is speculated that this mode 
is clathrin independent (it still occurs when pitstop2TM is added later on following 
the pre-stimulation step), it would seem that the SVs that are still able to 
exocytose (as seen in Figure 4.3) must have been those that represented the 
RRP SVs. Similarly, as HK5C induces KR of the RRP that is dynamin 
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independent then it would appear that the SVs that are still able to exocytose 
(as seen in Figure 4.2) must also be those that represented the RRP SVs. We 
can test to see whether the SVs available for release following the blockade of 
dynamin or clathrin before the pre-stimulation, do represent the RRP since we 
can stimulate with 4AP5C which exclusively releases just this pool (Figure 
4.4,4.5 and 4.6). 
 
 
Figure 4.4. The effect that 160 µM DYN treatment before pre-stimulation exerts 
on the subsequent 4AP5C evoked glutamate release. Glutamate release has 
been expressed as percentage of maximum control. Error bars indicate S.E.M. 
The results were repeated with 3 individual experiments with numerous 
independent measurements (i.e. n3), p<0.05 was considered significant).  The 
difference was not significant. 
 
Compared to the non-drug treated control, there was no significant decrease in 
4AP5C evoked Glu release observed when synaptosomes were pretreated with 
160 µM DYN prior to the pre-stimulation with HK5C. This suggests that the 
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inhibition of dynamins does not perturb the release of the 4AP5C-sensitive pool 
which is the RRP.     
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Figure 4.5. The effect that 15 µM pitstop2TM treatment before pre-stimulation 
exherts on the subsequent 4AP5C evoked glutamate release. Glutamate 
release has been expressed as percentage of maximum control. Error bars 
indicate S.E.M. The results were repeated with 3 individual experiments with 
numerous independent measurements. The difference was NS.  p<0.05 was 
considered significant. 
 
Following blockade of clathrin-dependent processes with pitstop2TM and the 
succeeding HK5C evoked exocytosis and subsequent recycling, and reloading 
of SVs, there was no significant difference in the 4AP5C evoked Glu release 
compared to the non-drug treated control. This suggests that the inhibition of 
clathrin does not perturb the release of the 4AP5C-sensitive pool which is the 
RRP. 
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Figure 4.6. The effect that 160 µM DYN plus 15 µM pitstop2TM treatment 
before pre-stimulation exherts on the subsequent 4AP5C evoked glutamate 
release. Glutamate release has been expressed as percentage of maximum 
control. Error bars indicate S.E.M. The results were repeated with 3 individual 
experiments with numerous independent measurements (i.e. n3). The 
difference was NS. (p<0.05 was considered significant). 
 
Pre-treatment of synaptosomes with DYN and pitstop2TM perturbs all dynamin 
and clathrin-dependent processes, but subsequent HK5C pre-stimulation, and 
further (after recovery) 4AP5C evoked Glu release indicated that even this 
double drug treatment did not perturb the amount of release induced by 4AP5C 
relative to the non-drug treated control. Clearly, the 4AP5C sensitive pool (the 
RRP) can still occur following blockade of these two major endocytotic proteins. 
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4.3 Discussion 
4.3.1 Dynamin dependent and clathrin dependent recycling 
The results indicate that some SVs that normally recycle after the pre-
stimulation (and get loaded by FM2-10 dye) can be prevented from re-releasing 
if prior to the initial pre-stimulation dynamins are inhibited. Similarly, some SVs 
that recycle after the pre-stimulation are unavailable for re-release if clathrin is 
inhibited. These results indicate that there are dynamin-dependent recycling 
processes for some SVs as well as some clathrin dependent processes for 
some SVs. As there are two processes that require both clathrin and dynamin 
(CDE and ultra-fast endocytosis) and a third that may only require dynamin 
(bulk endocytosis) it is interesting that the amount of release induced by ION5C 
(Figure 4.2 and Figure 4.3) is similar whether clathrin or dynamins are inhibited 
before the pre-stimulation step. This may indicate that the pools that are 
perturbed are those which depend upon both proteins and that bulk endocytosis 
may not be participating during the stimulation induced by HK5C. Another 
possibility is that the bulk endocytosis also has a clathrin requirement. Finally, 
the role of dynamin in bulk endocytosis (Clayton et al., 2010) is actually very 
controversial and experiments with dynamin knock out mice suggest that this 
pathway might not actually require dynamin (Wu et al., 2014). Despite these 
problems the results clearly indicate that there appears to be some SVs that 
can recycle in the absence of functional dynamins. This fits in with work with 
single (Lou et al., 2008) and double knockout mice (Raimondi et al., 2011) for 
dynamins 1 and 3 where it is apparent that some SVs can recycle and rerelease 
even in the absence of these dynamins (with the caveat that the tiny amount of 
dynamin 2 present does not contribute to this recycling). The results also 
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highlight that DYN and pitstop2TM are active and working on their expected 
substrates to produce a particular phenotype. 
4.3.2 RRP SVs recycle independent of clathrin and dynamins 
The nature of the SV pool that was available for release, even after inhibiting 
dynamins and clathrin prior to the pre-stimulation step, was examined by 
exclusively stimulating the RRP SVs with 4AP5C. It would appear that the pool 
of SVs that was available for release was the RRP as the drug treatments did 
not perturb 4AP5C evoked Glu release (Figure 4.4, 4.5 and 4.6). As during the 
pre-stimulation with HK5C the RRP would have recycled by a KR mechanism 
that was independent of dynamin – it is dependent on myosin-II activity – it 
would seem that the simplest explanation is that the pool of SVs released by 
4AP5C (or by ION5C) is these RRP SVs that had recycled by a KR mechanism. 
Before these experiments, we knew that the RRP SVs could undergo 
exocytosis by a KR mechanism. However, we had not checked whether such 
SVs would actually be available for a second round of release, but results 
suggest that such vesicles are available. Thus, it would seem that the RRP SVs 
can recycle and re-release independently of clathrin and dynamin. Data with the 
FM2-10 dye release would suggest that such SVs probably undergo KR during 
the first round of HK5C stimulation (the pre-stimulation when dye is taken up) 
and then undergo KR again during the second round but this is dependent upon 
the stimulus (e.g. ION5C and HK5C would induce RRP to undergo KR whilst 
with 4AP5C some of the RRP undergoes KR and some undergoes FF). 
Obviously, if an experiment was designed to do three stimulations one might 
find that the third round (following the same initial pre-treatment) still induce the 
RRP to fully release (if you use HK5C, second stimulus and ION5C or HK5C for 
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third stimulus) whilst clearly the use of 4AP5C in the second stimulus may only 
allow a sub-population of SVs to be released during the third stimulation period: 
this would be those SVs that underwent KR in the second round whilst those 
that underwent FF would be blocked. 
4.3.3 RP is not available for release if the action of dynamins 
and clathrin is inhibited prior to prestimulation with HK5C 
If the RRP SVs are those that can recycle independently of dynamins and 
clathrin following the inhibition of these proteins prior to the pre-stimulation with 
HK5C, then the pool of SVs that is no longer able to release is the RP. This fits 
in perfectly with the ideas presented throughout this thesis. It was always 
expected that those SVs that undergo FF would recycle by CME or via 
dynamin-dependent bulk endocytosis. Thus, the RP SVs would no longer 
recycle during the protocol employed herein and so they would be unavailable 
for release during the second stimulation. In fact, this result may help us justify 
the claim that the KR mode can be switched to FF by various conditions (as 
outlined throughout this thesis). There was always the possibility that when 
more FM210 dye released was induced by various drug treatments what 
actually was happening was that the fusion pore opening time was extended (or 
closure time slowed down) so that the dye eventually departitioned and was 
released. This would still indicate that KR existed but would not indicate a 
switch to FF. Furthermore, you could go further and say that the RP that 
appeared to be undergoing FF actually just had a longer pore opening time. 
However, if this is the case it would be hard to explain why the RP SVs did not 
recycle following inhibition of clathrin and/or dynamin as all forms of KR 
(including extended opening of the pores) is supposed to be clathrin 
independent. 
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Furthermore, the preliminary results obtained with 3 µM PAO (refer to chapter 
6) by Ashton and colleagues, not published and not reported herein; suggest 
that whilst KR is not perturbed by reducing the levels of PIP2, FF is totally 
inhibited. This result - which is currently being reinvestigated as 3 µM PAO 
interferes with synaptosomal bioenergetics (as stated in chapter 7 and appendix 
1)- indicates that for the vesicular membrane to fully insert into the plasma 
membrane during FF requires intact levels of PIP2 whereas the production of 
the fusion pore and KR does not have such a requirement. This can be 
explained by the fact that many proteins are regulated by binding to the PIP2 
and may play a role in exocytosis/endocytosis (e.g. synaptojanin; Voronov et 
al., 2008). It is much more difficult to understand why the extension of the fusion 
pore opening time would require intact levels of PIP2 whilst its actual initial 
production does not. 
4.3.4 RRP SVs can recycle independently of the RP  
These results also suggest that the RRP SVs can recycle independently of the 
RP and be available for release again. This was a major conclusion of a paper 
by Ashton and Ushkaryov (2005) that showed that the synaptosomes could 
keep recycling and re-releasing the RRP of SVs independently of the RP. 
Indeed, it was suggested in this paper that one possibility for such RRP SVs 
recycling and re-releasing was because they were undergoing KR. We have 
now provided more evidence for this (Ashton and Ushkaryov, 2005). 
4.3.5 KR is distinct to ultrafast endocytosis 
Even though, this is a small chapter the results obtained are very important for 
the whole debate about KR. Recently, ultra-fast endocytosis has been 
described which apparently allows SVs to re-enter the terminals within 30 msec 
(Wantanabe et al., 2013, 2014). These authors believe that such a mode means 
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that there is absolutely no need for a KR mode because this has been 
suggested to recycle in a slower period of <500 msec. KR was originally argued 
for on the basis that it allowed SVs to recycle much more quickly than CDE or 
bulk endocytosis and that this mechanism would help maintain synaptic 
transmission during periods of prolonged stimulation where these other two 
mechanisms might not be able to keep up with the demand for SV recycling. 
Clearly, those studying ultra-fast endocytosis believe it can allow this fast 
recycling and so one does need to evoke the idea of KR. This is actually 
disingenuous to the KR mode because whilst vesicular membranes recycle in 
about 30 msec by the ultrafast mechanism, such vesicular membranes fuse to 
form an endosome and subsequently SVs are pinched off from there, and then 
they can load up with neurotransmitter and be able to contribute to synaptic 
transmission again. However, this seems to take at least 5 sec which is slower 
than how quickly a KR SV may be able to release neurotransmitter again 
(approximately 2 sec: rate limiting step is reloading with neurotransmitter). 
The most important result from this chapter is that the KR mechanism that we 
are studying is not the same as the ultra-fast endocytosis that has been recently 
described. Ultrafast endocytosis has both a dynamin dependence (Wantanabe 
et al., 2013) and a clathrin dependence (Wantanabe et al., 2014). However, the 
mode we are studying does not require clathrin and the fusion pore can be 
closed by a non-dynamin-dependent mechanism (depending upon the stimulus 
employed). 
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Chapter 5 
Investigating the Role of 
Protein Kinase A 
 121 
5.1 Introduction 
cAMP plays the role of a critical secondary messenger involved in synaptic 
transmission. Binding of the appropriate ligand to the G-protein-coupled 
receptor, located on the cell surface, results in the intracellular production of 
cAMP through adenyl cyclase associated with that particular receptor. This then 
allows cAMP to diffuse through the cytoplasm and bind to its targets, the most 
studied one being PKA. Thus, PKA pathway serves an important intracellular 
signalling pathways (Yao and Sakaba, 2010). The main aim of this chapter was 
to investigate if this pathway could regulate synaptic vesicular exocytosis, 
various activators and inhibitors were employed. 
Much research has been carried out on the role of both cAMP and PKA on 
neurotransmitter release (Leenders and Sheng, 2005). Some of the studies 
have found a direct link between changes in cAMP levels and 
activation/deactivation of PKA whilst others have investigated PKA-independent 
processes requiring changes in cAMP (e.g. exchange proteins directly activated 
by cAMP, (EPAC)- see chapter 1 for more information on EPAC). In some 
studies, the target for the PKA that might regulate release is known. cAMP has 
been shown to regulate release (e.g. Santafe et al., 2009). It has been 
suggested that cAMP can regulate the Ca2+ sensitivity of certain SVs (Yao and 
Sakaba, 2010). Other groups have also shown that cAMP and PKA can 
regulate the population of silent synapses (Crawford and Steven Mennerick, 
2012). This latter result may be related to a novel form of synaptic plasticity that 
has been described, in which release sites which are switched off during low-
frequency depression can be reactivated. This reactivation involves PKA 
induced phosphorylation of synapsin I (Doussau et al., 2010). Indeed, PKA-
mediated synapsin I phosphorylation is a central modulator of Ca2+-dependent 
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synaptic activity (Menegon et al., 2006). EPAC has been shown to be a second 
target for cAMP and activation can enhance neurotransmitter release (Gekel 
and Neher, 2008). Finally, cAMP has been shown to regulate the fusion pore of 
vesicles undergoing exocytosis from rat lactotrophs (Calego et al, 2014). 
5.2 Results 
{(9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1oxo-9,12-
epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-][1,6]benzodiazocine-10-
carboxylic acid hexyl ester} (i.e. KT 5720) is a cell permeable inhibitor of cAMP 
dependent protein kinase A (E.C.2.7.11.11). It blocks PKA signalling through 
competitive inhibition at the active site on target protein (Huang et al., 2000). 
PKA is an enzyme which performs a variety of functions in eukaryotic cells by 
adding phosphates to proteins to “target sites” (Huang et al., 2000). For this 
study, the effect of 2 µM KT 5720 (see Huang et al., 2000) on synaptic vesicular 
exocytosis was investigated through its action on the glutamate and FM 2-10 
dye release assays (Figure 5.1 and 5.2). 
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Figure 5.1. The effect of 2 µM KT 5720 on glutamate release. No significant 
difference in the glutamate release is observed between control and KT 5720-
treated terminals for any of the three stimuli, (A) HK5C, (B) ION5C and (C) 
4AP5C are employed. The data points represent the glutamate released and 
are expressed as a percentage of the maximum control release. The error bars 
represent S.E.M. These are the results of 3 independent experiments (i.e 
performed on different days) with numerous independent sample replicates (i.e. 
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prepared on same day) per experiment and a p<0.05 was considered 
significant. 
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Figure 5.2. The effect of 2 µM KT 5720 on FM 2-10 dye release. The error bars 
represent S.E.M.. These are the results of 3 independent experiments (i.e. 
performed on different days) with numerous independent sample replicates (i.e. 
prepared on same day) per experiment and a p<0.05 was considered 
significant. 
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No significant change in FM2-10 dye release is observed with HK5C release 
with or without KT 5720 treatment. However, when ION5C and 4AP5C are 
employed as stimuli a significant increase in the FM2-10 dye release is 
observed in the KT 5720 treated terminals: the p value was less than 0.0001 for 
both stimuli. The data points represent the FM dye released and are expressed 
as a percentage of maximum control release.  
Clearly, inhibition of PKA causes the SVs to undergo more FF for ION5C and 
4AP5C. 
5,6-dichloro-1-b-D-ribofuranosylbenzimidazole-3′,5′-
cyclicmonophosphorothioate (i.e cBIMPS) is a selective, cAMP-analogue 
protein kinase activator. For this study, the effect of 50 µM cBIMPS (Kidokoro 
et. al., 2004) on synaptic vesicular exocytosis was investigated through its 
action on glutamate and FM 2-10 release from synaptosomes (Figure 5.3 and 
5.4). 
  
 127 
 
 
 
Figure 5.3. The effect of 50 µM cBIMPS on glutamate release. cBIMPS 
produces no significant difference in the glutamate release for any of the three 
stimuli employed: HK5C, ION5C and 4AP5C. The data points represent the 
glutamate released and are expressed as a percentage of maximum control 
release. The error bars represent S.E.M. These are the results of 3 independent 
experiments (i.e performed on different days) with numerous independent 
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sample replicates (i.e. prepared on same day) per experiment and a p<0.05 
was considered significant. 
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Figure 5.4. The effect of 50 µM cBIMPS on FM 2-10 dye. No significant change 
in FM2-10 dye release is observed for 4AP5C stimulation following cBIMPS 
treatment. However, when ION5C and HK5C are employed as stimuli, a 
significant decrease in the FM2-10 dye release is observed after such drug 
treatment: p value was less than 0.0001 for both. The data points represent the 
FM dye released and are expressed as a percentage of maximum control. The 
error bars represent S.E.M. These are the results of 3 independent experiments 
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(i.e performed on different days) with numerous independent sample replicates 
(i.e. prepared on same day) per experiment and a p<0.05 was considered 
significant. 
 
These results indicate that activation of PKA causes most of the SVs to undergo 
KR with HK5C and ION5C and that this action is specific for the RP since 
4AP5C does not release the RP. In order to show that the cBIMPS action is 
specific and does activate PKA, we tested whether cBIMPs exerted any action 
following blockade of PKA with KT 5720 (Figure 5.5, 5.6 and 5.7). 
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Figure 5.5. The effect of 2 µM KT 5720 and 50 µM cBIMPS on FM 2-10 dye 
release. Pretreatment with KT 5720 followed by cBIMPS produces no significant 
change in the release of FM dye induced by HK5C or ION5C compared to the 
non-drug treated control. The data points represent the FM dye released and 
are expressed as a percentage of maximum control. The error bars represent 
S.E.M.. These are the results of 3 independent experiments (i.e performed on 
different days) with numerous independent sample replicates (i.e. prepared on 
same day) per experiment and a p<0.05 was considered significant. 
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Figure 5.6. Comparison of the effect of 2 µM KT 5720 plus 50 µM cBIMPS vs 2 
µM KT 5720 on HK5C evoked FM 2-10 dye release. There is no change in FM 
2-10 dye release between the conditions: p=0.4 These are the results of 3 
independent experiments (i.e. performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment and 
a p<0.05 was considered significant. 
 
Figure 5.7. Comparison of the effect of 2 µM KT 5720 and 50 µM cBIMPS vs 50 
µM cBIMPS on HK5C evoked FM 2-10 dye release. The FM dye release for the 
double treatment of 2 µM KT 5720 and 50 µM cBIMPS was significantly greater 
than the FM dye release for 50 µM cBIMPS alone. The error bars represent 
S.E.M.. The p value obtained was < 0.01. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment and 
a p<0.05 was considered significant.    
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9-Cyclopentyladenine mesylate; or mononmethanesulphonate i.e. 9-CP-Ade is 
a cell permeable and non-competitive adenylate cyclase (AC) inhibitor that 
targets the P site domain (Johnson et. al., 1997). 
For this study the effect of 100 µM 9-Cp-Ade (Fresco et al, 2004) on synaptic 
vesicular exocytosis was investigated through its action on glutamate and FM 2-
10 dye release assay (Figure 5.7 and Figure 5.8). 
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Figure 5.8. The effect of 100 µM 9-Cp-Ade on glutamate release. No significant 
difference in the glutamate release is observed when comparing control to 9Cp-
Ade treated terminals for any of the three stimuli are employed. The data points 
represent the glutamate released and are expressed as a percentage of 
maximum control release. The error bars represent S.E.M. These are the 
results of 3 independent experiments (i.e performed on different days) with 
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numerous independent sample replicates (i.e. prepared on same day) per 
experiment and a p<0.05 was considered significant. 
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Figure 5.9 The effect of 100 µM 9-Cp-Ade on FM 2-10 dye release. 9-Cp-Ade 
had no significant effect on the FM dye release evoked by HK5C, ION5C and 
4AP5C. The data points represent the dye released and are expressed as a 
percentage of maximum control release. The error bars represent S.E.M.. 
These are the results of 3 independent experiments (i.e performed on different 
days) with numerous independent sample replicates (i.e. prepared on same 
day) per experiment and a p<0.05 was considered significant.      
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[3R-(3α,4aβ,5β,6β,6aα,10α,10aβ,10bα)]-5-(Acetyloxy)-3ethenyldodecahydro-
6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1Hnaphtho[2,1-b]pyran-1-one 
(i.e. Forskolin) is a cell permeable adenylate cyclase activator AC activator. The 
effect of 100 µM forskolin (Herrero and Sanchez-Prieto, 1996) on the switch in 
the mode of exocytosis was investigated by measuring glutamate and FM 2-10 
dye release Figure 5.10 and Figure. 5.12. Similarly, a 100 µM 1,9-
dideoxyforskolin an inactive homologue of forskolin (Herrero and Sanchez 
Prieto, 1996) was tested as a control to ensure forskolin is acting specifically on 
adenylate cyclase (Figure 5.11).  
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Figure 5.10. The effect of 100 µM forskolin on glutamate release. No significant 
difference in the 4AP5C evoked glutamate release was observed between 
control and forskolin treated terminals. However, when HK5C and ION5C were 
employed as stimuli the glutamate release for 100 µM forskolin treated samples 
was significantly reduced when compared to control: the p value for HK5C was 
< 0.0002 while the p value obtained for ION5C was < 0.0001. The data points 
represent the glutamate released and are expressed as a percentage of 
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maximum control release. The error bars represent S.E.M.. These are the 
results of 3 independent experiments (i.e. performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment and a p<0.05 was considered significant. 
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Figure 5.11 The effect of 100 µM 1,9-dideoxy-forskolin on HK5C evoked 
glutamate release. 1,9-dideoxy-forskolin is an inactive homologue of forskolin. 
There was no significant difference in the HK5C evoked glutamate release 
between this drug treatment and the non-drug treated control. The data points 
represent the glutamate released and are expressed as a percentage of 
maximum control release. The error bars represent +S.E.M.. These are the 
results of 3 independent experiments (i.e. performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment and a p<0.05 was considered significant.   
 
This result emphasizes that the effect of forskolin on HK5C evoked Glu release 
is specific and is likely to involve changes in cAMP levels (see below for further 
evidence of this). Although, the forskolin inhibits the release of the RP evoked 
by ION5C and HK5C it does not block the release of the RRP as shown by the 
lack of effect of this drug on 4AP5C release. Thus, we can still investigate 
whether forskolin could possibly have an effect on the mode of exocytosis of the 
RRP by studying FM dye release induced by 4AP5C. 
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Figure 5.12. The effect of 100 µM forskolin on 4AP5C evoked FM 2-10 dye 
release. On employing 4AP5C as stimulus, 100 µM forskolin significantly 
reduces the amount of dye released in comparison to control: the p value was < 
0.0001. The data points represent the FM dye released and are expressed as a 
percentage of maximum control release. The error bars represent S.E.M.. 
These are the results of 3 independent experiments (i.e. performed on different 
days) with numerous independent sample replicates (i.e. prepared on same 
day) per experiment and a p<0.05 was considered significant. 
 
9-Cp-Ade inhibits activation of adenylate cyclase but has no effect on SV 
exocytosis including their mode. Thus, we can employ this drug to prove that 
the action of forskolin on 4AP5C induced SV exocytosis is truly due to activation 
of adenylate cyclase. The protocol is shown in the time line in Figure 5.13 and 
Figure 5.14. 
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Figure 5.13. The effect of 100 µM 9-Cp-Ade and 100 µM forskolin on 4AP5C 
evoked glutamate release. There is no significant difference in the 4AP5C 
evoked glutamate release between this double treatment (100 µM 9-Cp-Ade 
and 100 µM forskolin) and non-drug treated control. The data points represent 
the glutamate released and are expressed as a percentage of maximum control 
release. The error bars represent S.E.M. These are the results of 3 independent 
experiments (i.e. performed on different days) with numerous independent 
sample replicates (i.e. prepared on same day) per experiment and a p<0.05 
was considered significant. 
 
 
Figure 5.14. The effect of 100 µM 9-Cp-Ade plus 100 µM forskolin on 4AP5C 
evoked FM2-10 release. There is no significant difference in the 4AP5C evoked 
FM dye release for this double treatment (100 µM 9-Cp-Ade and 100 µM 
forskolin). The data points represent the FM dye released and are expressed as 
a percentage of maximum control release. The error bars represent S.E.M.. 
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These are the results of 3 independent experiments (i.e performed on different 
days) with numerous independent sample replicates (i.e. prepared on same 
day) per experiment and a p<0.05 was considered significant. A timeline for the 
experiment has been shown above. 
The results in Figure 5.14 clearly show that the action of forskolin on switching a 
majority of the RRP SVs to KR depends upon activation of adenylate cyclase as 
it fails to act when the enzyme is inhibited by 9-Cp-Ade. This is emphasized 
even further by plotting the results for forskolin vs 9-Cp-Ade plus forskolin 
(Figure 5.15). 
 
 
Figure 5.15. Comparing the effect of 100 µM 9-Cp-Ade plus 100 µM forskolin 
with 100 µM forskolin alone on 4AP5C evoked FM 2-10 dye release. The FM 2-
10 dye released for forskolin is significantly lower than the FM 2-10 dye release 
for 100 µM 9-Cp-Ade and 100 µM forskolin treatment: the p value was < 0.0001. 
The error bars represent S.E.M.. These are the results of 3 independent 
experiments (i.e performed on different days) with numerous independent 
sample replicates (i.e. prepared on same day) per experiment and a p<0.05 
was considered significant. 
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The results with forskolin are intriguing because increases in cAMP cytosolic 
levels appears to have two distinct effects: (i) blockade of the RP: (ii) an 
increase in the KR of the RRP. 
Clearly, the activation of adenylate cyclase by forskolin increases the cAMP 
levels within the nerve terminals. However, whilst an increase in cAMP induces 
some SVs to switch from FF to KR when exocytosis is evoked by 4AP5C, 
activation of PKA (a downstream target for cAMP) fails to induce such a switch 
when 4AP5C is employed as the stimulus. This result suggests that the action 
of forskolin may be due to cAMP activating a distinct enzyme to PKA. An 
obvious alternative target is exchange protein directly activated by cAMP 
(EPAC) Grandoch et al., 2010). To help prove that the action of forskolin is 
independent of PKA activation, synaptosomes were pre-treated with KT 5720 
prior to the addition of forskolin (Figure 5.16). 
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Figure 5.16. The effect of 2 µM KT 5720 followed by 100 µM forskolin on 
4AP5C evoked FM2-10 dye release. The FM 2-10 dye released for 2 µM KT 
5720 plus 100 µM forskolin is significantly larger than the FM 2-10 dye release 
for control non-treated terminals. The error bars represent S.E.M. These are the 
results of 3 independent experiments (i.e. performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment and a p<0.05 was considered significant. 
 
Forskolin does not override KT 5720 action completely as there is much more 
dye release than with forskolin alone. Similarly, KT 5720 does not completely 
override the action of forskolin as there is less dye release for the joint 
treatment than with KT 5720 alone. This may be due to two sub-populations of 
RRP SVs. This has been discussed in detail later on in the discussion. 
Ashton’s group have previously shown that 0.8 M okadaic acid (OA) – by 
inhibiting protein phosphatase 2A – induces all RRP SVs to switch to FF. This 
includes those that were undergoing KR following 4AP5C stimulation or all RRP 
SVs that were originally undergoing KR following HK5C or ION5C stimulation. 
Herein, we repeated the experiment for 4AP5C evoked release (Figure 5.17).  
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Figure 5.17. The effect of 0.8 µM OA on 4AP5C evoked FM2-10 dye release. 
The amount of 4AP5C evoked FM 2-10 dye release in terminals treated with 0.8 
µM OA is significantly higher than release from controls: p value was < 0.0001. 
The error bars represent S.E.M.. These are the results of 3 independent 
experiments (i.e performed on different days) with numerous independent 
sample replicates (i.e. prepared on same day) per experiment and a p<0.05 
was considered significant. 
 
Thus, as predicted OA switches those SVs undergoing KR to a FF mode. We 
then tested to see whether OA would still switch these SVs to a FF mode 
following forskolin treatment (Figure. 5.18).      
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Figure 5.18. The effect of 0.8 µM OA plus 100 µM forskolin on 4AP5C evoked 
FM2-10 dye release. The amount of FM 2-10 dye released for 0.8 µM OA plus 
100 µM forskolin is significantly less than the FM 2-10 dye released from control 
terminals: p value was < 0.0001. The error bars represent S.E.M.. These are 
the results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment and a p<0.05 was considered significant. 
 
OA failed to prevent forskolin (via cAMP production) from switching RRP SVs 
to KR. To emphasize that OA failed to perturb forskolin’s action on 4AP5C 
evoked FM dye exocytosis, forskolin was compared to forskolin plus OA on 
the same graph (Figure. 5.19). 
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Figure 5.19. A comparison of the effect of 100 µM forskolin with 100 µM 
forskolin plus 0.8 µM OA on 4AP5C evoked FM 2-10 dye release. There was no 
change in FM 2-10 dye release when the two drug treatments were compared.  
Error bars represent S.E.M.. These are the results of 3 independent 
experiments (i.e. performed on different days) with numerous independent 
sample replicates (i.e. prepared on same day) per experiment and a p<0.05 
was considered significant. 
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5.3 Discussion 
This chapter demonstrates the effect of cAMP and PKA pathways on synaptic 
vesicular exocytosis and attempts to interpret these results and determine if 
one can learn more about the protein requirements for the fusion modes. 
5.3.1 Effect of Inhibition of PKA using KT 5720 
Clearly, inhibition of PKA causes the RRP SVs to undergo more FF for ION5C 
and 4AP5C (Figure 5.1 and 5.2). This observed effect was similar to the effect 
produced when the action of dynamins was blocked using 160 µM DYN (refer 
to chapter 3). In particular, the specificity for a PKA requirement for ION5C 
and 4AP5C – but not HK5C – is similar to that specificity of these two stimuli 
for a dynamin requirement whilst HK5C evoked release for the RRP SVs is 
dynamin independent. Therefore, there might be an interaction between PKA 
and dynamins that can regulate the exocytotic mode. Previous data has 
indicated that dynamin can be phosphorylated on several sites (Graham, et. 
al., 2007) and that certain phosphorylation sites are induced by CDK5 (Cyclin-
dependent kinase 5) (Tan et al., 2003), GSK-3 (Glycogen synthase kinase 3) 
(Clayton et al., 2010) and PKC (Powell, et al., 2000). However, there has been 
no report of a direct phosphorylation of dynamin (herein, we are discussing 
dynamin I) by PKA. Thus, it is likely that if the phosphorylation of dynamin is 
regulated by PKA, this is because PKA regulates another protein that can 
control the phosphorylation of dynamin (e.g. another kinase or a 
phosphatase). Alternatively, PKA could control the protein-protein interactions 
that dynamin participate in (Hill et al., 2001; Clayton et al, 2009; Gonzalez-
Jamett et al., 2010) such that dynamin is not available to interact and close the 
fusion pore.  
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5.3.2 Effect of activation of PKA using cBIMPS 
Results from Figure 5.3 and 5.4 indicate that activation of PKA causes most of 
the 
SVs to undergo KR with HK5C and ION5C and that this action is specific for 
the RP since PKA activation does not affect 4AP5C induced release of SVs 
(4AP5C only releases the RRP). This is shown by the fact that cBIMPS 
produces no effect on the sub population of RRP vesicles undergoing 
exocytosis by FF when 4AP5C is employed as stimuli which demonstrates that 
the action of cBIMPS by increasing PKA activity is specific for the RP. These 
observations are similar to the results obtained when the action of PP2B was 
blocked using 1 µM cyclosporine A. This may indicate that a substrate 
phosphorylated by PKA is normally dephosphorylated by PP2B and that such 
a phosphorylated protein induces the KR mode of the RP of SVs. When 
comparing results with the inhibition of PKA with the results with activation of 
PKA it is intriguing that the effects are on distinct pools of SVs. This probably 
suggests that different proteins are involved in regulating the properties of the 
two pools. This was the conclusion with studies using cyclosporine A which 
has a specific action only for the RP of SVs. Thus, PKA induced 
phosphorylation of a target protein appears to prevent dynamin closing the 
fusion pore for RRP SVs whilst phosphorylation of a distinct target may allow 
closure of the fusion pore for RP SVs. 
5.3.3 Effect of double treatment of cBIMPS and KT 5720 
To ascertain if the effect produced by cBIMPS was due to the activation of 
PKA, synaptosomes were pre-treated with KT 5720 and then treated with 
cBIMPS. HK5C induced KT 5720 and cBIMPS FM dye release was similar to 
HK5C induced control FM dye release. The same result was observed when 
ION5C was employed as the stimuli as shown in Figure 5.5. There is no 
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difference in the amount of HK5C induced FM dye release for KT 5720 
treatment alone vs the double treatment of cBIMPS plus KT 5720 (Figure 5.6). 
But when one compares HK5C induced FM dye release for KT 5720 plus 
cBIMPS with cBIMPS alone, the amount of FM dye for the latter is significantly 
lower than the former (Figure 5.7). This clearly indicates that the specific 
activation of PKA can lead to a switch in the mode of some RP SVs. 
Previously, we have also found such switching with cyclosporine A treatment, 
but just as here, we do not apparently switch all SVs to a KR mode. This could 
suggest that there is heterogeneity in the RP of SVs such there are sub-pools 
of these. However, some previous results from Ashton’s laboratory indicate 
that one possible explanation is that not all RP can undergo SV fusion via KR 
when all the RRP are already undergoing KR. This may indicate that there is a 
limit to the number of SVs that can undergo this mode. Such ideas have come 
about because it would appear that under some conditions where one induces 
the RRP SVs to undergo FF, then one can then induce all the RPs to undergo 
KR. This is a complicated issue and will require much further experimentation 
to fully elucidate. 
5.3.4 Effect of activation of adenylate cyclase using Forskolin 
The effect of forskolin on HK5C, ION5C and 4AP5C evoked Glu release 
(Figure 5.10) was similar to the effect produced by blocking the action of 
CAMKII using 10μM KN-93 (Ashton, unpublished observations). This suggests 
that increased levels of cAMP can prevent the RP of SVs from exocytosing 
and that this may somehow be related to inhibition of CAMKII. Clearly, this 
may involve either direct or non-direct interactions between these two kinase 
pathways. This result does not involve distinctions in the mode of exocytosis 
but actually involves studying the properties of the different pools. Clearly, 
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much earlier work has been carried out on what controls release of the two 
releasable pools of SVs and this has implicated the phospho-protein synapsin 
I. It is believed that synapsin 1 interacts with both the SV (it is a SV peripheral 
membrane protein) and the actin cytoskeleton (Cesca et al., 2010). Further, it 
has been suggested that various phosphorylations on distinct sites on 
synapsin 1 leads to dissociation of the synapsin I from both SVs (Menegon et 
al., 2006) and from attachment to the cytoskeleton (Fornasiero et al., 2012). 
Thus, it is thought that such phosphorylated regulation of SV association with 
the cytoskeleton and with other SVs can lead to the RP SV being either 
available or not available for release. Future work on this topic might help 
reveal the importance of such interactions and possibly reveal other 
interactions e.g. dynamins are known to interact with the actin cytoskeleton 
(Gu et al., 2010) and this may have some role to play. 
5.3.5 Effect of double treatment of 9-Cp-Ade and Forskolin 
Statistically there is no difference between control and 100 µM 9-Cp-Ade plus 
100 µM forskolin treated terminals (Figure 5.14), although the values for the 
latter show slightly lower amounts of FM dye release at all time points. This 
may be because 100 µM 9-Cp-Ade might have failed to block all the adenylate 
cyclase in the 5 min treatment period before the addition of forskolin so there 
might have still been some action of forskolin on residual enzyme activity. 
However, this result does indicate that forskolin does act via activation of 
adenylate cyclase and, therefore, through an increase in cAMP levels within 
the terminal.    
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5.3.6 Effect of double treatment of KT 5720 and Forskolin 
Careful comparison between the action of KT 5720 (Figure 5.2), forskolin 
(Figure 5.12) and KT 5720 plus forskolin (Figure 5.16) reveal that the latter 
condition produces a distinct effect from either of the drugs alone. Thus, 
forskolin does not override KT 5720 action completely as there is much more 
dye release than with forskolin alone. Similarly, KT 5720 does not completely 
override the action of forskolin (there is less dye release for the joint treatment 
than with KT 5720 alone). A possible explanation is that there are two sub-
populations of RRP SVs (as has been suggested by many previously) (Neher, 
2015). Those SVs that normally undergo KR following 4AP5C stimulation may 
switch to FF following blockade of PKA. However, those that normally undergo 
FF may switch to KR when there is an increase in cAMP. Thus, each sub-pool 
of RRP SVs may have distinct requirements. This is a very interesting 
possibility as previously Ashton’s group had not really considered such 
diversity between RRP SVs and most results had not revealed this. However, 
it clearly warrants further research and it may well be that this finding may help 
to explain other observations which Ashton and his colleagues failed to 
completely understand. It is apparent that some of the action of forskolin is 
due to an increase in cAMP but not due to activation of PKA, and, therefore, 
another enzyme regulated by cAMP may be involved. This data had led to the 
hypothesis that EPAC enzymes (Grandoch et al., 2010; Schmidt et al., 2013) 
may be activated by the increase in cAMP induced by forskolin and that these 
may contribute to the action of forskolin on SV exocytosis. It should be noted 
that EPAC has been implicated in the regulation neurotransmitter release 
(Gekel and Neher, 2008) and synaptic plasticity in nerve terminals (Fernandes 
et al, 2015). Recent experiments in the Ashton laboratory (whilst this thesis 
was being prepared) have tested whether EPAC plays a role by inhibiting this 
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with the inhibitor ESI09 (Tsalkova et al., 2012). They have already established 
that the forskolin induced inhibition of the HK5C evoked release of the RP is 
actually due to activation of EPAC. This is because pretreatment of the EPAC 
inhibitor ES109 prior to addition of forskolin prevents the latter from blocking 
the release of the RP evoked by HK5C. Future experiments will investigate the 
role of EPAC activation on the modes of the RRP SVs. Clearly, this result may 
also indicate the heterogeneity in the RRP SVs. 
5.3.7 Effect of double treatment of Forskolin and Okadaic acid 
The final result in this chapter showed that whilst OA switched the KR SVs 
evoked by 4AP5C to FF, forskolin prevented this action. Furthermore, forskolin 
still induced the SVs that usually undergo FF when evoked by 4AP5C to now 
switch to KR. Thus, forskolin not only reversed the OA action but it also 
exerted its normal effect. As it is known that OA maintains the phosphorylation 
of Ser795 on dynamin I molecules, future experiments will ascertain whether 
this is prevented by forskolin. Clearly, the role of forskolin via PKA or EPAC on 
the phosphorylation of dynamin I needs to be studied in the future to help us 
elucidate the mechanisms involved. Indeed, similar experiments need to study 
the specific phosphorylation sites on myosin-II that might be changed following 
OA, forskolin or forskolin plus OA in view of the fact that OA normally switches 
the RRP of SVs induced by HK5C to FF from a KR mode.    
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5.4 Conclusion 
These results clearly indicate that both PKA, and cAMP (via PKA and other 
enzymes) can regulate the mode of exocytosis. This adds to the knowledge 
we have already gathered concerning the Ca2+ dependent enzymes that also 
regulate this process. In order to complete this study and interpret all our data 
correctly, there is a need to measure the effect of the drugs employed in this 
chapter (KT 5720, cBIMPs, forksolin, 9-Cp-Ade plus various combinations) on 
stimulus evoked changes in [Ca2+]i. Such experiments using Fura-2 are 
already planned (Please refer thesis done by Dilip Bhuva, 2014). Likewise, it 
will be necessary to check that the effect of some of the combinations of drugs 
employed herein are also tested on stimulated evoked Glu release. As most of 
the drugs employed do not perturb the relevant stimulated release, it is 
envisaged that the joint treatments will not perturb Glu release but we still 
have to check this. We have checked in another chapter that the drugs 
employed herein do not disturb the bioenergetic integrity of the synaptosomes 
(see chapter 6). 
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Chapter 6 
Bioenergetics
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6.1 Introduction 
Synaptosomes are isolated nerve terminals or varicosities whose axonal 
attachments have been severed due to homogenization. Synaptosomes thus 
function as mini-cells in which mitochondria exist in a physiological cytoplasm, 
fed by physiological cytoplasmic metabolic pathways and supplying ATP to the 
cytoplasm and plasma membrane, the latter accommodating a variety of ion 
channels and pumps as well all the machinery required for exocytosis and 
recovery. Another advantage of using synaptosomes is that they can be 
prepared easily from any animal of any age unlike primary neuronal cell cultures 
(Nicholls, 2003). Mitochondria play a vital role in supporting neuronal energy 
requirements. Bioenergetics failure may result in impaired neuronal 
transmission and thereby contribute to neurodegenerative diseases like 
Parkinson’s and Alzheimer’s (Pathak et al, 2015, Choi et al 2009). 
Our understanding about synaptosomal bioenergetics has been limited because 
of the lack of resolution of established assays, this study aims to investigate the 
change in mitochondrial function on application of various drugs as a change in 
mitochondrial function would imply a change in synaptic transmission. 
6.2 Mitochondrial stress test assay 
For this study, the Seahorse XFp flux analyser was used to measure 
mitochondrial respiration in synaptosomes. Various modulators which act on the 
electron transport chain were employed to provide an insight of the 
mitochondrial function (Figure 6.1). 
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Figure 6.1 Measurement of mitochondrial respiration through sequential 
injections of various compounds (oligomycin, FCCP, antimycin A and rotenone). 
Key parameters measured were ATP production, proton leak, maximal 
respiration, spare respiratory capacity and non-mitochondrial respiration. 
(Seahorse bioscience, ND) 
 
Oligomycin acts on complex V (ATP synthase) thereby reducing the ATP 
function and decreasing OCR after it is injected. This effect helps measure ATP 
production.  FCCP (Carbonyl cyanide-4-phenylhydrazone) acts as an 
uncoupling agent for oxygen from ATP thus collapsing the proton gradient and 
causing a disruption in the membrane potential. This results in an uninhibited 
electron flow and maximum consumption of oxygen to complex IV, an increased 
effect on OCR. This effect of FCCP helps measure the spare respiratory 
capacity which provides an estimate of the ability of the synaptosome to 
respond to an increased demand for energy. Rotenone acts as an inhibitor of 
complex I and antimycin A acts an inhibitor of complex III, the last injection is a 
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combination of both of these drugs which shuts down the mitochondrial 
respiration (see Figure 6.2 and Figure 6.1) and helps calculate non-
mitochondrial respiration, which occurs outside the mitochondria. This 
combination decreases OCR (Figure 6.1). The company that supplies the 
Seahorse system recommends that one carries out titration of FCCP for the 
particular cell system/synaptosomes that you are using: refer appendix 1 for 
titration. Initially, a prepared mixture of the drugs was purchased supplied in a 
kit but this proved very expensive so these drugs separately were purchased 
separately. To give the same efficacy as the drugs supplied in the kit the final 
concentration of the injected drugs used was (in the order oligomycin, FCCP, 
actimycin A/ rotenone) 4 µM ,2 µM and 0.5 µM; while the drug concentrations of 
the kit were 1 µM, 2 µM and 0.5 µM, (refer appendix 1 for graph for the 
difference in concentration). 
 
 
Figure 6.2. The effect of modulators on ETC cycle. See text above (Seahorse 
bioscience, ND) 
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In this study, the effect of PAO on bioenergetics of synaptosomes was 
investigated. This was a prelude to using this drug to investigate the role of 
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in synaptic vesicle exocytosis. 
This is a phospholipid that plays a variety of roles in cell signaling. 
Phosphorylation of phosphatidylinositol (PI) through PI(4)-kinase (E.C. 2.7.1.64) 
leads to the synthesis of PI(4)P in turn synthesizing the production of 
phosphatidylinositol 4,5-bisphosphate synthesis. PAO inhibits the production of 
PI(4)-kinase by forming stable dithioarsine rings by reacting two thiol groups of 
closely spaced cystenyl residues (Oda et al. 2000). Ashton and Ushkaryov 
(2005) have shown that 3 µM PAO apparently did not affect the release of the 
RRP but it did perturb the release of RP. This indicated that these two pools of 
SVs had different biochemical requirements. Tarasenko et al (2005) have 
shown that PAO inhibits the SV acidic pool thereby inhibiting the refilling of 
vesicles and thus reducing the calcium stimulated exocytosis. They also 
suggested that 1 µM PAO does not block exocytosis but modifies the endocytic 
activity while 10 µM PAO completely inhibits exocytosis. In a preliminary study 
conducted by Ashton et. al., the effect of PI4- kinase on RRP and RP was 
investigated and it was found that PAO is not pool dependent but rather mode 
dependent i.e. its action was not specific to any pool of vesicles but its action 
inhibits SVs releasing by FF and thereby affecting the glutamate release (Refer 
appendix 1 for biochemical results). Thus, 3 µM PAO was used for this study. 
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6.3 Results 
6.3.1 Determining the appropriate concentration of 
phenylarsine oxide (PAO) 
As mentioned earlier through preliminary biochemical studies it was determined 
that the optimum concentration of PAO 3 µM and hence this concentration was 
used for determining the effect of PAO on bioenergetics of synaptosomes using 
the mito stress test (Figure 6.3).  This was done after determining the optimum 
FCCP concentration. 
 
 
Figure 6.3. The effect of 3 µM PAO on the bioenergetics of synaptosomes. Error 
bars indicate S.E.M.. These are the results of 3 independent experiments (i.e 
performed on different days) with numerous independent sample replicates (i.e. 
prepared on same day) per experiment. 10 µg of synaptosomes was used per 
well.  
This result clearly shows 3 µM PAO perturbs the bioenergetics of 
synaptosomes and reduces the OCR in comparison to control. Therefore, the 
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effect of lower concentrations of PAO on synaptosomes was investigated 
(Figure 6.4). 
 
 
Figure 6.4 Comparison of the effect exerted by 1 µM and 0.3 µM of PAO on the 
bioenergetics of synaptosomes. Error bars indicate S.E.M.. These are the 
results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. 10 µg of synaptosomes was used per well. 
 
This result clearly shows 1 µM and 0.3 µM PAO perturbs the bioenergetics of 
synaptosomes and reduces the OCR in comparison to control. Therefore, the 
effect of 0.1 µM of PAO on synaptosomes was investigated.   
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Figure 6.5. The effect of 0.1 µM PAO on the bioenergetics of synaptosomes. 
Error bars indicate S.E.M.. These are the results of 3 independent experiments 
(i.e performed on different days) with numerous independent sample replicates 
(i.e. prepared on same day) per experiment. 10 µg of synaptosomes was used 
per well. 
 
This result shows that the OCR trace obtained for the action of 0.1 µM PAO on 
synaptosomes was similar to the control OCR trace and did not exert any 
detrimental effect. 
  
 164 
6.3.2 Effect of various concentrations on mitochondrial 
respiration parameters 
After the mito stress test, various parameters could be directly measured from 
the traces. The parameters measured were average spare capacity (Figure 
6.6), average ATP production (Figure 6.7), average proton leak (Figure 6.8) and 
average maximum respiration (Figure 6.9). 
 
 
Figure 6.6. Comparison between the effect exerted by 0.1 µM, 0.3 µM and 3 µM 
PAO and control on the spare respiratory capacity. These are the results of 3 
independent experiments (i.e. performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant and expressed as a percentage. 
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Spare respiratory capacity is an indicator of the cell’s flexibility. It measures the 
capability of the cell to respond to an energy demand and also helps measure 
how closely the cell respires to its theoretical maximum. In this bar chart, as the 
dosage of PAO is increased the cell’s flexibility is reduced along with the 
capability of the cell to respond to an energy demand. 
 
 
Figure 6.7. Comparison between the effect exerted by 0.1 µM, 0.3 µM and 3 µM 
PAO and control on the average ATP production. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant and expressed as a percentage. 
 
ATP production helps meet the energy demand of the cell. Upon injection of 
oligomycin (which blocks the action of complex V) a decrease in the OCR can 
be observed which represents the portion of the basal respiration being used to 
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drive ATP production. The graph indicates that there is no significant difference 
in the ATP production on application of 0.1 µM, 0.3 µM and 3 µM PAO. 
 
 
Figure 6.8. Comparison between the effect exerted by 0.1 µM, 0.3 µM and 3 
µM PAO and control on the average proton leak. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant and expressed as a percentage. 
 
Proton leak is an indicator of mitochondrial damage or as a mechanism used for 
regulating mitochondrial ATP production. It is the remaining basal respiration 
that is not coupled to ATP production. 
The graph shows no significant difference in proton leak on application of 0.1 
and 0.3 µM PAO. However, a significant increase in proton leak can be 
observed on application of 3µM PAO, thereby indicating significant 
mitochondrial damage. 
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Figure 6.9.  Comparison between the effect exerted by 0.1 µM, 0.3 µM and 3 
µM PAO and control on the average maximum respiration. These are the 
results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. p<0.05 was considered significant and expressed as a percentage. 
 
Maximum respiration rate stimulates the respiratory chain to operate at 
maximum capacity thereby causing rapid oxidation of substrates to meet the 
high energy demand. The graph shows no significant change in maximum 
respiration on application of 0.1 µM PAO. However, a significant decrease is 
observed as the concentration of PAO is increased to 0.3 µM and there is a 
larger decrease with 3 µM. 
The aim of this study was to investigate the effects of varying concentrations 
(0.1 µM, 0.3 µM and 3 µM) of PAO on the bioenergetics of the cell. The change 
in bioenergetics of the cell was measured using Seahorse flux analyzer. This 
study, the first study of its use by Ashton et al., after purchasing the Seahorse 
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XFp analyzer. This study is completely novel as the effect of blocking PI4-
kinase activity on the electron transport chain has never been investigated 
before.  This test measures the oxygen consumption rate to assess the 
bioenergetics parameters. The results show that 0.1µM PAO has the least 
detrimental effect on the various bioenergetics parameters, when comparing it 
to the control trace (Figure 6.5 to 6.9). 0.3 µM PAO in comparison to 0.1µM and 
the control trace showed more of a detrimental effect as shown in Figure 6.4 to 
Figure 6.9, while Figure 6.3 and Figure 6.5 to 6.9 shows that 3 µM PAO had the 
most detrimental effect in comparison to the other two concentrations and the 
control trace. 
Prior to this study, the effect of 3 µM PAO was investigated on SV exocytosis. 
However, this assay helped indicated that at such a high concentration the 
terminals would be bioenergetically compromised. Therefore, it will be essential 
to repeat such studies at lower PAO concentrations (such as 0.1 µM which does 
not compromise its action as a PI(4) kinase inhibitor). 
In view of this result, it is essential to determine if any drug that we had used in 
our SV exocytotic assays and Glu assays to ensure that their actions were not 
due to compromising the bioenergetics of the synaptosomes. Thus, this assay 
was used to test the effect of cBIMPS (Figure 6.10), forskolin (Figure 6.11), 9-
Cp-Ade (Figure 6.12), Cys A (Figure 6.13), KT 5720 (Figure 6.14), blebb (Figure 
6.15), Go 6983 (Figure 6.16) and OA (Figure 6.17) on the bioenergetics of 
synaptosomes.     
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Figure 6.10: Top: effect of 50 µM cBIMPS on synaptosomes as shown by the 
mito stress test. Bottom (clockwise): Effect of 50 µM cBIMPS on spare capacity, 
ATP production, maximum respiration and proton leakage. These are the 
results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment.  p<0.05 was significant. No significant change can be observed 
with any parameters, indicating that 50 µM cBIMPS does not perturb the 
bioenergetics of synaptosomes.     
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Figure 6.11. Top: effect of 100 µM forskolin on synaptosomes as shown by the 
mito stress test. Bottom (clockwise): Effect of 100 µM forskolin on spare 
capacity, ATP production, maximum respiration and proton leakage. These are 
the results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. p<0.05 was considered significant.    
No significant change can be observed with any parameters, indicating that 100 
µM forskolin does not perturb the bioenergetics.     
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Figure 6.12. Top: effect of 100 µM 9-Cp-Ade on synaptosomes as shown by the 
mito stress test. Bottom (clockwise): Effect of 100 µM 9-Cp-Ade on spare 
capacity, ATP production, maximum respiration and proton leakage. These are 
the results of 3 independent experiments (i.e. performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. p<0.05  was considered significant. 
No significant change can be observed with any parameters, indicating that 100 
µM 9-Cp-Ade does not perturb the bioenergetics. 
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Figure 6.13 Top: effect of 1 µM Cys A on synaptosomes as shown by the mito 
stress test. Bottom (clockwise): Effect of 1 µM Cys A on spare capacity, ATP 
production, maximum respiration and proton leakage. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant. No significant change can be observed with 
any parameters, indicating that 1 µM Cys A does not perturb the bioenergetics.      
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Figure 6.14 Top: effect of 2 µM KT 5720 on synaptosomes as shown by the 
mito stress test. Bottom (clockwise): Effect of 2 µM KT 5720 on spare capacity, 
ATP production, maximum respiration and proton leakage. These are the 
results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. p<0.05  was considered significant. 
No significant change can be observed with any parameters, indicating that 2 
µM KT 5720 does not perturb the bioenergetics.     
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Figure 6.15 Top: effect of 50 µM blebb on synaptosomes as shown by the mito 
stress test. Bottom (clockwise): Effect of 50 µM blebb on spare capacity, ATP 
production, maximum respiration and proton leakage. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant. No significant change can be observed with 
any parameters, indicating that 50 µM blebb does not perturb the bioenergetics.     
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Figure 6.16. Top: effect of 1 µM GO 6983 on synaptosomes as shown by the 
mito stress test. Bottom (clockwise): Effect of 1 µM GO 6983 on spare capacity, 
ATP production, maximum respiration and proton leakage. These are the 
results of 3 independent experiments (i.e performed on different days) with 
numerous independent sample replicates (i.e. prepared on same day) per 
experiment. p<0.05 was considered significant. 
No significant change can be observed with any parameters, indicating that 1 
µM GO 6983 does not perturb the bioenergetics. 
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Figure 6.17. Top: effect of 0.8 µM OA on synaptosomes as shown by the mito 
stress test. Bottom (clockwise): Effect of 0.8 µM OA on spare capacity, ATP 
production, maximum respiration and proton leakage. These are the results of 3 
independent experiments (i.e performed on different days) with numerous 
independent sample replicates (i.e. prepared on same day) per experiment. 
p<0.05 was considered significant.      
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No significant change can be observed with any parameters, indicating that 0.8 
µM OA does not perturb the bioenergetics. 
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6.4 Discussion 
The nature of the results in this chapter actually represent an important set of 
controls that probably should be carried out with any drug that one investigates 
in this system. There is an assumption that the drug employed does not have a 
detrimental effect on the bioenergetics of the tissue being used in the study and 
that is action can be completely explained by the specificity that has been 
described in the literature. However, the first drug that was tested was PAO 
(Figure. 6.3 to 6.9) which showed that the concentration being used would 
perturb many more parameters in the synaptosomes than just regulating the 
fusion mode. Indeed, many of the studies that were carried out using 3 µM PAO 
must now have to be performed using a lower concentration such that the drug 
concentration will still perturb the PIP2 production but not bioenergetics. 
However, it was reassuring that many of the drugs that we have been 
employing in our studies do not have such detrimental effects to the 
bioenergetics of the synaptosomes. 
50 µM cBIMPS had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage and this indicates that activation of PKA does 
not perturb the bioenergetics of the nerve terminals (Figure 6.10). The effect of 
activation of PKA on the bioenergetics of synaptosomes has previously not 
been investigated. 
100 µM forskolin had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.11). This indicates that activation of AC 
does not perturb the bioenergetics of syanptosomes. Again, this is a novel 
result. 
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100 µM 9-Cp-Ade had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.12). Therefore, inhibition of AC does 
not perturb the bioenergetics of synaptosomes. Again, this is a novel result. 
1 µM Cys A had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.13).  This novel result demonstrates 
that the inhibition of PP2B does not perturb bioenergetics of the nerve 
terminals. 
2 µM KT 5720 had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.14).  Therefore, this original 
observation indicates that inhibition of PKA bioenergetics of the nerve terminals. 
50 µM blebb had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.15).  The novel conclusion is that the 
inhibition of myosin-II does not perturb the bioenergetics of synaptosomes. 
1 µM GO 6983 had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.16) thereby suggesting that inhibition 
of PKCs does not perturb the bioenergetics of synaptosomes. This result is 
novel as the effect of inhibition of PKCs on bioenergetics of synaptosomes has 
never been investigated before. 
Finally, 0.8 µM OA had no effect on spare capacity, ATP production, maximum 
respiration and proton leakage (Figure 6.17).  This indicates that inhibition of 
PP2A does not perturb the bioenergetics of synaptosomes and this result has 
not been previously reported. 
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Due to time constraints, this bioenergetics assay could not be carried out the 
other drugs employed in this thesis. However, subsequently many of these have 
been tested and have been shown to have negligible effects on the 
bioenergetics of the synaptosomes (e.g. PMA, DYN). Herein, we did not report 
the effect of the drugs on the basal respiration but it would appear that some of 
the other drugs actually make the terminals work harder after their addition such 
that the basal respiration increases. This normally indicates that the drug 
causes an increase in ATP production. However, in every case whilst the 
maximal respiration is similar the spare capacity has been reduced as some of 
this is being used because of the drug addition. 
One problem with this assay is that to measure all the bioenergetic parameters 
of the synaptosomes using the ‘mito stress test’ assay takes 100 min. In all the 
experiments reported, herein, this test has been carried out at 37oC. Normally in 
our SV exocytotic studies the synaptosomes were treated with the drugs for 5 
min (10 min when carrying various double drug additions) at 37oC, but the Glu 
release and FM dye release are measured at room temperature (20 to 24oC) 
within 30 min of the drug application. This has not proven to be a problem for all 
the drugs tested that had negligible effects but may prove problematic for some 
drugs such as PAO which affect glutamate release (3 µM PAO treated 
synaptosomes show a decrease in the glutamate release on comparison to 
control synaptosomes while the rest of the drugs that were utilised for this study 
did not perturb the glutamate release on comparison to control synaptosomes). 
Very recently, Seahorse have introduced an adaptor that allows one to carry out 
the experiments at lower temperatures than at 37oC. Ashton and colleagues 
have now reproduced the normal conditions for release assays for 
measurement of the bioenergetics of synaptosomes and have shown that the 
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prolonged 37oC temperature exposure may produce results that are not 
applicable at lower temperatures i.e. there may be spontaneous release of the 
RRP (Ashton et al., unpublished). In particular, they have recently discovered 
that whilst 3 µM PAO is still detrimental to nerve terminals with the modified 
temperatures, 0.3 µM PAO does not interfere with the bioenergetics of the 
synaptosomes. This indicates that this concentration could be employed to 
reinvestigate SV exocytosis modes. Also, the author of this thesis would like to 
remind the reader that these particular bioenergetics study is completely novel 
and thus there is a lack of citations in text. 
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Chapter 7 
Phosphorylation Studies
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7.1 Investigating the role of phosphorylation of 
dynamins in switching the mode of synaptic 
vesicular exocytosis 
7.1.1 Introduction 
Eddie Fischer and Ed Krebs in 1955 discovered phosphorylation as a regulatory 
physiological mechanism (reviewed by Johnson, 2009). It is a molecular 
mechanism through which protein function can be regulated in response to 
stimuli present inside the cell or outside the cell. Most of the neuronal proteins 
are regulated via phosphorylation as stated in chapter 1. Proteins are known to 
undergo covalent modification in many ways for e.g. ADP-ribosylation, 
acylation, carboxymethylation, tyrosine sulphation and glycosylation. However, 
none of these modification pathways are as widespread and readily subject to 
regulation in response to physiological stimuli as phosphorylation. Thus, 
regulation of protein phosphorylation is important for neuronal function (Siegel 
et al., 1999). Phosphatases and kinases mediate protein phosphorylation. 
Protein kinases can be classified as serine-threonine kinases (which 
phosphorylate serine or threonine residues), tyrosine kinases (which 
phosphorylate tyrosine residues) and kinases that perform dual function of 
phosphorylating serine-threonine and tyrosine residues. Over 95% of protein 
phosphorylation occurs at serine-threonine residues and less than 1% at 
tyrosine residues. Phosphate groups carry a negative charge, and 
phosphorylation of proteins results in a conformational change by altering the 
localized charge on the protein at the phosphorylated amino acid. This 
conformational change can alter the functional activity of the protein. There are 
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various ways in which extracellular signals can regulate neuronal function via 
protein phosphorylation. 
 
Figure 7.1. Schematic representation of the various ways in which biological 
responses can be altered. Second messengers include cAMP, cGMP, Ca2+ 
and DAG. Major second messenger-dependent protein kinases include PKC, 
PKA, Ca2+ / calmodulin kinases, CDKs, MAP kinases. Major second 
messenger-independent protein ser/thr kinases include CMGC kinases, CK1 
kinases, STE kinases. Third messengers include DNA-binding proteins. There 
exists molecular cross-talk between different signalling pathways. (Siegel et. 
al.,1999). 
 
Exocytosis of SVs is mediated by protein complexes that are regulated in a 
Ca2+ dependent manner. Dynamins are well characterized members of the 
dephosphin family. They are one of the most prominent nerve terminal proteins 
regulated in response to changes in Ca2+ concentrations. Dynamin can be 
phosphorylated on numerous sites in its amino acid sequence and these 
phosphorylations affect the properties of the protein. Huang et al (2004) have 
suggested that phosphorylation of serine residue 857 by Dyrk 1A (Dual 
specificity tyrosine-phosphorylation-regulated kinase 1A) reduces the binding of 
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dynamin I to amphyphysin I and Grb 2 (Growth factor receptor-bound protein 2). 
Chircop et al (2011) have suggested that Ser-512, Ser-851, Ser-822 and Ser-
347 can regulate the activity of dynamin I and Ser-853 for dynamin III. However, 
the exact function of these sites is still unknown. Also, these authors showed 
that phosphorylation of dynamin II at Ser-764 by CDKI (Cyclin Dependent 
Kinase I) is associated with cytokinesis. 
Graham et. al., (2007) have identified two serine residues- Ser774 and Ser-778 
in the PRD of dynamin 1 and 3 (for dynamin 3 the equivalent sites are Ser-759 
and Ser-763 respectively) which act as substrates for calcineurin and CDK5 and 
GSK3. The phoshophorylation/ dephosphorylation of dynamin 1 on Ser-774 and 
Ser-778 play an important part in their actions on CME and ADBE. The role of 
dynamin 1 and its phosphorylation in this latter process, which is also called 
bulk endocytosis, is controversial and this has been discussed in other chapters 
of this thesis. Ser-774 and Ser-778 are known to regulate the GTPase activity of 
dynamins which is absolutely essential for dynamins function (Smillie and 
Cousin, 2005). Phosphorylation of Ser-774 and Ser-778 stimulates the 
recruitment of syndapin I (Anggono and Robinson, 2007). Powell et. al., (2000) 
have shown that phosphorylation of dynamin I on Ser-795 by PKC blocks its 
association with phospholipids.  In this study the effect of phosphorylation of 
serine residues 774, 778 and 795 on dynamin I in KR mode of exocytosis has 
been investigated. This study is completely novel as the role of the 
aforementioned sites has never been implicated in KR mode of exocytosis.  
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Figure 7.2. Schematic diagram showing the domain structure and 
phosphorylation sites for dynamin 1 A. Schematic diagram showing the 
domain structure of dynamin 1. B. Phosphorylation sites present in vitro and in 
vivo on dynamin 1. Ser774 and Ser-778 indicate GSK3 and CDK5 
phosphorylation sites. Ser-795 has been shown to undergo phosphorylation by 
PKC in vitro but not in vivo under conditions tested by these authors. (Smillie 
and Cousin, 2005). 
 
In this study the effect of various kinases and phosphatases on the 
phosphorylation of Ser-774, Ser-778 and Ser-795 were investigated by using 
site-specific antibodies. 
 
7.2 Results 
7.2.1 Investigating the role of Ser-774, Ser-778 and Ser-795 in 
KR exocytosis. 
In order to investigate the possible role of ser-774, ser-778 and ser-795 of 
dynamin 1 in the KR mode of exocytosis, the change in phosphorylation level of 
each serine residue was determined upon the application of various drug 
treatments. These included treatments with OA, Cys A, KN-93, active phorbol 
ester which is PMA (Ph est) and Blebb. As RRP would have released within 2 
sec and RP would start to release after 2 sec the stimulation time chosen for 
 187 
anlaysis was 15 sec. However, most experiments involved a time course 
varying from 2 sec to 300 sec. 
For HK5C stimulation, RRP exocytoses via KR and RP by FF. 0.8µM OA blocks 
the effect of PP2A and induces the release of RRP and RP by full fusion 
(Ashton et. al., unpublished). 1 µM Cys A blocks the action of PP2B and 
induces the release of RRP and RP by KR. 10µM KN-93 blocks the effect of 
CAMKII and this blocks the release of RP but it converts RRP SVs to FF 
(Ashton et. al., unpublished). 1 µM Ph est supra-maximally all terminal PKCs 
and this actually induces RRP and RP by FF. This is distinct from the use of 40 
nM Ph est that activates some PKCs (at the active zone) which can regulate the 
properties of both dynamins and myosin-II (chapter 3).  50µM Blebb inhibits the 
action of myosin-II. As shown earlier this drug has different effects depending 
upon the stimulation employed. With HK5C Blebb induces RRP to release by 
FF and RP by FF whilst it does not perturb ION5C or 4AP5C effects on the 
mode. 1 µM Go 6983 inhibits all PKCs, it can change the requirement for the 
different proteins for closing the fusion pore (chapter 3) and it also inhibits the 
action of Ph est. (Ashton et. al., unpublished) Results from Ashton and 
colleagues have shown that many of these drugs that induce changes in protein 
phosphorylation also induced changes in the mode of exocytosis. The aim here 
was to determine if phosphorylation changes of dynamin-1 are related to these 
changes in mode of exocytosis. 
Western blotting was carried out using the respective primary and secondary 
antibodies against each of the aforementioned phospho-serine residues. For 
recognising phospho-serine-774, the primary antibody used was 1:1000 p-
Dynamin (ser-774) while the secondary antibody used was 1:5000 donkey anti-
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sheep HRP conjugate. For recognising phospho-serine-778, the primary used 
was 1:400 p-Dynamin (ser-778) while the secondary antibody used was 1:5000 
donkey anti-sheep HRP conjugate. For recognising phospho-serine-795, the 
primary used was 1:100 p-Dynamin (ser-795) while the secondary antibody 
used was 1:5000 donkey anti-goat HRP conjugate.  Later these blots were 
reprobed with 1:1000 dynamin 4E67 (a pan-dynamin antibody that recognizes 
all the dynamin 1 protein whether phosphorylated or not) and the secondary 
antibody used was 1:5000 of goat anti-mouse HRP conjugate. This antibody 
serves as an internal control for investigating the total dynamin 1 protein 
content. In the histograms produced after statistical analysis the change in the 
amount of phosphorylation was expressed as a percentage of the maximum Lo 
+ control and the error bars represent S.E.M.. 
7.2.2 Phospho-serine-778 content of dynamin 1 
Synaptosomes were treated with the various drugs for 5 min at 37oC and 
following washing steps samples were taken and stimulated for 15 s with HK5C 
(Figure. 7.3). The actual protocol was identical to that employed in the release 
studies except release was terminated with the SDS-sample buffer. This 
denatures all the kinases and phosphatases and effectively maintains the 
phosphorylated state of proteins at the precise time just before solubilisation 
with this sample buffer. 
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Figure 7.3.  The effect of OA, Cys A, KN-93, Ph est, and Blebb drug treatments 
on phosphorylation of ser-778 of dynamin 1 following the application of HK5C 
stimulation for 15 sec. The three blots are from 3 independent experiments. The 
representative blots are indicative of different sample sets with the same drug 
and stimulation conditions. The protein ladder represents the weight of protein 
in kilo Dalton (kDa). 
 
Figure 7.4. Reprobing blots presented in Figure 7.3 with anti-dynamin 4E67.  
All the blots show same levels of intact dynamin 1. The three blots are from 3 
independent experiments shown in Figure 7.3.     
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Figure 7.5 Bar chart showing changes produced in p-Dyn778 phosphorylation 
after the various drug treatments and comparing basal (Lo to HK5C). Data are 
mean and S.E.M, n=3.  p<0.05 for HK5C compared to control. 
 
Figure. 7.5 shows changes in p-Dyn778 following various drug treatments and 
stimulation. It can be observed that following various drug treatments and upon 
stimulation with HK5C, all drug treatments show a decrease in phosphorylation 
at the Ser-778 site on dynamin compared to the basal Lo apart from Blebb 
treatment which seems to have no effect. However, only the control and 
samples treated with Okadaic Acid show a statistically significant decrease. 
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7.2.3 Phospho-serine-774 content of dynamin 1 
Synaptosomes were prepared exactly as outlined for phospho-ser-778 except 
these samples were probed with an antibody specifically recognizing 
phosphoserine -774 of dynamin 1 (Figure 7.6). 
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Figure 7.6. The effect of OA, Cys A, KN-93, Ph est, and Blebb drug treatments 
on phosphorylation of ser-774 of dynamin 1 following the application of HK5C 
stimulation for 15 sec. The three blots are from 3 independent experiments. The 
representative blots are indicative of different sample sets with the same drug 
and stimulation conditions. 
 
Figure 7.7. Reprobing blots presented in Figure 7.6 with anti-dynamin 4E67 (top 
and bottom blot) or anti-synaptophysin (middle blot). 
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Top and bottom blots show the level of dynamin 1 in each track. A second 
control was used wherein the middle blot was probed with 1:1000 
antisynaptophysin antibody. 
Figure 7.8. Bar chart showing changes produced in p-Dyn774 phosphorylation 
after the various drug treatments and comparing basal (Lo to HK5C). Data are 
mean and S.E.M, n=3.  p<0.05 for HK5C compared to control. 
 
Figure 7.8 shows changes in p-Dyn774 following various drug treatments and 
stimulation. It can be observed that following various drug treatments and upon 
stimulation with HK5C, many samples show a decrease in phosphorylation at 
the Ser-774 site on dynamin compared to the basal Lo. 
Whilst the control and samples treated with OA and Ph est show a significant 
decrease those treated with KN-93 show some reduction which is not 
statistically significant whilst both Blebb and Cys A may actually prevent this 
stimulation induced dephosphorylation. 
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7.2.4 Phospho-Ser-795 
Synaptosomes were prepared exactly as outlined for phospho-ser-778 except 
these samples were probed with an antibody specifically recognizing  
phosphoserine-795 of dynamin 1 (Figure 7.9). 
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Figure 7.9.  The effect of OA, Cys A, KN-93, Ph est, and Blebb drug treatments 
on phosphorylation of ser-795 of dynamin 1 following the application of HK5C 
stimulation for 15 sec. The three blots are from 3 independent experiments. The 
representative blots are indicative of different sample sets with the same drug 
and stimulation conditions. It can be observed that bands appear only for the 
samples treated with Ph est and faint bands can be observed for samples 
treated with OA (see over-exposed image of bottom blot in Figure 7.9.a). 
 
Figure 7.9a. Over-exposed image of bottom blot in Figure 7.9. Faint bands can 
be observed with OA treated samples and dark bands can be observed with Ph 
est treated samples.     
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Figure 7.10. Reprobing blots presented in Figure 7.9 with anti-dynamin 4E67. 
All the blots show same levels intact dynamin 1 except for the OA samples in 
the bottom gel which seemed to contain less total dynamin 1. The three blots 
are from 3 independent experiments shown in Figure 7.9. 
 
7.2.5 Regulation of phospho-Ser 795 on dynamin 1 by Ph est 
and determination as to whether this is due to activation PKC 
The large phosphorylation of Ser-795 of dynamin 1 induced by 1 µM Ph est was 
assumed to be due to activation of PKCs but this was determined using a 
double drug treatment (similar to that outlined in earlier chapters) where in 
some cases the PKC inhibitor Go 6983 (1 µM) was incubated with 
synaptosomes prior to the addition of Ph est with subsequent stimulation with 
basal or HK5C for 15 sec prior to the addition of SDS-sample buffer.        
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Figure 7.11: Effect of Ph est and GO 6983 + Ph est treatment on phosphorylation of 
Ser-795 on dynamin 1 following the application of HK5C stimulation for 15 sec. The 
three blots are from 3 independent experiments. The representative blots are indicative 
of different sample sets with the same drug and stimulation conditions.    
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Figure 7.12. Reprobing blots presented in Figure 7.11 with anti-dynamin 4E67. All 
the blots show similar levels intact dynamin 1. The three blots are from the 3 
independent experiments shown in Figure 7.11. 
 
A large phospho-Ser-795 content of dynamin 1 was found following 
pretreatment with 1 µM Ph est but there was no phosphorylation at this site if 
terminals were treated with Go 6983 prior to the addition of Ph est. This 
indicates that Ph est act by activating PKCs which then regulate the 
phosphorylation of Ser-795. 
  
 199 
7.2.6 The effect that pre-treatment with the conventional PKC 
inhibitor, Go 6976, has on phosphorylated Ser795 of dynamin 
as revealed by OA treatment 
Synaptosomes were treated, using various conditions (as outlined in results 
below) and were analysed using western blotting (Figure 7.13). The three blots 
shown represent different stimulation times induced by the addition of Lo, HK5C 
and ION5C: top blot (2 s); middle blots (15 s); bottom blot (120 s). 
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Figure 7.13 The effect of OA, GO 6976, OA+Go 6976 drug treatments on the 
phosphorylation of Ser-795 on dynamin 1 seen after stimulation. This experiment was 
repeated 3 times with representative blots being indicative of different sample sets with 
the same drug and stimulation conditions. Top blot represents the 2 sec stimulation 
time point blot. Middle blot represents the 15 s stimulation time point. Bottom blot 
represents the 120 secs stimulation time point 
 
Figure 7.14.  Reprobing blots shown in Figure 7.13 with anti-dynamin 4E67. This 
indicates that there are similar amounts of total dynamin protein in each track for the 2 
s time point (top blot), 15 s time point (middle blot) and 120 s time point (bottom blot).       
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By comparing Figure 7.13 and Figure 7.14 we can make some observations. It 
would appear that after 2 s of stimulation there is some phospho-Ser795 
present in dynamin 1 even in the non-OA treated samples. However, this did 
not seem to be reduced by the pre-treatment with the Go 6976 inhibitor. There 
is a slight increase in the amount of phospho-Ser795 in those samples also 
treated with OA and this increase was till prevalent in samples treated with both 
Go 6976 and OA.  Clearly at later times there appears to be greater amounts of 
phosphorylated Ser795 dynamin 1 in all those samples treated with OA with or 
without pre-treatment with Go 6976. However, there is still a small amount of 
phosphorylation at this site for controls or those treated with the PKC inhibitor. 
Neither 15s or 120 s reveal any real difference between control samples and Go 
6976 samples. This indicates that in the time scale of this experiment 
endogenous conventional PKCs are not causing the phosphorylation of Ser795 
on dynamin 1. 
What is interesting is that there appears to be stimulated mediated reduction in 
the phosphorylation of Ser795 on dynamin 1 that is time dependent and 
stimulus dependent. This is difficult to study in any of the samples without OA 
but is very clear in those samples that were treated with OA. These changes 
can be quantitated at the different time points when comparing basal stimulation 
(Lo) with HKC and ION5C at 2 s (Figure 7.15), 15 s (Figure 7.16) and 120 s 
(Figure 7.17). 
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Figure 7.15 Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 2 s stimulation in samples treated with OA or OA plus Go 6976. Data are 
mean and the S.E.M. from 3 independent experiments.  There was no significant 
difference between HK5C or ION5C when compared to the control basal (p<0.05 was 
considered as significant 
 
Figure 7.15 indicates that following a 2 s stimulus, there is no difference in the 
amount of phospho-Ser795 present in the OA treated synapsotomes for HK5C 
or ION5S stimulus compared to the basal stimulus. Futhermore, this also 
applied to samples treated with Go 6976 and then OA. Finally, there is no 
difference between the samples that did or did not have a pre-treatment with Go 
6976. This S.E.M.i-quantitative analysis reinforces the comment above that 
inhibition of conventional PKCs does not prevent OA revealing phosphorylation 
of Ser795 on dynamin 1.   
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Figure 7.16 Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 15 s stimulation in samples treated with OA or OA plus Go 6976. Data are 
mean and the S.E.M. from 3 independent experiments. There is a significant difference 
only for the HK5C stimulated sample in the OA treated synaptosome when compared 
to the basal (p<0.05). 
 
Comparing Figure 7.15 and Figure 7.16, there appears to be a quantitative 
decrease in the amount of phosphorylated Ser795 in dynamin 1 following a 15 s 
stimulus with HK5C or ION5C compared to negligible change found in 2 s. 
However, statistically only the HK5C stimulated sample for OA treated 
synaptosomes showed a significant decrease.     
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Figure 7.17 Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 120 s stimulation in samples treated with OA or OA plus Go 6976. Data are 
mean and the S.E.M. from 3 independent experiments.  There is a significant 
difference for ION5C and HK5C stimulated sample in both the OA treated and OA plus 
Go 6976 treated synaptosome when compared to the basal (p<0.05). 
 
There is clearly a significant decrease in the amount of phosphorylated Ser795 
dynamin 1 following the applications of either HK5C or ION5C for 120 s 
compared to the basal control. This applies to synaptosomes treated with OA 
alone or treated with OA plus Go 6976. Thus, phospho-Ser795 is capable of 
being regulated in vivo inside the terminals even when PP2A is blocked by OA. 
However, it is apparent that Go 6976 neither inhibits the amount of 
phosphorylated Ser795 present in OA treated terminals nor does it prevent the 
reduction of this phosphorylation following relevant application of the stimuli.   
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7.2.7 The effect that pre-treatment with the broad spectrum PKC 
inhibitor Go 6983 has on phospho-Ser795 of dynamin as 
revealed by OA treatment. 
Synaptosomes were treated as outlined above except the broad spectrum PKC 
inhibitor Go 6983 was employed. The various conditions were run on western 
blots (Figure 7.18). The three blots shown represent different stimulation times 
induced by the addition of Lo, HK5C and ION5C: top blot (2 s); middle blots (15 
s); bottom blot (120 s). 
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Figure 7.18. The effect of OA, GO 6983, OA+Go 6983 drug treatments on the 
phosphorylation of Ser-795 on dynamin 1 seen after stimulation. This experiment was 
repeated 3 times with representative blots being indicative of different sample sets with 
the same drug and stimulation conditions. Top blot represents the 2 sec stimulation 
time point blot. Middle blot represents the 15 s stimulation time point. Bottom blot 
represents the 120 secs stimulation time point. 
 
Figure 7.19.  Reprobing blots shown in Figure 7.18 with anti-dynamin 4E67. This 
indicates that there are similar amounts of total dynamin protein in each track for the 2 
s time point (top blot), 15 s time point (middle blot) and 120 s time point (bottom blot).    
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By comparing Figure 7.18 and Figure 7.19 we can make some observations. It 
would appear that after 2 s of stimulation there is some phospho-Ser795 
present in dynamin 1 even in the non-OA treated samples. This did seem to be 
reduced slightly by the pre-treatment with the Go 6983 inhibitor. There is an 
increase in the amount of phospho-Ser795 in those samples also treated with 
OA and this increase was still prevalent in samples treated with both Go 6983 
and OA.  Clearly at later times there appears to be a greater amounts of 
phosphorylated Ser795 dynamin 1 in all those samples treated with OA with or 
without pretreatment with Go 6983. However, there is still a small amount of 
phosphorylation at this site for controls or those treated with the PKC inhibitor. 
15s or 120 s may reveal a slight difference between control samples and Go 
6983 samples with the latter containing slightly less phospho-Ser795. This is 
not perfect and some specific lanes do not appear to agree with this idea. 
However, in could be that in the time scale of this experiment some 
endogenous PKCs are causing the phosphorylation of Ser795 on dynamin 1 but 
these are not the conventional PKCs whose action were not perturbed by 
treatment with Go 6983. However, this difference is not really revealed when 
you compare the OA versus OA plus Go 6983. 
Again as expected from Figure 7.13, there appears to be stimulated mediated 
reduction in the phosphorylation of Ser795 on dynamin 1 that is time dependent 
and stimulus dependent shown in Figure 7.18. This is very clear in those 
samples that were treated with OA. These changes can be quantitated at the 
different time points when comparing basal stimulation (Lo) with HKC and 
ION5C at 2 s (Figure 7.20), 15 s (Figure 7.21) and 120 s (Figure 7.22).      
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Figure. 7.20. Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 2 s stimulation in samples treated with OA or OA plus Go 6983. Data are 
mean and the S.E.M. from 3 independent experiments.  There was no significant 
difference between HK5C or ION5C when compared to the control basal (p<0.05 was 
considered as significant. 
 
Although, we were unable to prove statistically that there was a difference 
between OA and OA plus Go 6983, the values for basal, HK5C and ION5C are 
all lower for the double treatment than in the equivalent OA treated samples.  
However, 2 s did not appear to induce only evoked change in the phospho-
Ser795 content of dynamin 1.     
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Figure 7.21 Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 15 s stimulation in samples treated with OA or OA plus Go 6983. Data are 
mean and the S.E.M. from 3 independent experiments. There appears to be no 
significant difference between stimuli and the basal condition (p<0.05). 
 
There appears to be no difference between OA and OA plus Go 6983 in the 15 
s stimulated samples (Figure. 7.21) which may infer that the 2 s time point 
(Figure 7.20) may be incorrect. Furthermore, 15 s did not appear to induce only 
evoked change in the phospho-Ser795 content of dynamin 1 for any of the 
stimuli. This is also different from the results reported earlier for OA alone 
(Figure 7.16). However, the only difference was for the HK5C sample. Clearly, 
more of these types of experiments need to be carried out to sort out such 
discrepancies. 
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Figure 7.22. Bar chart showing the changes produced in p-Dyn795 phosphorylation 
following 120 s stimulation in samples treated with OA or OA plus Go 6983. Data are 
mean and the S.E.M. from 3 independent experiments.  There is only a significant 
difference for ION5C stimulated sample for OA plus Go 6976 treated synaptosome 
when compared to the basal (p<0.05). 
 
The results for OA treated synaptosomes look very different between Figure 
7.17 and 7.22. This indicates the difficulty of quantitating the amounts of 
phosphorylated Ser795 on dynamin 1. Visual inspection of the blots shown in. 
Figure 18 would suggest that there is a stimulus dependent decrease in the 
phosphorylation of Ser795 after 120 s exposure for both HK5C and ION5C in 
OA treated terminals.   This suggests that one of the three independent 
experiments may not have worked correctly and so such quantitation does not 
reveal the correct result.  Again, this suggests that this type of experiment may 
need to be done many more times. Intriguingly, in the blots in Figure 7.17, one 
can see some stimulus evoked decrease in phospho-Ser795 even in the non-
drug treated terminals and this also occurs in the Go 6983 treated terminals. 
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However, these changes were not quantitated as there is large variation 
between experiments when one is looking as such low levels of 
phosphorylation. 
7.2.8 Investigating the role of PKA on phosphorylation of Ser-
778 and Ser-774 on Dynamin 1 
From the results reported in this chapter we found no correlation between 
changes in phosphorylation of Ser774 and Ser778 on dynamin 1 and the mode 
of SV exocytosis. Interestingly, we found some interesting observations with 
phospho-Ser795 that need to be further studied. One problem we had with this 
site is that we could not determine what the endogenous kinase was that 
phosphorylated it. It was clear that exogenous activation of PCKs with 1 µM Ph 
est could phosphorylate Ser795 on dynamin 1 but when we inhibited PKCs with 
inhibitors (Go 6983 or Go 6976) we did not seem to reduce the amount of 
phosphorylation of Ser795. This problem led us to determine whether there may 
be other kinases that can regulate the mode of exocytosis and also the 
phosphorylation of dynamin (see earlier chapters). It was clear that both 
changes in cAMP and PKA could regulate the mode. Therefore, in an initial 
attempt to discover whether PKA could regulate the mode of exocytosis by 
changing the phosphorylation state of dynamin 1, we investigated whether PKA 
could regulate the phosphorylation of Ser774 and Ser778. This was done 
initially to perhaps show that these sites were not involved before the more 
difficult experiments on phosphorylation of Ser795 could be attempted. 
As we were investigating these pathways, it seemed relevant to mention a few 
properties about PKA. PKA (E.C. 2.7.11.11) functions as a canonical signal 
transducer of cAMP and plays a vital role in neuronal outgrowth, survival and 
regeneration and in axonal growth. Based on the regulatory subunit, the PKA 
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isoforms can be classified into two categories type I and type II, with type II 
specifically IIb existing as the predominant form in neurons (Zhong et. al.,2009). 
PKA exerts its regulatory effect through phosphorylation of proteins. Abel and 
Ngyen have suggested that phosphatases like PP1 and calcineurin can 
dephosphorylate the proteins which have been previously phosphorylated by 
PKA, thus reversing the effect exerted by phosphorylation of PKA. Cribbs and 
Strack (2007) have shown that reversing the phosphorylation of Drp1 
(dynaminrelated protein1) on Ser 656 by PKA and calcineurin helps regulate 
mitochondrial fission and cell death. The function of PKA has been well 
described in regulating SNARE complex and thus modulating synaptic function 
(Baba et. al.,2005) The role of PKA has been well described in neurosecretory 
pathway, it affects the size of RRP in adrenal chromaffin cells by 
phosphorylating SNAP-25, thus altering the rate of vesicle depriming 
(Heidelberger and Matthews, 2004). However, the role of PKA in KR mode of 
exocytosis of synaptic vesicles has not been investigated before. 
The aim of this study was to investigate the role of PKA in phosphorylation of 
ser-778 and ser-774 on dynamin I. The drug treatments employed for the study 
were 2 µM KT 5720 (PKA inhibitor), 50 µM cBIMPS (PKA activator) and 1µM 
Cys A (PP2B inhibitor). It seems relevant just to remind ourselves as to what 
these drugs do in terms of regulating the mode of SV exocytosis. 1µM Cys A 
blocks the action of PP2B and induces the release of the RP by KR. Inhibition of 
PKA via 2 µM KT 5720 causes the SVs of the RRP to undergo more FF for 
ION5C and 4AP5C, however no change is observed with HK5C. Activation of 
PKA by 50 µM cBIMPS induces the release of RP by KR on employing HK5C 
and ION5C as stimulus. The effect produced by 50 µM cBIMPS is similar to the 
effect exerted by 1µM CysA. The stimulation employed for this study were 
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ION5C and HK5C and the timepoints used for this study were 2 secs, 15 secs, 
30 secs and 120 secs which should encompass both the time required for the 
RRP release (2 s) and the RP (complete by about 2 mins). Following the 
relevant stimulation time point the reactions were terminated with SDS-sample 
buffer and samples were used to carry out western blotting using the relevant 
antibodies (as highlighted above). 
In the histograms produced after the S.E.M.i-quantitative densitometric analysis 
the change in the amount of phosphorylation was expressed as a percentage 
maximum of respective control. Due to time constraint, this study could only be 
carried out with one sample set. Therefore, no statistical analysis could be 
employed and there are no measures for S.E.M.. 
7.2.9 Phospho-serine -774 content of dynamin 1 following 
manipulation of PKA and PP2B 
Synaptosomes were treated as outlined above and the various conditions were 
run on western blots (Figure 5.13). The four blots shown represent different 
stimulation times induced by the addition of Lo, HK5C and ION5C: first blot (2 
s); second blot (15 s); third blot (30 s); fourth blot (120 s).     
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Figure 7.23 The effect of Cys A, cBIMPS, KT 5720 drug treatments on phosphorylation 
of Ser-774 in dynamin 1 following the application of basal (Lo), HK5C and ION5C 
stimuli for the time in s: 2 (first blot); 15 (second blot); 30 (third blot); 120 (fourth blot). 
 
Figure 7.24. Reprobing blots presented in Figure 7.23 with anti-dynamin 4E67. The 
blots show similar levels of total dynamin.     
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There is clearly a time dependent decrease in phosphorylation of ser-774 when 
synaptosomes are stimulated with HK5 or ION5C relative to control. In general, 
it would appear that there is more dephosphorylation induced by ION5C than by 
HK5C. All these blots underwent some S.E.M.i-quantative analysis (see below) 
but it is clear that Cys A inhibits the action PP2B (calcineurin) and prevents to a 
large extent the dephosphorylation of Ser-774. This result has been well 
categorised previously. However, it is interesting since it means that dynamin.1 
will not be available to contribute to CME or bulk endocytosis (with the caveats 
already discussed throughout this thesis) and this could possibly explain why 
the RP SVs which normally require such pathways for recycling may switch to 
KR as they don’t have the same requirement for Ser774 phosphorylation of 
dynamin 1.    
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Figure 7.25. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser774 in non-drug treated synaptosomes. Note in this graphic the basal 
sample at the different time points is used to normalise the results for the other two 
stimuli. 
 
Both HK5C and ION5C stimulation induced a time dependent reduction in 
phosphorylation of Ser774 on dynamin 1 but ION5C seems to act more quickly 
(change by 15 s for this but not for HK5C) and it also seems to lead by 120s to 
a greater reduction in the content of this phosphorylated site.  
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Figure 7.26. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser774 in Cys A treated synaptosomes. Note in this graphic the basal sample 
at the different time points is used to normalise the results for the other two stimuli. 
 
For both HK5C and ION5C stimulation, Cys A pretreatment by inhibiting PP2B 
prevents the dephosphorylation of ser-774 for the first three time points 
although there is reduction by 120 s when compared to the results for non-drug 
treated terminals (Figure 7.25). The result for this 2 min time point may reflect 
that other phosphatases or pathways can reduce this phosphorylation by this 
time. There are some values which reduce and then gain following longer 
incubation time points which is not really possible and this just reflects the fact 
that the experiment needs to done many more times.    
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Figure 7.27. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser774 in cBIMPS treated synaptosomes. Note in this graphic the basal 
sample at the different time points is used to normalise the results for the other two 
stimuli. 
 
The results when terminals are treated with cBIMPs is that the two stimuli each 
reduce the phosphorylation content of Ser774 from 15 s onwards and from 
these results there seems to be already a reduction by 2 s. Whereas HK5C 
seems to reduce the level of Ser774 until it reaches a level that does not 
change. 
The results when terminals are treated with cBIMPs is that the two stimuli each 
reduce the phosphorylation content of Ser774 from 15 s onwards and from 
these results there seems to be already a reduction by 2 s. Whereas HK5C 
seems to reduce the level of Ser774 until it reaches a level that does not 
change (approx. 50%) even after 120 s, the ION5C continues to decrease the 
level. Comparing these results (Figure 7.27) with the non-drug treated control 
synaptosomes might suggest (Figure 7.25) that the activation of PKA by 
cBIMPS actually leads to a greater stimulated reduction in phospho-Ser774 in 
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dynamin 1 than with control terminals. This does not fit in with the results with 
Cys A treated terminals (Figure 7.26) in which there is a great reduction in the 
stimulus evoked decrease in phosphor-Ser-774 in dynamin 1 (Figure 7.26). This 
may be very significant as both treatments switched the mode of the RP of SVs 
to KR and yet they induce completely different patterns of phosphorylation 
changes in Ser774. This may well indicate that the changes in phospho-Ser-774 
are not related to the modes of exocytosis. This was the conclusion of studies 
using other drug treatments not connected to PKA pathways. 
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Figure 7.28. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser774 in KT 5720 treated synaptosomes. Note in this graphic the 
basal sample at the different time points is used to normalise the results for the 
other two stimuli. 
 
Figure 7.28 indicates that there is a time dependent stimulus evoked reduction 
of the content of phospho-Ser774 dynamin in terminals treated with the PKA 
inhibitor KT 5720. As with other treatments the ION5C seems to cause a larger 
reduction in phosphor-Ser775 in dynamin 1 than HK5C does. However, 
comparison between Figure. 7.25 for non-drug treated terminals and Figure 
7.28 for KT 5270 treated terminals indicate that these changes look very similar 
i.e. inhibition of PKA does not affect the phosphorylation changes induced in 
this phosphorylation site. KT 5720 can switch the RRP SVs to a FF mode for 
ION5C but not for HK5C but this treatment appears to not affect dynamin 1 
phophorylation at Ser774 may also suggest that this site in not relevant for 
defining the mode of exocytosis that maybe controlled by dynamin. 
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7.2.10 Phospho-serine -778 content of dynamin 1 following 
manipulation of PKA and PP2B 
Synaptosomes were treated as outlined above and the various conditions were 
run on western blots (Figure 7.29) and probed with the antibody to phospho-
Ser-778 and for pan-dynamin. The four blots shown represent different 
stimulation times induced by the addition of Lo, HK5C and ION5C: first blot (2 
s); second blot (15 s); third blot (30 s); fourth blot (120 s). 
  
 222 
 
Figure 7.29 The effect of Cys A, cBIMPS, KT 5720 drug treatments on phosphorylation 
of Ser-778 in dynamin 1 following the application of basal (Lo), HK5C and ION5C 
stimuli for the time in s: 2 (first blot); 15 (second blot); 30 (third blot); 120 (fourth blot). 
 
Figure 7.30. Reprobing blots presented in Figure 7.29 with anti-dynamin 4E67. The 
blots show similar levels of total dynamin.     
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By comparing Figure. 7.29 and 7.30 one can determine that there is a stimulus 
evoked  time dependent decrease in phosphorylation of ser-778 on dynamin 1 
can be observed. Both HK5C and ION5C induce this but just as for the 
phospho-Ser-774 site, it would appear that ION5C has a larger effect in 
reducing the phosphorylation. Again, it would appear that Cys A can greately 
reduce the dephosphorylation of this site although there is some reduction after 
120 s which could be due to the same reasons mentioned above for the Ser774 
site. S.E.M.i-quantative analysis of these blots was performed to see if this 
could reveal some information that was not so obvious from just examining the 
blots visually.   
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Figure 7.31. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser778 in non-drug treated synaptosomes. Note in this graphic the basal 
sample at the different time points is used to normalise the results for the other two 
stimuli. 
 
Figure 7.31 reveals simply that in non-drug treated terminals there is a stimulus 
evoked reduction the phosphorylation of ser-778 of dynamin 1 and that this 
comes mainly apparent after 30 s. However, ION5C seems to induce a faster 
and stronger reduction in this phosphorylation than does HK5C. This is similar 
to what occurs with phospho-Ser774 (Figure. 7.25).     
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Figure 7.32. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser778 in Cys A treated synaptosomes. Note in this graphic the basal sample 
at the different time points is used to normalise the results for the other two stimuli. 
 
It would appear that the sample for 2 s ION5C stimulation in Figure.7.32 might 
be wrong since this appears to induce an increase in the phosphorylation of 
Ser788 in dynamin 1. However, if you take this as an error than the first two 
stimulation time points (2 and 15 s) do not cause a change in this 
phosphorylation site in synaptosomes in which PP2B is inhibited. However, by 
30 s there is a substantial reduction in the phosphorylation of Ser778 for both 
HK5C and ION5C stimulation although this does not decrease much further 
after 120 s stimulation. This result for phospho-Ser778 is reminiscent of the 
result for phosphor-Ser774 (Figure. 7.26) although the former seems to undergo 
some dephosphorylation earlier than the latter site. Note that there is still some 
substantial amount of phospho-Ser778 even after 120 s stimulation and this is 
most certainly not the case in the non-drug treated terminals with the ION5C 
stimulus.       
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Figure 7.33. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser778 in cBIMPS treated synaptosomes. Note in this graphic the basal 
sample at the different time points is used to normalise the results for the other two 
stimuli. 
 
The activation of PKA with cBIMPs induces the stimuli (HK5C and ION5C) to 
cause a quicker reduction in phospho-Ser778 (Figure 7.33) than found in the 
control (Figure 7.31). Again this is completely different to the effect seen for Cys 
A treated terminasl (Figure. 7.32) even though both drug treatments convert RR 
SVs to a FF mode. Again, this could rule out a role of phospho-Ser778 in 
regulation the mode of the fusion pore.    
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Figure 7.34. Bar chart showing the stimulus evoked time dependent reduction in 
phospho-Ser778 in KT 5720 treated synaptosomes. Note in this graphic the basal 
sample at the different time points is used to normalise the results for the other two 
stimuli. 
 
It would appear that there is an error for the HK5C sample for 2 s stimulation in 
KT 5720 treated synaptosomes since this appears to induce an increase in the 
phosphorylation of Ser788 in dynamin 1. For all other time points both HK5C 
and ION5C induce a dephosphorylation of Ser778 of dynamin 1. Indeed, this 
might be slightly faster than that in the control samples (Figure 7.31). In fact, 
this result looks quite similar to the one obtained in synaptosomes treated with 
cBIMPs (Figure 7.33). This pattern of dephosphorylation of Ser778 is distinct 
from the change seen for phospho-Ser774 in the KT 5720 treated terminals 
(Figure. 7.28). In the case of phospho-Ser778 we have an inhibitor of PKA and 
an activator of PKA actually gives you quite similar phosphorylation changes 
upon the application of a stimulus. However, these two conditions work on 
different pools and cause opposite switches in the mode.    
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7.3 Discussion 
Much of the results in this chapter were discussed during the result section as 
this led onto the next set of experiments. Manipulation of synaptosomes with 
the various drugs that regulate PKC, Blebb, PP2B and PP2A failed to really 
show any correlation between the phosphorylated state of dynamin 1 at Ser774 
or Ser-778 and the specific mode of certain pools of SVs that these various 
drugs induced. Likewise, initial studies with manipulation of PKA failed to show 
a correlation with the mode of exocytosis and the phosphorylation state of 
Ser774 and Ser778 of dynamin 1. Data herein was able to show stimulation 
specific reduction in these sites which may be important for CME and bulk 
endocytosis but clearly these sites do not seem to be involved in defining the 
mode of exocytosis. 
The results with OA and with PKC and PKC blockers on the phosphorylation of 
Ser795 seemed more promising as there were conditions in which the mode of 
exocytosis was switched to FF which corresponded to phosphorylation of this 
site. Recent experiments carried out in the lab definitely suggest that normally 
the stimuli employed may only work on a sub-population of SVs. This is 
probably those SVs at the AZ. This could explain why it is so difficult to find a 
substantial change in say Ser795 if only a small population of this is being 
phosphorylated. Immunoprecipitation of such a phosphorylated pool of dynamin 
may prove useful although if it is so low this still may present problems of 
detection. 
The use of Ph est may phosphorylate the Ser-795 of all the dynamin 1 in the 
terminal. Ashton’s group have recently obtained good data for a correlation 
between this exogenous activated PKC phosphorylation and the modes. 
Clearly, this treatment will work not only on the relevant pool of dynamin 1 (e.g. 
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those at the AZ or associated with the pools of SVs) but on all the rest of the 
dynamin throughout the terminal. Hence, this will be easy to detect unlike 
perhaps the stimulus induced changed in Ser795 of a sub pool of dynamin 1. 
A big question that needs to be answered to clarify the situation is what do 
these drug treatments do to the various phosphorylation sites on non-muscle 
myosin-II. Clearly, there has to be conditions where a drug that switches both 
ION5C and HK5C evoked SV exocytosis either to FF (e.g. OA acting on the 
RRP SVs) or to KR (e.g. Cys A acting on the RP of SVs) must act both on 
dynamin 1 and on myosin-II. There is currently a large research effort in the 
Ashton lab to establish these sites on myosin-II that maybe important in mode 
switching (remember our wdata suggest that myosin-II is activated by a PKC 
mediated phosphorylation). There needs to be a good correlation between 
activation of myosin-II by specific phosphorylation sites and inactivation of 
dynamin 1 on specific phosphorylation sites (Ser795). This research has 
obtained some very interesting preliminary data about phospho-Ser sites on 
the myosin-II HC (e.g. Ser1943, Ser1916) that could play a role. Just like the 
Ser795 site it would appear that drug treatments such as activation of PKC 
with Ph est can show this important change under conditions where ION5C 
can switch its requirements from dynamin 1 to myosin-II to close the RRP SVs 
fusion pore (using 40 nM PMA, see earlier chapters for discussion about this). 
However, it has proven much more difficult to see HK5C phosphorylating 
dynamin 1 at Ser795 and inactivating it and at the same time activating the 
phosphorylation of various sites on the myosin-II molecule. This may also be 
to do with the fact that there may be only a sub pool of myosin-II within the 
terminal that is acted upon by HK5C but this is located at the relevant site (e.g. 
 230 
AZ, SVs) whilst a large amount of myosin-II may not be phosphorylated by 
HK5C. 
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Chapter 8 
General Discussion and 
Conclusion
 232 
8.1 General discussion and conclusion 
SVs can exocytose via FF or by the highly debated mechanism KR. This study 
presents strong evidence to prove the existence of KR. Elegant studies 
conducted by Ashton et al have established that a switch in the mode of 
exocytosis can be brought about by regulating the intracellular calcium levels or 
by protein phosphorylation. Cerebrocortical synaptosomes derived from adult 
male Wistar rats have been used as model system. 
HK5C, ION5C and 4AP5C induce SV exocytosis through distinct mechanisms 
in a Ca2+-dependent manner. HK5C produces a relatively fast and large 
increase in [Ca2+]i in comparison to ION5C and 4AP5C which do not produce 
such a large increase in Ca2+ at this region. This is due to the strategic 
localization of voltage-dependent Ca2+ channels here. However, HK5C and 
ION5C induce release of both releasable SV pools with exocytosis of RRP by 
KR and the RP undergoing FF, whilst 4AP5C results in the exocytosis of RRP 
by a mixture of KR and FF. 
In this study, the role of two major proteins, dynamins and non-muscle myosin-II 
involved in KR mode of exocytosis has been investigated. It has been shown 
here, in the results presented in chapter 3, the activity of both these proteins in 
regulating the fusion pore can mediated through the action of PKCs and through 
the increase in [Ca2+]i  at the AZ (see diagram 8.1).   
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Figure 8.1. A schematic representation of the action of PKCs. HK5C induced increase 
in [Ca2+]i results in activation of PKCs which results in inactivation of dynamins 
through activation of a novel PKC isoform and activation of myosin II via conventional 
PKC isoform. Thus myosin-II mediates the action of the fusion pore causing the 
vesicles to KR. 1µM Ph est superactivates PKCs resulting in inhibition of dynamins and 
activation of myosin-II. For ION5C and 4AP5C the action of the fusion pore is dynamin-
dependent resulting in KR of SVs. The figure suggests that the [Ca2+] induced at the 
AZ may actually lead to an inhibition of PKCs. However, it is more likely that it just does 
not activate PKCs so dynamin is not inactivated whilst myosin-II is not activated.  
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Chapter 6, elucidates the importance of bioenergetics assay which helped 
decipher the optimum concentration of PAO. Thus, the bioenergetics 
observations for the other drugs help conclude that the drugs are target specific 
and do not perturb the mitochondrial respiration. 
The last part of the study was investigating the role of phosphorylation of 
Ser778, Ser-774 and Ser-795 on dynamins. It was concluded that Ser-774 and 
Ser-778 may play a role in CDE and bulk endocytosis (the changes in 
phosphorylation of these sites correspond nicely with possible pathways 
involving these two processes) as previously documented but these sites do not 
show any correlation with dynamin’s activity towards regulating closure of the 
fusion pore. However, the results also suggest that the phosphorylation of Ser-
795 may play an important role in the inhibition of dynamin’s activity and 
thereby preventing it from closing the fusion pore of exocytosing vesicles. 
Phosphorylation studies involving the combination treatment of Ph est and Go 
6983 indicated that the phosphorylation of Ser-795 may be under the regulation 
of PKC. It is possible that PKC may phosphorylate this site when a very high 
Δ[Ca2+]i is achieved at the active zone. Furthermore, on investigating the role 
of PKCs on the phosphorylation of ser-795 on dynamin-I, it was observed that 
due to the low phosphorylation levels obtained on employing Go 6983 and Go 
6976 drug treatments, it was difficult to obtain a conclusion as to which PKC 
isoform could regulate the mode of SV exocytosis by phosphorylation of 
Ser795. This could of course mean that there is a distinct phosphorylation site 
on dynamin 1 that is regulated but which we have not investigated. For the 
phosphorylation studies conducted to decipher the role of PKA on the 
phosphorylation of ser-774 and ser-778 on dynamin 1, it was observed that 
again ser-774 and ser-778 do not show any correlation with dynamin’s activity 
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towards regulating closure of the fusion pore for PKA drug treatments. The 
experiment needs to repeated to confirm these findings. 
8.2 Future directions 
This study gives an insight into the activity of PKA and PKC in regulating the 
mode of synaptic vesicle fusion. However, a substantial amount of work still 
needs to be undertaken to elucidate the mechanism of SV exocytosis. 
a) The effect of HK5C and ION5C on ser-774and ser778 phosphorylation 
for PKA drug treatments needs to be repeated to provide a definitive 
conclusion about the role of regulation of PKA on Ser-774 and Ser-778 in 
phosphorylation of dynamin 1. One also needs to investigate the role of 
PKA drug treatments on the phosphorylation of Ser-795. The 
experiments also need to be carried out with 4AP5C stimulation. After 
the role of dynamins has been elucidated, it is important to elucidate the 
role of myosin-II phosphorylation sites. If we are unable to prove that the 
well-characterised phosphorylation sites play a role then we need to find 
evidence that other phosphorylation sites are involved. This can be 
investigated by immunoprecipitating dynamins or myosin II by using 
antibodies that specifically recognise phosphorylated serine residues. 
Alternatively, further analysis could be carried out by using 
phosphoproteomic techniques to enrich the phosphorylated proteins and 
utilising mass spectrometry to determine the phosphorylation sites. 
b) Immunoprecipitation of the distinct dynamin isoforms may help elucidate 
the specific phosphorylation changes. Although, not discussed herein 
there are some splice variants of dynamin 1 and it may be a specific type 
that plays a role in modulating the mode of exocytosis. 
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c) To carry out bioenergetics assay for the rest of the drug treatments so as 
to investigate their effects on mitochondrial respiration. In particular, we 
have not tested the double drug treatments and as this may provide 
some essential information we need to make sure that such treatments 
are not actually detrimental to the bioenergetics integrity of the nerve 
terminals. 
d) To repeat the biochemical experiments carried out with 0.3 µM PAO 
instead of 3µM PAO so as to elucidate the role of inhibition of PI(4)kinase 
on regulation of SV exocytosis. 
e) To establish the role of EPACS in the mode of release and also establish 
its role in conjunction with other drug treatments. 
f) To investigate the role of dynamin 1 by using dynole-34-2TM (since 
20µM dynole specifically blocks dynamin 1). Also, to investigate the role 
of dynamin 2 using dyngo, as 50µM specifically blocks dynamin 2. This 
has already been performed for simply measuring ION5C evoked release 
but more can be done (see below). 
g) To investigate further the role of dynamin 2 by comparing the actions of 
dyngo on 4AP5C and HK5C. Our argument about dynamin 1 not being 
active at active zone with HK5C due to PKC stimulation should not apply 
to the RP which sees a lot less calcium and PKC should not be activated. 
So dyngo may be able to regulate RP stimulation by HK5C and should 
have no effect on 4AP5C which doesn’t release the RP. 
h) To investigate the PKC isoform involved in mode switching and also the 
myosin-II isoform and sub-units that are involved in this process. This would 
be an exciting set of experiments which can be done. There are several 
isoforms of PKC and these can be inhibited by specific inhibitors against those 
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isoforms. So rather than using GO 6983 which blocks all PKC isoforms, 
specific inhibitors can be used to determine which PKC isoform 
phosphorylates dynamin and which phosphorylates myosin-II. This may reveal 
that distinct PKCs regulate these two different proteins. HK5C. 
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Appendix 1 
FCCP titration 
 
freshly prepared terminals. 
 
FCCP 
from stock. 
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The effect of 0.1µM PAO pre-treatment on HK5C evoked Glu release. 
 
 
0.3 µM PAO pre-treatment on HK5C evoked Glu release. 
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Effect of 3 micromolar PAO on glutamate release using HK5C stimulation. 
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Appendix 3 
For ease of presentation, full sized blots were not presented, only the region 
that contained the band of interest were presented. However, full sized blots 
can be obtained by emailing the author on the email address: 
singhdeeba@gmail.com  
A representative blot has been shown below 
(A) Using antibody against phosphorylated ser-778 residue on dynamin I 
 
 
(B) The above blot was stripped and probed with Dynamin-I (4E67) 
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Dynamin-I (4E67) binds to dynamin-I and helps estimate the total amount of 
dynamin-I present in the synaptosomes. Please note that this antibody does not 
bind to the western standard loaded into wells present on both end of the gels. 
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Appendix 4 
The step by step guideline for the calculations please refer to appendix 6c of 
MSc thesis by Pooja M Babar. Due to the extensively long text which represents 
46 pages, it was deemed considerable to omit the information and cite the work 
by Pooja Babar. 
 
 
